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 The continual rise of microbial resistance is a pressing concern throughout the world, 
resulting in several thousands of deaths each year. Most of these deaths are a result of Gram-
negative infections as no new class of Gram-negative antibiotics has been introduced in several 
decades. The problematic nature of this epidemic lies in the composition of the Gram-negative 
bacterial membrane, as it is impermeable to most organic small-molecules. The eNTRy rules, 
developed by the Hergenrother lab, can guide the synthesis of Gram-negative-active antibiotic 
leads as they predict the likelihood of compound accumulation in Gram-negative bacteria. In 
general, for a compound to accumulate in Gram-negative bacteria, it must possess an ionizable 
nitrogen, be relatively flat, and rigid. A major hurdle to this approach is installation of the 
nitrogen without disturbing target engagement. A solution to this involves appendage of 
ionizable nitrogens on a prodrug moiety such that it crosses the outer membrane and is cleaved 
within Gram-negative bacteria, releasing the active antibiotic. Such novel strategy can be a 
powerful approach to combat disease-causing pathogens as it addresses the major limitation of 
discovering new broad-spectrum antibiotics: passage across the outer membrane, and ultimately 
accumulation. 
 The chapters herein emphasize the importance of combating antibiotic resistance, 
specifically against Gram-negatives, and provide actionable strategies by which to accomplish 
this mission. Chapter 1 focuses on the challenges of generating Gram-negative actives and 
describes novel solutions to this problem. This chapter also describes the structure-activity 
relationship of Gram-positive only antibiotic fusidic acid. Chapter 2 discusses the ring distortion 
of the alkaloid sinomenine using the complexity-to-diversity (CtD) approach to generate 66 total 
compounds, which played a key role in identifying the 3-dimensionality parameter, globularity 
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(Glob), as important for accumulation in Gram-negative bacteria, and eventual discovery of the 
eNTRy rules. Chapter 3 describes our initial efforts to convert fusidic acid using the eNTRy rules 
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CHAPTER 1: INTRODUCTION 
1.1. Rise of antibiotic resistance 
 In the United States, two million people are infected with antibiotic-resistant bacteria and 
at least 23,000 people die from these infections each year.1 While progress toward treatments for 
Gram-positive infections has been steady, treatment of Gram-negative bacterial infections has 
significantly lagged in the past few decades.2 In fact, a new antibacterial class active against 
Gram-negative organisms has not been introduced since the quinolones in 1968.3 Furthermore, 
there are vanishingly few Gram-negative antibiotics in the drug-development pipeline.4 Lack of 
new drugs for Gram-negative infections has led to a dangerous situation, with increasing drug-
resistant infections and death. This is particularly alarming as 4 of 6 ESKAPE pathogens 
responsible for hospital acquired infections, 9 of the 14 bacteria listed as a pressing concern by 
the CDC, and more recently, 9 of the 12 priority bacteria disclosed by the WHO in 2017 are 
Gram-negative pathogens.5-11 In Europe, three-quarters of deaths caused by antibiotic-resistant 
bacterial infections arise from Gram-negative pathogens (Chart 1.1).12 Additionally, Gram-
negative bacteria with multiple resistance genes (i.e. NDM-1) are becoming detected 
worldwide.13-14 Alarmingly, resistant bacteria for Gram-negative antibiotic of last resort, colistin, 




Chart 1.1. Infections and deaths as a result of antibiotic-resistant bacteria in Europe (EU and 
EEA, 2015). Data from Cassini et al.12 
 
1.2. Challenges of crossing the outer membrane of Gram-negative bacteria 
 The problematic nature of Gram-negative pathogens arises from the composition of the 
cellular membrane. Unlike Gram-positive bacteria, Gram-negative bacteria possess two lipid 
bilayers, which function synergistically to prevent the accumulation of most small molecules.16 
The outer membrane, which is unique to Gram-negative organisms, consists of negatively 
charged, tightly packed lipopolysaccharides, which prevent most small molecules from 
penetrating into the organism.16 Small molecules that successfully enter the cell do so via 
passage through small channels called porins, proteins with a barrel structure lined with charged 
amino acids.17 Retrospective analyses by O’Shea and Moser have shown that small molecules 
effective against Gram-negative bacteria tend to be small and very polar.17 However, there are 
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Infections With Antibiotic-resistant Bacteria (EU and EEA, 2015) 
Gram-negative 
Gram-positive 
3rd-generation cephalosporin-resistant E. coli 
3rd-generation cephalosporin-resistant K. pneumoniae 
Carbapenem-resistant P. aeruginosa 
Carbapenem-resistant Acinetobacter spp. 
Methicillin-resistant S. aureus 
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Gram-negatives indicating that there are other properties dictating accumulation. Furthermore, 
the data sets from these retrospective analyses are highly skewed due to overrepresentation of 
certain drug classes, namely beta-lactams.17-19 
 Prior to our work (described below) the exact properties that favor small molecule 
penetration and accumulation in Gram-negative bacteria were unknown, and this “Gram-
negative problem” is widely recognized as a major question in microbiology.5-11 
1.3. Development of the eNTRy rules 
1.3.1. Approach to develop eNTRy rules 
 As mentioned, there is limited knowledge on the properties that favor compound 
accumulation in Gram-negative organisms. To overcome this problem, we strategized to develop 
guidelines for accumulation in Gram-negative bacteria. This required 1) synthesizing and testing 
a diverse set of compounds, 2) developing an LC-MS/MS based assay to measure accumulation 
in Gram-negative bacteria, 3) using computational analysis to analyze data, and 4) establishing 
trends in accumulation and compound properties that favor accumulation in Gram-negative 
bacteria. Through this approach, guidelines for accumulation in E. coli were eventually 
established (Figure 1.1).20-21 First, an unbiased and complex compound collection of 100 
compounds was obtained from the complexity to diversity (CtD) compound collection in our 
lab.22-27 Next, assessment of accumulation was accomplished by modifying a whole-cell assay 
utilized by Bazile and coworkers,28 using LC/MS to individually quantify the accumulation of 
compounds in E. coli. After this initial evaluation, it was found that charge was important for 
accumulation. Specifically, positively charged compounds containing a primary amine were 
found to accumulate. After a rigorous SAR campaign to confirm this observation (construction 
of systematic derivatives whereby the amine is converted to the amide, azide, nitrile, etc.—none 
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of which accumulate), a total of 63 primary amines were synthesized and gathered from other 
sources and were tested for accumulation. Interestingly, 31 of 63 primary amines did not 
accumulate indicating that charge was key for accumulation, but not the only factor. Almost 
three hundred different physicochemical parameters of the 63 primary amine compound set were 
then calculated and were used to create binary decision trees to classify compounds as 
accumulators or non-accumulators. From this detailed computational analysis, flexibility and 3-
dimensionality were found to be important parameters influencing accumulation, with 
globularity (Glob)29-31 used to assess 3-dimensionality and number of rotatable bonds (RB)32 
used for flexibility. Results from this unbiased approach indicate that generally compounds with 
a primary amine and a Glob ≤ 0.25 and RB ≤ 5 are competent for accumulation in E. coli. The 
relationship between Glob and RB for the compound set of antibacterials from the O’ Shea and 
Moser study17 was then examined, and we found that the same trend of factors (ionizable 
nitrogen, Glob ≤ 0.25 and RB ≤ 5) is needed for activity vs. Gram-negatives. The name eNTRy 
rules was coined to describe the following properties: to increase the chances of a compound to 
accumulate in E. coli, it must contain a non-sterically congested ionizable Nitrogen, have some 





Figure 1.1. Discovery of the eNTRy rules. 
1.3.2. Application of eNTRy rules 
To demonstrate that these guidelines are actionable, we have used them to successfully 
convert a derivative of the Gram-positive only natural product deoxynybomicin (DNM) into a 
compound that is active in E. coli. DNM20, 33 is an optimal candidate for this for conversion into 
a broad-spectrum agent due to its low 3-dimensionality (Glob = 0.02) and rigidity (RB = 0). 
DNM derivative 6DNM was chosen for conversion as it retains activity in S. aureus (MIC = 
0.06–1 µg/mL) but is not active against E. coli (MIC > 32 µg/mL), as shown in Table 1.1. 
6DNM-NH3 was then designed as a derivative that meets all the guidelines for accumulation 
(indicated by green font in Table 1.1). Synthesis of 6DNM-NH3 followed by assessment of the 
accumulation of 6DNM-NH3 revealed a high degree of accumulation in E. coli (1114 nmol/1012 
CFUs) relative to that of 6DNM (298 nmol/1012 CFUs). Excitingly, 6DNM-NH3 displays high 
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6DNM-NH3 display low accumulation and low activity in E. coli, which indicates that the free 
primary amine is indeed important. The 6DNM derivatives were tested in multiple strains, 
including clinical isolates, of the Gram-negative ESKAPE pathogens and 6DNM-NH3 displayed 
activity in 20 clinical isolates. It was also active (MIC = 4 µg/mL) against a multi-drug resistant 
New-Delhi metallo-betalactamase-1 producing strain of E. coli (ATCC BAA-2469), which is 
resistant to many antibiotics.20 Conversion targets of other Gram-positive-only antibiotics, 
namely debio 1452,34 ribocil C, and fusidic acid have also been successful and are currently 
being further assessed and are in preclinical development. 
 
Table 1.1. Conversion of Deoxynybomycin derivative 6DNM to 6DNM-NH3. MICs in µg/mL; 
n = 3. * = solubility limit. Accumulation in E. coli MG1655. Accumulation in nmol/1012 CFU. 
Error = standard error of the mean of 3 biological replicates. Data from Richter et al.20 
 
1.4. Exploiting self-promoted uptake pathway to make broad-spectrum antibiotics 
1.4.1. Self-promoted uptake pathway 
 Thus far the discussion has been about converting Gram-positive only antibiotics into 
broad-spectrum agents using the eNTRy rules. These rules were developed to predict 






























Species Strain MIC (µg/mL) MIC (µg/mL) 
S. aureus ATCC 29213 0.06–1 0.03–0.5 
E. coli MG1655 > 32 0.5 
A. baumannii ATCC 19606 16 2 
K. pneumoniae ATCC 29893 > 32 1 










t t (+) antibacterial 
activity 
 
No Primary Amine 
RB = 0 
Glob = 0.04 
Accum. = 298 ± 110 
6DNM-NH3 
Primary Amine 
RB = 0 
Glob = 0.04 
Accum. = 1114 ± 135 
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promoted uptake pathway (Figure 1.2), in which a small molecule with multiple positive charges 
can displace the divalent cations on the surface of the bacterial cell to ultimately gain entry.35-38 
This self-promoted uptake pathway has been exploited and translated into highly positively 
charged, FDA approved broad-spectrum antibiotics (Figure 1.2).39-42 Furthermore, these 
antibiotics lie outside of the eNTRy rules suggesting that if a compound is sufficiently positively 
charged38 it can cross the outer membrane of Gram-negative bacteria regardless of its flexibility 
or 3-dimensionality.  
 The experimental evidence of Gram-negative only colistin membrane permeability has 
been shown in pan-drug resistant Gram-negative isolates through different techniques including 
leakage, electron microscopy, and construction of an artificial membrane model using 
liposomes.43 For azithromycin, aminoglycosides (kanamycin), and other polymyxins, incubation 
of the antibiotic with bacteria in the presence of a fluorescent small-molecule is performed. Since 
the self-promoted uptake pathway requires partial destabilization of the outer membrane, 
compounds that enter via this route cause the bacteria to take up the small-molecule probe.42 
Another commonly used assay involves assessment of antibacterial activity in the presence of 
magnesium, which should be decreased if compound is entering via self-promoted uptake.44 The 
validity of these assays has been questioned in the literature and likely better assays for self-




Figure 1.2. Self-promoted uptake pathway and clinically approved positively charged 
antibiotics. 
 
1.4.2. Discovery of broad-spectrum antibiotics by installing positive charges 
 There has been success in generating small molecules containing multiple positive 
charges to yield leads with broad-spectrum antibiotic activity (Figure 1.3).21, 46-48 Nabriva 
Therapeutics developed a broad-spectrum pleuromutilin derivative by inversion of a stereocenter 
and installation of a polycationic amine chain.46 Actelion Pharmaceuticals increased the potency 
of tetrahydropyran 4 in Gram-negative pathogens by replacing a hydroxyl group with a primary 
amine (tetrahydropyran 21) complimenting the secondary amine already present on the 
scaffold.47 The most recent example from Genentech involves broadening the spectrum of the 
arylomycins through a rigorous SAR campaign and ultimately installation of three primary 
amines to convert G8126 into G0775.48 These examples highlight the promise in broadening the 
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Figure 1.3. Broad-spectrum leads that exploit self-promoted uptake pathway. 
1.4.3. Challenges of installing one or multiple positive charges 
 While utilization of self-promoted uptake can be an attractive strategy, installation of one 
or multiple positive charges can be problematic with the possibility of long synthetic steps, and 
the inability of compounds to engage their biological target with the burden of a positive charge 
embedded in its structure. This has been the case with attempts at converting Gram-positive only 
antibiotics into broad-spectrum agents (Figure 1.4.). The polycationic derivative of fusidic acid 
(7 steps) loses complete activity when the C-ring hydroxyl is replaced with a polyamine chain. 
Dr. Sarah Tasker generated a linezolid derivative (9 steps) containing a primary amine on the 
morpholine ring, which made it inactive. Dr. Bryon Drown’s attempt to broaden the spectrum of 
zoliflodacin was unsuccessful when he appended a primary amine (14 steps) on the 
oxazolidinone moiety. Additionally, conversion attempts of 6-azaindazole (Sarah Perlmutter) 
yielded an inactive derivative when a primary amine was substituted in place of the primary 
alcohol. It should be noted that in all four case the amine-containing compound increased 
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no new activity in E. coli was observed indicating that these derivatives were not interacting with 
the biological target, likely due to the positive charge. 
Installation of multiple positive charges on compounds brings up the topic of toxicity. 
Several polyamines have been shown to be safe and tolerable in humans (Chapter 3)49-53, with 
Syprine (trientine)52, 54 being FDA approved with a high oral maximum tolerable dose (MTD) of 
3600 mg/day,54 suggesting that appending multiple charges on potential antibiotics can likely be 
safe and tolerable in humans. 
 
Figure 1.4. Failed attempts at broadening spectrum of Gram-positive only antibiotics due to lack 
of target engagement after amine additiond. All amine compounds have increased accumulation 
in E. coli. 
1.5. Prodrugs 
1.5.1. Chemical vs. enzymatic activation 
 Prodrugs are biologically inactive forms of an active compound that must be activated by 
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approved including anti-inflammatory agent Aspirin57 and DNA alkylator Temozolomide 
(TMZ).58 In fact, 7% of the world’s clinically approved drugs are prodrugs.55, 59 Additionally, 7 
of 32 (15%) FDA approved small-molecule drugs in 2015 were prodrugs.60 There are advantages 
and disadvantages to both approaches of prodrug biotransformation listed in Figure 1.5. 
Enzymatic activation is the primary mode of prodrug activation and offers several advantages 
including rapid and selective activation at the desired site.59, 61 Some disadvantages include 
unreliable extent of activation in patients with liver diseases.62-63 Chemical hydrolysis (by water) 
offers alternative advantages including that water is the same in every patient and therefore the 
same rate of hydrolysis will be observed in everyone.58 A major disadvantage to chemical 
activation, and likely the reason why enzymatic prodrugs are more common, is that they tend to 
be unstable and the hydrolysis event cannot be controlled.63 
 
Figure 1.5. Enzymatic vs chemical activation of prodrugs. 
1.5.2. Utilization of prodrugs in antibiotic drugs 
Prodrugs have historically been used to enhance oral bioavailability, increase solubility, 
enhance stability, and improve many properties of drug candidates.55 The prodrug approach has 
1.  Extent of enzymatic 
activation can be 
unreliable (i.e. liver 
diseases) 
2.  Activation may be 
different from patient to 
patient 
1.  Water is chemically the 
same in every patient  
2.  Allows for same rate and 
extent of hydrolysis in 
every patient 
Enzymatic Activation Chemical Activation (by H2O) 
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1.  Activation at site of 
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2.  Rapid activation at 
desired site 
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enhanced drug-like properties of several antibiotics64 including colistin methanesulfonate,65 an 
antibiotic of last resort for multi-drug resistant bacteria. There are currently no examples of 
prodrug antibiotics that leverage the self-promoted uptake pathway to gain entry into the 
bacterial cell. Developing such prodrug antibiotics from clinically approved antibiotics could 
prove to be a powerful approach for increasing the spectrum of Gram-positive only antibiotics 
and combat microbial resistance. Such a strategy has been developed with the antibiotic fusidic 
acid and is further discussed in chapter 3. 
1.6. Fusidic acid 
Work described throughout this thesis surrounds the antibiotic fusidic acid (Figure 1.6). 
Fusidic acid was first isolated from the fungus Fusidium coccineum in 1960.66-68 It is active 
against Gram-positive pathogens through the inhibition of synthesis by binding to elongation 
factor G (EF-G) during translation of proteins in the ribosome.67-70 Fusidic acid displays no 
cross-resistance with other clinically used antibiotics due to its unique mechanism of action.67-68 
Fusidic acid is approved and in 23 countries including South Korea, Japan, UK, Canada, and 
others.71 There are approximately 21.3 million prescriptions of fusidic acid annually with oral, 
intravenous, and topical formulations.71-72 In the United States, oral delivery of fusidic acid is 
being developed by Cempra pharmaceuticals as Taksta for the treatment of acute bacterial skin 
and skin structure infections (ABSSSI) and recently achieved its primary endpoint in Phase 3 
clinical trials, non-inferiority to oral linezolid.73-74 The current dosing regimen in clinical trials 
for fusidic acid is a loading dose of 1500 mg twice on the first day followed by 600 mg twice 
daily.75-76 Despite the high resistant frequency of fusidic acid (10-6),68 this optimized dosing 




Figure 1.6. Chemical structure of fusidic acid. 
1.7. Structure-activity relationship of fusidic acid  
1.7.1. Overview 
 Given the efficacy of fusidic acid, there is an abundance of information on the SAR of 
fusidic acid. Fusidic acid consists of four-fused rings, a tetrasubstituted olefin acting as a bridge 
to the carboxylic acid and the aliphatic prenyl side chain (Figure 1.6).66-67 While there has been 
great interest in fusidic acid and its derivatives, most of this work was performed on outdated 
bacterial strains and is reported in IC50, not minimal inhibitory concentrations (MICs).66, 78-82 
Recent work performed by the Hergenrother lab sheds important insight on the SAR of fusidic 
acid. This work includes many novel compounds whose MICs were determined and/or fusidic 
acid derivatives that have no MIC data reported in the literature. Known fusidic acid derivatives 
with literature reported MICs will also be overviewed.  
1.7.2. Side chain 
 Much of the current up to date work has been performed on the prenyl side chain of 
fusidic acid. The literature suggests that heteroatoms including positively charged nitrogens are 
detrimental to the antibacterial activity of fusidic.66, 78 Figure 1.7 shows that indeed positively 
charged nitrogens (1-1–1-3) are detrimental to antibacterial activity as well as several 




















are not tolerated. Acid 1-5 regains some activity when converted to methyl ester 1-6 but is still 
inactive. Epoxidation (1-7) and dihydroxylation (1-8) lead to inactive derivatives. Furthermore, 
oxidation of both prenyl methyl groups leads to inactive tetraol 1-9. Some oxidations are 
moderately tolerated on the side-chain, while others are extremely tolerated. Aldehyde 1-10 is 
slightly active while methyl ester 1-11 and aniline 1-12 are moderately active. Alcohol 1-13 is 
moderately active but becomes very active when methylated (1-14). Surprisingly, primary 
alcohol 1-15 has an MIC = 1 µg/mL. 
 
Figure 1.7. Inactive side chain derivatives of fusidic acid. In-house MIC data. Compounds 
synthesized by Martin Garcia-Chavez. All compound MIC determined by Alfredo Garcia. MICs 
in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. 
 
 Simple hydrocarbon incorporation onto the side chain led to fusidic acid derivatives that 
were active and some that were as active as fusidic acid. Figure 1.8 shows the structure and 
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activity of these side chain derivatives. Terminal olefin 1-16 is only slightly active while olefin-
reduced derivative 1-17 retains most of the activity, suggesting that the trisubstituted olefin of 
fusidic acid is not absolutely necessary. In addition, cyclopentene 1-18 and cyclohexene 1-19 are 
as active as fusidic acid in S. aureus. Derivative 1-19 is more active than fusidic acid in E. coli 
with an MIC = 256 µg/mL. 
 
Figure 1.8. Aliphatic side chain derivatives. In-house MIC data. Compounds synthesized by 
Martin Garcia-Chavez. All compound MIC determined by Alfredo Garcia. MICs in µg/mL; n = 
3. S. aureus ATCC 29213 and E. coli MG1655. 
 
1.7.3. Carboxylic acid 
 The carboxylic acid of fusidic acid is essential for antibacterial activity. All antibacterial 
activity is vanquished when carboxylic acid is methylated (1-20), or converted into primary 
amide 1-21 and amino amide 1-22 (Figure 1.9). There has been work on generating bioisosteres 
for the carboxylic acid of fusidic acid for antiplasmodial activity. However, none of these 
derivatives were assessed in S. aureus for antibacterial activity.83 A few of these bioisosteres 
from the previously mentioned publication were synthesized and tested in both S. aureus and E. 
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Figure 1.9. Carboxylic acid derivatives. Carboxylic acid is important for activity. In-house MIC 
data. Compounds synthesized by Martin Garcia-Chavez. All compound MIC determined by 
Alfredo Garcia. MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. 
 
1.7.4. A-ring 
 Modifications to the A-ring hydroxyl group result in compounds that are less active than 
fusidic acid (Figure 1.10). Azide 1-23 and amine 1-24 contain an inverted stereocenter and are 
inactive. The epimers with the same stereochemical configuration as fusidic acid for these two 
compounds have been reported in the literature to be inactive (IC50).66 Oxidation of the A-ring 
hydroxyl (and C-ring) also leads to inactive diketone 1-25. Finally, the A-ring does not tolerate 
ring expansion, as cyclic lactam 1-26 is inactive in S. aureus. 
 
Figure 1.10. A-ring modifications to fusidic acid. In-house MIC data. Compounds 1-25 and 1-26 
synthesized by Martin Garcia-Chavez. All compound MIC determined by Alfredo Garcia. MICs 
in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. 
 
1.7.5. B-ring and D-ring 
Modification of the B-ring via oxidation has been previously reported using 
microbiological processes (Figure 1.11).66, 81 Triol 1-27 has been reported to retain only 10% of 
anti-staphylococcal activity but is twice as active as fusidic acid in S. pyogenes.66 Ketone 1-28 
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and alpha hydroxyl ketone 1-29 are completely inactive. There is no SAR data for the D-ring 
except for modifications to the acyl group, which will be covered in section 1.5.7. 
 
Figure 1.11. Literature B-ring oxidations. No MIC data reported for these structures. 
1.7.6. C-ring 
 Modification of the C-ring hydroxyl leads to derivatives that retain partial activity and 
some that are completely inactive (Figure 1.12). Substitution of the hydroxyl group (and reduced 
trisubstituted olefin) for an amine leads to loss of activity (1-30). Amine epimer 1-31 at the same 
position is inactive as well as its N-dimethylated analogue 1-32. Oxidation of the hydroxyl group 
leads to ketone 1-33, which retains much of the activity in S. aureus MIC = 0.5 µg/mL. 
Formation of an ether bridge between the C-ring hydroxyl and the 1,5 methyl group leads to 1-
34, which retains all activity in S. aureus and only loses 2-fold activity in E. coli. Modifications 
via oxidation to the position alpha to the hydroxyl group are known but no MIC data is 
reported.66 













































Figure 1.12. C-ring modifications of fusidic acid. Compound 1-33 was synthesized by Martin 
Garcia. All compounds MIC determined by Alfredo Garcia. MICs in µg/mL; n = 3. S. aureus 
ATCC 29213 and E. coli MG1655. 
 
1.7.7. Acetoxy group 
 The acetoxy group has been extensively modified in the literature.66 Different types of 
amides have been formed as well as ethers that lead to compounds that retain much of the 
activity of fusidic acid (IC50).66 Thioacetoxy derivatives exist that are claimed to be more potent 
than fusidic acid.66 However, no MIC data or synthetic procedures exist for many of these 
derivatives. Figure 1.13 shows that cleavage of the acetoxy group leads to complete inactivity (1-
35). Substitution of the acetoxy group with an alpha azido ketone leads to 1-36, which is 
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Figure 1.13. Modifications to the acetoxy group of fusidic acid. In-house data. MICs in µg/mL; 
n = 3. S. aureus ATCC 29213 and E. coli MG1655. 
 
1.7.8. Tetrasubstituted olefin 
 The literature reports that switching the stereochemical configuration of the 
tetrasubstituted olefin leads to an inactive derivative.84 Duvold et al. reported the synthesis of 
two of the four diastereomers of the reduced, tetrasubstituted olefin, and reported MIC data for 3 
out of the 4 (Figure 1.14).84 Derivative 17R, 20S-tetrahydrofusidic acid (1-38) was moderately 
active while 17R, 20R-tetrahydrofusidic acid (1-39) had “little or no antibiotic activity.” 
Derivative 17S, 20R-tetrahydrofusidic acid (1-40) was synthesized by Duvold et al. and 
exhibited no activity. The final derivative, 17S, 20S-tetrahydrofusidic acid (1-41) retained the 
activity in S. aureus and several other Gram-positive strains. Conformational modeling of these 
four analogues suggested that the side chain and carboxyl group in only 1-41 were in the same 
active bio conformation as in the fusidic acid side chain and carboxyl group. 
 
Figure 1.14. Tetrahydofusidic acid derivatives. MICs in µg/mL. S. aureus ATCC 29213 and E. 
coli HA 44. Numbers in parenthesis represent the concentration interval containing the real MIC 
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1.7.9. Summary of SAR 
 
The updated SAR of fusidic acid is nicely summarized in Figure 1.15. Some oxidation at 
the A-ring hydroxyl is tolerated. Positively charged amines are not tolerated at this position. Ring 
expansion of the A-ring via a 7-membered ring lactam is leads to inactivity. Oxidative 
modifications to the B-ring are only active in S. pyogenes and not S. aureus.66 The C-ring 
tolerates oxidation at the hydroxyl group but not either epimer of the primary amine. Bridged 
ethers to the C-ring methyl group are well tolerated. Derivatives for the D-ring acyl group can 
vary but there must be some functionality on the hydroxyl group. Positively charged nitrogens 
are not tolerated on the acyl moiety. Only one diastereomer (S,S) of the tetrasubstituted olefin 
leads to an active derivative of fusidic acid.84 The carboxylic acid is essential to antibacterial 
activity and no suitable bioisostere in bacteria has been found to date. The side chain can tolerate 
some functionality changes. The trisubstituted olefin is not required for activity, but addition of 
oxygen or nitrogen heteroatoms across this double bond leads to inactivity. Some oxidative 
cleavage products of the olefin are tolerated as well as some allylic functionality of the methyl 
groups present on the prenyl moiety. This updated SAR on fusidic acid will provide insight on 




Figure 1.15. Structure-activity relationship of fusidic acid. 
1.8. Summary and conclusion 
The rise of antimicrobial resistant is a pressing concern throughout the U. S. and across 
the world. Approaches to efficiently combat these infections are in dire need as new strains of 
bacteria are emerging that are resistant to last line of defense antibiotics. The eNTRy rules were 
developed by the Hergenrother lab to parameterize the necessary properties that dictate 
compound accumulation in Gram-negative bacteria. Application of the eNTRy rules has led to 
conversion of Gram-positive only antibiotics into broad-spectrum agents. While this is a 
powerful strategy with a track record of success, this relies on meticulous selection of good 
conversion candidates and can sometimes lead to long synthetic campaigns ultimately resulting 
in derivatives where accumulation has been enhanced, but no longer engage with their target 
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is a promising approach to funnel potential drug candidates through the outer membrane. Several 
companies have taken advantage of the self-promoted uptake pathway to generate broad-
spectrum leads. As with the eNTRy rule approach, this can sometimes lead to inactive 
derivatives due to lack of target engagement as a result of excess positive charge. A 
complimentary strategy involves taking advantage of the prodrug approach to exploit the self-
promoted uptake pathway to delivery an active antibiotic across the outer membrane of Gram-
negative bacteria. This approach would require a polycationic promoiety. The SAR of Gram-
positive only fusidic acid revealed several suitable modification sites. A polycationic prodrug 
approach to convert fusidic acid into a broad-spectrum agent is described in Chapter 3.  
1.9. Methods and characterization 
 Methods and characterization for in-house generated compounds described in this chapter 
will be characterized in chapter 3 along with all other fusidic acid derivatives. Characterization 
data for compounds synthesized by Martin Garcia-Chavez is not provided in this thesis. 
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CHAPTER 2: RING DISTROTION SINOMENINE AND APPLICATION TO ENTRY 
RULES 
 Portions of this chapter are reprinted with permission from Garcia, A.; Drown, B. S.; 
Hergenrother, P. J., Access to a structurally complex compound collection via ring distortion of 
the alkaloid sinomenine. Org. Lett. 2016, 18, 4852–4855, © 2016 American Chemical Society. 
and Richter, M. F.; Drown, B.S.; Riley, A.P.; Garcia, A.; Shirai, T.; Svec, R.L.; Hergenrother, P. 
J., Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 2017, 545, 
299–304, © 2017 Springer Nature. Contributions of others are noted where applicable. 
2.1. Introduction 
2.1.1. High-throughput screening (HTS) in drug discovery 
 High-throughput screening (HTS) is the primary method for lead generation in drug 
discovery.1 In fact, 90% of first-in-class drugs from 1999 to 2008 originated from a screen. 
Compounds found in HTS libraries have been heavily scrutinized, as they are mostly flat, 
aromatic, and contain a low percentage of sp3 hybridization.2 Such small-molecules have been 
successful in providing hits for targets that accommodate these structures (e.g., ATP binding site 
for kinase inhibition3 certain tubulin binders4-5) but are less optimal for other targets such as 
protein–protein interactions.6-9 Several strategies have been developed to populate screening 
collections with complex compounds including diversity-oriented synthesis (DOS),10-15 biology-
oriented synthesis (BIOS),16 and construction of natural product inspired scaffolds.17-21 
2.1.2 Complexity-to-diversity (CtD) 
 We have previously developed a strategy for generation of complex and diverse 
compounds to supplement those already found in standard screening collections. Complexity-to-
diversity (CtD) has been coined to describe our strategy in which we identify inexpensive, 
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readily available, and complex natural products and subject them to a series of ring distortion 
reactions to arrive at compounds with different scaffolds.22-27 This strategy has been applied to 
the natural products gibberellic acid,22 adrenosterone,22 quinine,22 abietic acid,23 pleuromutilin,24, 
28 sinomenine,25 and lycorine.26 To date, compounds generated through CtD (>700) have been 
critical for developing predictive guidelines for compound accumulation in Gram-negative 
bacteria (eNTRy rules),29-30 development of a tool compound for studying ferroptosis,28 and are 
currently being used for developing guidelines for blood-brain barrier (BBB) penetrance. With 
this impressive track record of scientific discovery, CtD has proven to be an elite method for 
rapid construction of complex and diverse small-molecule compound collections. As such, 
efforts in subjecting other suitable natural products through the CtD approach are ongoing in the 
Hergenrother lab. This chapter will focus on the ring distortion of the alkaloid sinomenine using 
the CtD approach.25 
2.2. Synthesis of complex compound collection from sinomenine via ring distortion 
2.2.1. Sinomenine 
 Sinomenine (S1) is isolated from the roots and stems of the plant Sinomenium acutum, 
native to Japan and China (first isolation reported in 1920).31 It is clinically approved in Asia for 
the treatment of rheumatoid arthritis and possesses immunosuppressive, anti-inflammatory, and 
anticancer properties.32-34 Structurally, it contains four fused rings and three contiguous 
stereocenters. Functionally, the core contains an anisole, tertiary amine, enol ether, and a ketone 
(Figure 2.1). These groups provide access to three of the four rings in the alkaloid and establish 
sinomenine as an outstanding candidate for subjection to CtD. Furthermore, it is inexpensive and 




Figure 2.1. Chemical structure of sinomenine and key functional groups. 
2.2.2. Strategy for ring distortion of sinomenine 
 There are several known chemical transformations that guided our design of synthetic 
routes to novel scaffolds from sinomenine (Scheme 2.1). These reactions include hydrolysis of 
the enol ether of S1 to diketone S233 and oxidative dearomatization of S1•HCl to yield p-quinone 
methide S3.35 Quinoxaline S4 was generated by condensing diketone S2 with o-
phenylenediamine.33 Treatment of S3 with different nucleophiles leads to several catechols (S5) 
substituted at the benzylic position.35 These known derivatives, along with anticipated reactivity 
of the other functional groups on sinomenine, provided strategic entry points into the ring 
system. A summary of routes and step counts to S6–S22 from S1 is provided in Scheme 2.2. 
 



















































































Scheme 2.2. Overview of scaffolds generated from the alkaloid sinomenine. 
2.2.3. Scaffolds generated through keto-enamine derivative S23 
 The synthesis of novel scaffolds from S1 began with treatment of S1 with hydrochloric 
acid and ammonium hydroxide to yield keto-enamine S23 (Scheme 2.3). We envisioned S23 as a 
key intermediate for ring distortions using oxidative cleavage and through formation of 
quinoxaline S4. Keto-enamine S23 was treated with lead tetracetate to yield nitrile ester S6 and 
resulting in a ring fusion and ring cleavage. Isolation of a single diastereomer of S6 suggests that 
the ring fusion event occurred before the oxidative cleavage. Lithium aluminum hydride 
reduction of S6 afforded amino alcohol S24 in excellent yield. Exposure to triphosgene led to a 
ring fusion resulting in 9-membered cyclic carbamate S7. Hoffmann-type elimination of S4 to 
realize a ring cleavage event was envisioned. Treatment of S4 with iodomethane followed by 
potassium carbonate led to an expected cleavage (S8) and a ring fusion of the A-ring anisole to 
the C-ring followed by a ring cleavage (S9). Formation of S9 is an unconventional 
transformation and is believed to involve an unidentified autoxidation36 event that ultimately 

















































































































































































Scheme 2.3. New scaffolds through intermediate S23. 
2.2.4. Scaffolds generated through catechol S25 
Catechol S2535 was identified as an intermediate for construction of various novel 
scaffolds from S1 (Scheme 2.4). Oxidation of the HCl salt of 1 with diacetoxyiodobenzene in 
water led to crude p-quinone methide S3, which was dissolved in methanol to generate S25 as a 
single diastereomer. Oxidative dearomatization of S25 using sodium periodate in methanol led to 
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produce diester S10 and its N-demethylated analogue S27. Catechols are known to react with 
dihalides to produce benzodioxoles.37 With this in mind, S25 was treated with dibromomethane 
and potassium carbonate to yield expected benzodioxole S11 and the oxidized variant, ketone 
S12. Subjection of S11 to Schmidt reaction conditions led to ring expanded 7-membered lactam 
S13. The reaction conditions also led to stereoretentive displacement of the methoxy group by 





Scheme 2.4. New scaffolds through intermediate S25. 
2.2.5 Other C and D-ring distortions 
 Further key manipulations of the C and D rings are shown in Scheme 2.5. Tosyl oxime 
S29 was easily synthesized from S1 in two short steps. Beckmann rearrangement of S29 with 
NaOH led to unexpected ring fused compound S15, which was characterized by X-ray 

























































S10; R = Me, 30% yield
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azirine intermediate is formed.38-39 Interestingly, S15 closely resembles the structure of (+)-
morphine. It is well known that treatment of (–)-morphine with methanesulfonic acid leads to 
apomorphine. Therefore, similar reaction conditions were used to arrive at ring rearranged and 
ring aromatized S16 that is the enantiomer of the apomorphine scaffold. Ring contracted S17 
was also isolated from the reaction mixture, which likely formed through a benzylic acid-type 
rearrangement. 
 
Scheme 2.5. Distortion of C and D ring system. 
2.2.6. Cepharatine A, sinoracutine, and other derivatives 
 Finally, the Schmidt reaction of the A-ring and the C-ring Hofmann-type ring opening 
were further utilized to arrive at other complex scaffolds from S1. In the presence of 
diacetoxyiodobenzene, S1 could be oxidized at the benzylic position to yield ketone S30 
(Scheme 2.6).35 Schmidt reaction of S30 lead to a chemoselective ring expansion of the C-ring 
(S18), which was followed by a Hofmann-type elimination to provide S19. Given this success, a 
direct ring cleavage was envisioned from S1. Unexpectedly, treatment of S1 with iodomethane 
































































by X-ray crystallography. N-oxidation of S20 was performed followed an iron-mediated 
demethylation to afford secondary amine S31. Exposure of S31 to HCl led to another alkyl shift 
and ring closure to arrive at known natural products cepharatine A (S21)40 and ring contracted 
sinoracutine (S22)41 in one pot. Cepharatine A42 and sinoracutine43 have been previously 
synthesized, but this 5-step, one-pot semi-synthesis from S1 reported herein is the shortest 
synthesis of both of these natural products reported to date. 
 
Scheme 2.6. Synthesis of S19, cepharatine A, and sinoracutine. 
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2.2.8. Figure of full 66 compound set from sinomenine 
 



































































































































































































































































































































































































































































































































2.3. Complexity and diversity analysis of the sinomenine collection 
2.3.1. Quantifying the molecular complexity of the sinomenine collection 
 Chemoinformatic diversity analysis was used to compare this collection to a 
commercially available screening collection. The set of 66 compounds (including sinomenine) 
contains the following complexity parameters (average): Fsp3 = 0.48, number of stereogenic 
centers = 3.1, ring fusion density44 = 0.37, ring complexity index = 1.40, and Glob45 = 0.36, 
which are markedly higher in value compared to Chembridge compounds (combined Diverset-
CL and Diverset-EXP) Fsp3 = 0.38, number of stereogenic centers = 0.55, ring fusion density = 
0.06, ring complexity index = 1.06, and Glob = 0.08 (Figure 2.3). 
 
Figure 2.3. Box plots comparing structural complexity of commercial libraries and the 66 
sinomenine-derived compounds (including sinomenine) from Figure 2.2. Box represents 
quartiles, whiskers represent 1st and 99th percentiles, and dot represents mean. Dvs-Cl = 




2.3.2. Quantifying the structural diversity of the sinomenine collection 
 The structural diversity of sinomenine derivatives was assessed by comparing the 
extended connectivity fingerprints46 using Tanimoto similarity coefficients.47 Extended 
connectivity fingerprints (ECFP) represent compounds as numerical fingerprints in which each 
atom of a compound contains a unique fingerprint that contains information about its atomic 
properties. Two compounds can be compared using these fingerprints to generate Tanimoto 
similarity coefficients. Identical compounds receive a score of 1 whereas compounds with no 
similar fingerprints receive a score of 0. The fingerprints in our analysis were generated in 
Canvas (Schrodinger, New York) using ECFP_6 three-bond radial fingerprints with Daylight 
invariant atom types. Atoms were distinguished by bond order. Tanimoto coefficients were 
calculated in Canvas for each pairwise combination. Heat maps were generated in Excel 
(Microsoft, Redmond WA) using the color scheme (3-color) set to 0 (R = 91, G = 139, B = 197), 
0.5 (R = 252, G = 253, B = 133), 1.0 (R = 248, G = 107, B = 107). 
 In the analysis of sinomenine compounds, Tanimoto coefficients were generated for the 
16 diverse scaffolds and sinomenine (Figure 2.4) and for the full 66 compound set (including 
sinomenine) shown in Figure 2.5. The structural diversity between all the compounds in Figures 
2.4 and 2.5 is clearly apparent with the low Tanimoto coefficients, as only the diagonal is 




Figure 2.4. Tanimoto similarity coefficients for 16 diverse scaffolds from sinomenine. 
 
Figure 2.5. Tanimoto similarity coefficients for full 66 compound collection from sinomenine. 
2.4. Application of sinomenine derivatives for discovery of eNTRy rules 
2.4.1. Sinomenine derivatives help identify importance of Glob for accumulation 
 A total of 15 sinomenine derivatives were used in the initial test set of 100 compounds 




	 S1	 S6	 S7	 S8	 S9	 S10	 S11	 S13	 S14	 S15	 S16	 S17	 S18	 S19	 S20	 S21	 S22	
S1	 1.00	 0.29	 0.27	 0.20	 0.15	 0.24	 0.38	 0.24	 0.22	 0.34	 0.18	 0.29	 0.36	 0.27	 0.24	 0.24	 0.29	
S6	 0.29	 1.00	 0.40	 0.13	 0.20	 0.13	 0.19	 0.17	 0.17	 0.43	 0.15	 0.43	 0.20	 0.17	 0.17	 0.17	 0.20	
S7	 0.27	 0.40	 1.00	 0.13	 0.20	 0.11	 0.17	 0.17	 0.15	 0.40	 0.15	 0.45	 0.19	 0.17	 0.15	 0.16	 0.20	
S8	 0.20	 0.13	 0.13	 1.00	 0.33	 0.08	 0.12	 0.12	 0.19	 0.14	 0.13	 0.13	 0.19	 0.27	 0.24	 0.32	 0.33	
S9	 0.15	 0.20	 0.20	 0.33	 1.00	 0.08	 0.13	 0.13	 0.15	 0.21	 0.13	 0.20	 0.14	 0.16	 0.18	 0.18	 0.20	
S10	 0.24	 0.13	 0.11	 0.08	 0.08	 1.00	 0.26	 0.20	 0.16	 0.17	 0.07	 0.13	 0.19	 0.14	 0.13	 0.10	 0.14	
S11	 0.38	 0.19	 0.17	 0.12	 0.13	 0.26	 1.00	 0.45	 0.32	 0.23	 0.11	 0.19	 0.26	 0.18	 0.17	 0.15	 0.19	
S13	 0.24	 0.17	 0.17	 0.12	 0.13	 0.20	 0.45	 1.00	 0.27	 0.21	 0.11	 0.17	 0.38	 0.21	 0.16	 0.14	 0.18	
S14	 0.22	 0.17	 0.15	 0.19	 0.15	 0.16	 0.32	 0.27	 1.00	 0.20	 0.10	 0.17	 0.20	 0.42	 0.22	 0.18	 0.19	
S15	 0.34	 0.43	 0.40	 0.14	 0.21	 0.17	 0.23	 0.21	 0.20	 1.00	 0.16	 0.43	 0.24	 0.21	 0.20	 0.18	 0.22	
S16	 0.18	 0.15	 0.15	 0.13	 0.13	 0.07	 0.11	 0.11	 0.10	 0.16	 1.00	 0.15	 0.15	 0.14	 0.14	 0.14	 0.17	
S17	 0.29	 0.43	 0.45	 0.13	 0.20	 0.13	 0.19	 0.17	 0.17	 0.43	 0.15	 1.00	 0.20	 0.17	 0.17	 0.17	 0.20	
S18	 0.36	 0.20	 0.19	 0.19	 0.14	 0.19	 0.26	 0.38	 0.20	 0.24	 0.15	 0.20	 1.00	 0.36	 0.24	 0.24	 0.28	
S19	 0.27	 0.17	 0.17	 0.27	 0.16	 0.14	 0.18	 0.21	 0.42	 0.21	 0.14	 0.17	 0.36	 1.00	 0.29	 0.27	 0.28	
S20	 0.24	 0.17	 0.15	 0.24	 0.18	 0.13	 0.17	 0.16	 0.22	 0.20	 0.14	 0.17	 0.24	 0.29	 1.00	 0.27	 0.28	
S21	 0.24	 0.17	 0.16	 0.32	 0.18	 0.10	 0.15	 0.14	 0.18	 0.18	 0.14	 0.17	 0.24	 0.27	 0.27	 1.00	 0.42	
S22	 0.29	 0.20	 0.20	 0.33	 0.20	 0.14	 0.19	 0.18	 0.19	 0.22	 0.17	 0.20	 0.28	 0.28	 0.28	 0.42	 1.00	
1.00 0.00 0.50 
		 S1	 S3	 S4	 S5	 S6	 S7	 S8	 S9	 S10	 S11	 S12	 S13	 S14	 S15	 S16	 S17	 S18	 S19	 S20	 S21	 S22	 S23	 S24	 S25	 S26	 S27	 S28	 S29	 S30	 S31	 S32	 S33	 S34	 S35	 S36	 S37	 S38	 S39	 S40	 S41	 S42	 S43	 S44	 S45	 S46	 S47	 S48	 S49	 S50	 S51	 S52	 S53	 S54	 S55	 S56	 S57	 S58	 S59	 S60	 S61	 S62	 S63	 S64	 S65	 S66	 S67	
S1	 1.00	 0.26	 0.39	 0.29	 0.27	 0.20	 0.15	 0.24	 0.38	 0.39	 0.24	 0.22	 0.34	 0.18	 0.29	 0.36	 0.27	 0.24	 0.24	 0.29	 0.40	 0.24	 0.41	 0.25	 0.19	 0.36	 0.59	 0.52	 0.21	 0.23	 0.24	 0.25	 0.44	 0.40	 0.38	 0.32	 0.41	 0.42	 0.39	 0.41	 0.32	 0.28	 0.29	 0.27	 0.34	 0.25	 0.71	 0.43	 0.55	 0.57	 0.50	 0.38	 0.37	 0.51	 0.49	 0.49	 0.28	 0.56	 0.35	 0.27	 0.27	 0.21	 0.44	 0.16	 0.64	 0.21	
S3	 0.26	 1.00	 0.10	 0.13	 0.12	 0.10	 0.08	 0.35	 0.24	 0.25	 0.17	 0.17	 0.17	 0.08	 0.13	 0.20	 0.14	 0.16	 0.13	 0.16	 0.17	 0.11	 0.26	 0.38	 0.27	 0.23	 0.17	 0.26	 0.13	 0.35	 0.37	 0.38	 0.25	 0.21	 0.19	 0.17	 0.20	 0.21	 0.20	 0.21	 0.18	 0.15	 0.15	 0.15	 0.18	 0.17	 0.19	 0.11	 0.20	 0.21	 0.20	 0.24	 0.23	 0.26	 0.25	 0.18	 0.16	 0.21	 0.18	 0.18	 0.19	 0.14	 0.11	 0.20	 0.20	 0.13	
S4	 0.39	 0.10	 1.00	 0.27	 0.22	 0.32	 0.26	 0.09	 0.15	 0.16	 0.15	 0.11	 0.23	 0.18	 0.23	 0.23	 0.19	 0.16	 0.19	 0.23	 0.36	 0.22	 0.17	 0.09	 0.05	 0.15	 0.32	 0.24	 0.13	 0.09	 0.09	 0.09	 0.19	 0.23	 0.23	 0.19	 0.17	 0.18	 0.19	 0.18	 0.19	 0.16	 0.16	 0.17	 0.20	 0.16	 0.38	 0.45	 0.25	 0.26	 0.26	 0.15	 0.15	 0.23	 0.22	 0.24	 0.18	 0.26	 0.22	 0.16	 0.16	 0.17	 0.46	 0.10	 0.38	 0.13	
S5	 0.29	 0.13	 0.27	 1.00	 0.40	 0.13	 0.20	 0.13	 0.19	 0.19	 0.17	 0.17	 0.43	 0.15	 0.43	 0.20	 0.17	 0.17	 0.17	 0.20	 0.34	 0.29	 0.16	 0.13	 0.09	 0.18	 0.23	 0.20	 0.14	 0.12	 0.13	 0.13	 0.18	 0.20	 0.18	 0.16	 0.15	 0.16	 0.15	 0.15	 0.18	 0.15	 0.15	 0.15	 0.17	 0.28	 0.26	 0.30	 0.20	 0.21	 0.19	 0.15	 0.18	 0.20	 0.19	 0.18	 0.16	 0.20	 0.20	 0.21	 0.18	 0.19	 0.30	 0.13	 0.28	 0.14	
S6	 0.27	 0.12	 0.22	 0.40	 1.00	 0.13	 0.20	 0.11	 0.17	 0.17	 0.17	 0.15	 0.40	 0.15	 0.45	 0.19	 0.17	 0.15	 0.16	 0.20	 0.27	 0.33	 0.15	 0.12	 0.08	 0.16	 0.22	 0.19	 0.14	 0.11	 0.12	 0.12	 0.16	 0.18	 0.16	 0.15	 0.14	 0.15	 0.15	 0.14	 0.16	 0.13	 0.15	 0.15	 0.16	 0.26	 0.24	 0.24	 0.19	 0.20	 0.19	 0.14	 0.17	 0.18	 0.18	 0.17	 0.15	 0.19	 0.18	 0.19	 0.18	 0.17	 0.25	 0.11	 0.27	 0.12	
S7	 0.20	 0.10	 0.32	 0.13	 0.13	 1.00	 0.33	 0.08	 0.12	 0.13	 0.12	 0.19	 0.14	 0.13	 0.13	 0.19	 0.27	 0.24	 0.32	 0.33	 0.20	 0.14	 0.14	 0.08	 0.06	 0.13	 0.17	 0.20	 0.19	 0.08	 0.09	 0.08	 0.16	 0.19	 0.19	 0.17	 0.17	 0.17	 0.17	 0.17	 0.28	 0.19	 0.20	 0.21	 0.17	 0.14	 0.20	 0.18	 0.17	 0.17	 0.17	 0.13	 0.12	 0.20	 0.19	 0.16	 0.22	 0.17	 0.27	 0.13	 0.13	 0.12	 0.19	 0.09	 0.19	 0.18	
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elaboration on eNTRy rules).29-30 Furthermore, primary amines were installed on a portion of the 
fusidic acid scaffolds upon identification of positive charge as important for accumulation.  A 
total of 5 compounds from the sinomenine collection containing an amine (other than the tertiary 
amine already present in sinomenine) were synthesized (Scheme 2.7) and further evaluated in the 
accumulation assay (Figure 2.6A). Globularity (Glob) was identified as being important for 
accumulation in E. coli using this test set and derivatives from other natural products. It is 
apparent if Figure 2.6A that the amine-containing sinomenine derivatives (S40, S63-S65) that 
possess a high Glob (> 0.25) do not accumulate whereas S31 which exhibits a low Glob (0.21) 
does indeed accumulate in E. coli. The difference in Glob is more visually apparent in Figure 
2.6B where compounds S40 and S41 are shown in a 3-dimentional confirmation. Non-
accumulating, higher Glob containing compound S40 appears more spherical whereas S31 is 
more flat-like, possess a lower Glob, and does accumulate in our assay.29  
 
Figure 2.6. A) Amine containing sinomenine derivatives accumulate in E. coli when Glob < 
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 In summary, sinomenine was subjected to our CtD ring distortion strategy to ultimately 
generate a compound collection of 16 scaffolds and 65 total compounds.25 A combination of ring 
expansion, fusion, contraction, aromatization, dearomatization, and rearrangement were used to 
carry out this project. The complete list of compounds is shown in Figure 2.2. The compounds 
reported in this chapter played a key role in developing the eNTRy rules, specifically in 
identifying the Glob parameter.29-30 
 Complex molecules are different from and complimentary to compounds in traditional 
screening collections. As we have demonstrated previously with gibberellic acid,22 
adrenosterone,22 quinine,22 abietic acid,23 pleuromutilin,24, 28 lycorine,26 and here with 
sinomenine,25 natural products are an outstanding starting point for the construction of complex 
and diverse small molecules. 
2.6. Methods and characterization 
2.6.1 General considerations 
Sinomenine was purchased from LKT Laboratories, Inc. as the hydrochloride salt. To 
obtain the free base, sinomenine hydrochloride was dissolved in a saturated aqueous solution of 
sodium bicarbonate, extracted with dicloromethane, and concentrated in vacuo. Other chemical 
reagents were purchased from commercial sources and used without further purification. 
Anhydrous solvents used during these studies were dried after being passed through columns 
with activated alumina. Flash chromatography was performed using silica gel (230–400 mesh). 
Various NMR experiments (including 2-D) were conducted in the NMR facilities at 
UIUC. 1H NMR and 13C NMR experiments were recorded on Varian Unity spectrometers at 500 
MHz and 125 Hz, respectively unless otherwise indicated. Spectra were obtained in the 
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following solvents (reference peaks also included for 1H and 13C NMRs): CDCl3 (1H NMR: 7.26 
ppm; 13C NMR: 77.26 ppm), d6-acetone (1H NMR: 2.05 ppm; 13C NMR: 206.26 ppm), CD3OD 
(1H NMR: 3.30 ppm; 13C NMR: 49.00 ppm), d7-DMF (1H NMR: 2.75 ppm; 13C NMR: 34.90 
ppm), D2O (1H NMR: 4.79 ppm), d6-DMSO (1H NMR: 2.50 ppm; 13C NMR: 39.52 ppm). NMR 
experiments were performed at room temperature unless otherwise indicated. Chemical shift 
values are reported in parts per million (ppm) for all 1H NMR and 13C NMR spectra. 1H NMR 
multiplicities are reported as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad.  
 High–resolution mass spectra were obtained using Waters Q-TOF Ultima ESI and 
Agilent 6230 ESI TOF LC/MS spectrometers. 
2.6.2. Accumulation Assay (Performed by Michelle Richter) 
 Procedure from Richter et al.:29 The accumulation assay was performed in triplicate in 
batches of ten samples, with each batch containing either tetracycline or ciprofloxacin as a 
positive control. E. coli MG1655 was used for these experiments as this strain has been only 
minimally altered from its K-12 progenitor33. For each replicate, 2.5 ml of an overnight culture 
of E. coli was diluted into 250 ml of fresh Luria Bertani (LB) broth (Lennox) and grown at 37 °C 
with shaking to an optical density (OD600) of 0.55. The bacteria were pelleted at 3,220 r.c.f. for 
10 min at 4 °C and the supernatant was discarded. The pellets were re-suspended in 40 ml of 
phosphate buffered saline (PBS) and pelleted as before, and the supernatant was discarded. The 
pellets were re-suspended in 8.8 mL of fresh PBS and aliquoted into ten 1.5 ml eppendorf tubes 
(875 µ l each). The number of colony-forming units (CFUs) was determined by a calibration 
curve. The samples were equilibrated at 37 °C with shaking for 5 min, compound was added 
(final concentration = 50 µ M), and then samples were incubated at 37 °C with shaking for 10 
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min. A 10 min time point was chosen because it is longer than the predicted amount of time 
required to reach a steady-state concentration34, but short enough to minimize metabolic and 
growth changes (no changes in OD600 observed; CFUs were reduced by a factor of five after 
ciprofloxacin treatment for 10 min, but no other antibiotics had an effect). After incubation, 800 
µ l of the cultures were carefully layered on 700 µ l of silicone oil (9:1 AR20/Sigma High 
Temperature, cooled to − 78 °C). Bacteria were pelleted through the oil by centrifuging at 13,000 
r.c.f. for 2 min at room temperature (supernatant remains above the oil); the supernatant and oil 
were then removed by pipetting. To lyse the samples, each pellet was dissolved in 200 µ l of 
water, and then they were subjected to three freeze-thaw cycle of three minutes in liquid nitrogen 
followed by three minutes in a water bath at 65 °C. The lysates was pelleted at 13,000 r.c.f. for 2 
min at room temperature and the supernatant was collected (180 µ l). The debris was re-
suspended in 100 µ l of methanol and pelleted as before. The supernatants were removed and 
combined with the previous supernatants collected. Finally, remaining debris was removed by 
centrifuging at 20,000 r.c.f. for 10 min at room temperature. Supernatants were analysed by LC–
MS/MS. Samples were analysed with the 5500 QTRAP LC/MS/MS system (AB Sciex) with a 
1200 series HPLC system (Agilent Technologies) including a degasser, an autosampler, and a 
binary pump. The liquid chromatography separation was performed on an Agilent SB-Aq 
column (4.6 Å~ 50 mm, 5 µ m) (Agilent Technologies) with mobile phase A (0.1% formic acid 
in water) and mobile phase B (0.1% formic acid in acetonitrile). The flow rate was 0.3 ml min−1. 
The linear gradient was as follows: 0–3 min, 100% mobile phase A; 10–15 min, 2% mobile 
phase A; 15.5– 21 min, 100% mobile phase A. The autosampler was set at 5 °C. The injection 
volume was 15 µ l. Mass spectra were acquired with both positive electrospray ionization at the 
ion spray voltage of 5,500 V and negative electrospray ionization at 
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 he ion spray voltage of − 4,500 V. The source temperature was 450 °C. The curtain gas, ion 
source gas 1, and ion source gas 2 were 33, 50 and 65, respectively. Multiple reaction monitoring 
was used to quantify metabolites. 
2.6.3 Ring distortion of sinomenine: synthesis and characterization 
Compound S3 
 
Procedure: In a vial with a stir bar, S1!HCl (719.6 mg, 1.967 mmol) was dissolved in water (15 
mL). Diacetoxyiodobenzene (771.5 mg, 2.395 mmol) was added to the reaction vial. The 
reaction mixture was stirred open to air for 1 hour and was then basified with a saturated solution 
of sodium carbonate. The contents of the vial were poured into a seperatory funnel and were 
extracted with dichloromethane (4x). The organic layers were combined, dried with sodium 
sulfate, and were concentrated under reduced pressure. The crude residue was purified by flash 
chromatography on silica gel (9:1 dichloromethane/methanol) to afford known quinone methide 
S3 (308.7 mg, 50% yield) as an orange solid. Spectral data (1H NMR) was consistent with 
literature reported values.35 
Compound S4 
 











































(10 mL). To this, o-phenylenediamine (261.3 mg, 2.417 mmol) was added and was allowed to 
stir for 15 hours capped under nitrogen. After this time, the reaction mixture was filtered and 
washed with water to afford the S4 as a white, waxy solid (311.3 mg, 61% yield). Spectral data 




Procedure: In a vial with a stir bar, keto-enamine S23 (82.3 mg, 0.2610 mmol) was dissolved in 
methanol (6 mL) and was cooled to 0 ºC in an ice/water bath. Lead (IV) tetracetate (410.6 mg, 
0.9260 mmol) was added to the vial and the mixture was allowed to stir in a closed vial at 0 ºC 
under nitrogen. After 40 min, ethylene glycol (2 mL) was added to the reaction along with a 
saturated solution of sodium bicarbonate. The contents were poured into a seperatory funnel and 
were extracted with dichloromethane (3x). The organic layers were combined, dried with sodium 
sulfate, and concentrated under reduced pressure. The crude residue was purified by silica gel 
chromatography (15:1 dichloromethane/methanol) to afford S6 (46.5 mg, 52% yield) as a light 
brown solid. 
1H NMR (CDCl3, 500 MHz): δ 6.76 (d, J = 8.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 5.13 (s, 1H), 
3.84 (s, 3H), 3.62 (s, 3H), 3.12 (dd, J = 6.1, 2.9 Hz, 1H), 3.08 (d, J = 16.3 Hz, 1H), 3.05–3.01 
(m, 1H), 2.92 (d, J = 18.8 Hz, 1H), 2.52–2.44 (m, 2H), 2.34 (s, 3H), 2.13 (td, J = 12.2, 2.9 Hz, 






















13C NMR (CDCl3, 125 MHz): δ 172.8, 143.8, 143.0, 127.1, 126.8, 121.3, 116.9, 114.5, 79.0, 
60.1, 56.7, 52.1, 49.0, 46.5, 42.8, 39.0, 37.7, 33.1, 19.6. 




Procedure: In a vial with a stir bar, amino alcohol S24 (14.8 mg, 0.0466 mmol) was dissolved in 
pyridine (6 mL). The reaction mixture was cooled to 0 ºC in an ice/water bath. After 10 minutes, 
1H NMR signals for 6 13C NMR signals for 6
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triphosgene (18.1 mg, 0.0610 mmol) was added to the reaction and the contents of the vial were 
capped under nitrogen and were stirred for 12 hours. The reaction was diluted with a saturated 
solution of sodium carbonate and water and was extracted with dichloromethane (3x). The 
organic layers were combined, dried over sodium sulfate, and concentrated under reduced 
pressure. The crude residue was purified by silica gel chromatography (9:1 
dichloromethane/methanol) to afford carbamate S7 (3.5 mg, 22% yield) as a white solid. 
1H NMR (d7-DMF, 80 ºC, 500 MHz): δ 7.01 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.62 
(d, J = 8.1 Hz, 1H), 4.65 (dd, J = 11.6, 4.6 Hz, 1H), 4.31 (t, J = 12.0 Hz, 1H), 4.11–4.03 (m, 1H), 
3.99 (dt, J = 11.8, 3.0 Hz, 1H), 3.83 (s, 3H), 3.34 (dt, J = 14.3, 3.1 Hz, 1H), 3.06–3.02 (m, 1H), 
2.85 (d, J = 18.9 Hz, 1H), 2.51 (dd, J = 18.6, 6.4 Hz, 1H), 2.43 (dt, J = 4.5, 3.2 Hz, 1H), 2.37 
(dd, J = 11.8, 4.3 Hz, 1H), 2.30 (s, 3H), 2.16 (td, J = 12.2, 3.3 Hz, 1H), 2.02 (td, J = 12.5, 4.9 Hz, 
1H), 1.59–1.50 (m, 2H), 1.14 (dt, J = 16.2, 2.8  Hz, 1H). 
13C NMR (d7-DMF, 80 ºC, 125 MHz): δ 158.7, 146.8, 142.4, 130.0, 128.8, 119.2, 114.9, 94.8, 
69.6, 63.6, 56.8, 47.8, 46.2, 43.9, 43.1, 43.0, 42.4, 33.4, 19.8. 






















Compounds S8 and S9 
 
Procedure: In a round-bottom flask, the S4 (489.8 mg, 1.264 mmol) was dissolved in 
dichloromethane (25 mL). Iodomethane (0.30 mL, 4.819 mmol) was added into the vial and the 
contents were allowed to stir under a nitrogen atmosphere for 20 hours. After this time, the 
mixture was diluted with water, and allowed to stir for 30 minutes. The mixture was poured into 
a round bottom flask and concentrated under reduced pressure. The residue was transferred into a 
vial and was allowed to dry under a high vacuum. The reaction mixture was used directly for the 
next reaction. Acetonitrile (10 mL) was added to the solid to form a solution. Potassium 
carbonate (668.0 mg, 4.833 mmol) was subsequently added and the vial was capped and placed 
in an 80 ºC oil bath. After 6 hours, the mixture was concentrated under reduced pressure, diluted 
with water, and extracted with dichloromethane (4x). The organic layers were combined, dried 
with sodium sulfate, and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (15:1dichloromethane/methanol) on silica gel to afford compounds S8 
(16.4 mg, 3% yield) and S9 (20.2 mg, 4% yield) as orange solids. 
S8 
1H NMR (CDCl3, 500 MHz): δ 8.03–7.94 (m, 2H), 7.70–7.64 (m, 2H), 6.82 (d, J = 8.3 Hz, 1H), 
6.75 (d, J = 8.3 Hz, 1H), 6.75 (s, 1H), 6.56 (d, J = 9.5 Hz, 1H), 6.47 (d, J = 9.5 Hz, 1H), 4.95 (d, 
J = 17.0 Hz, 1H), 3.81 (s, 3H), 3.54 (d, J = 16.7 Hz, 1H), 2.96–2.87 (m, 2H), 2.67 (dd, J = 12.0, 
10.3 Hz, 1H), 2.42 (s, 6H), 1.89 (dd, J = 12.1, 6.8 Hz, 1H). 
1. MeI
    CH2Cl2
2. K2CO3
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13C NMR (CDCl3, 125 MHz): δ 152.2, 149.9, 148.6, 148.4, 144.8, 142.7, 141.5, 132.6, 129.7, 
129.4, 128.8, 128.7, 126.8, 125.4, 124.9, 121.5, 121.0, 110.1, 56.2, 54.1, 42.6 (2C), 41.3, 40.7, 
33.5.  
HRMS(ESI): m/z calc. for C25H26N3O2 [M+H]+: 400.2025, found: 400.2017. 
 
S9 
1H NMR (CDCl3, 500 MHz): δ 8.10 (dd, J = 7.9, 1.7 Hz, 1H), 7.96 (dd, J = 7.9, 1.7 Hz, 1H), 
7.77–7.69  (m, 2H), 6.75 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.62 (d, J = 8.8 Hz, 1H), 
6.12 (dd, J = 9.2, 6.0 Hz, 1H), 6.04 (s, 1H), 3.79 (s, 3H), 3.34 (td, J = 12.6, 4.5 Hz, 1H), 3.12 
(dd, J = 16.5, 4.6 Hz, 1H), 2.95 (dt, J = 12.5, 5.3 Hz, 1H), 2.77–2.68 (m, 2H), 2.67 (s, 6H), 2.66–
2.55 (m, 1H), 2.30 (td, J = 13.0, 4.5 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 152.5, 148.2, 145.8, 144.9, 142.3, 142.0, 131.1, 129.8, 129.7, 
129.6, 128.7, 125.7, 125.0, 123.9, 119.1, 113.4, 90.5, 56.2, 55.0, 46.2, 43.8 (2C), 38.6, 34.3, 
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HRMS(ESI): m/z calc. for C25H26N3O2 [M+H]+: 400.2025, found: 400.2019. 
 
Compounds S10 and S27 
 
Procedure: In a vial with a stir bar, o-quinone S26 (51.8 mg, 0.1387 mmol) was dissolved in 
methanol (10 mL). The reaction mixture was capped and stirred under N2. After 5 min, lead(IV) 
tetracetate (106.2 mg, 0.2395 mmol) was added to the solution. The mixture was stirred for 45 
min, quenched with ethylene glycol, and was diluted with saturated sodium bicarbonate. The 
contents of the vial were extracted with dichloromethane (4x). The organic layers were combined 
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and dried with Na2SO4 and were concentrated under reduced pressure. The residue was purified 
by column chromatography (9:1 dichloromethane/methanol) to yield compounds S10 (17.9 mg, 
30% yield) and 27 (5.1 mg, 9% yield) as light yellow solids. 
S10 
1H NMR (CDCl3, 500 MHz): δ 5.68 (d, J = 2.0 Hz, 1H), 5.14 (s, 1H), 4.06 (s, 1H), 3.62 (s, 3H), 
3.61 (s, 3H), 3.59 (s, 3H), 3.57 (s, 3H), 3.36 (s, 3H), 3.19 (d, J = 2.8 Hz, 1H), 2.98 (td, J = 12.2, 
2.6 Hz, 1H), 2.93 (t, J = 2.1 Hz, 1H), 2.80 (d, J = 16.8 Hz, 1H), 2.60–2.56 (m, 1H), 2.56 (s, 3H), 
2.42 (d, J = 16.8 Hz, 1H), 2.02 (ddd, J = 13.3, 2.9, 1.5 Hz, 1H), 1.74 (td, J = 12.8, 5.0 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 191.4, 169.7, 166.9, 166.6, 151.1,140.2, 134.7, 118.0, 94.0, 
71.7, 60.7, 59.0, 56.7, 55.2, 51.8, 51.2, 48.9, 45.9, 43.2, 42.5, 40.4, 36.1. 
HRMS(ESI): m/z calc. for C22H30NO8 [M+H]+: 436.1971, found: 436.1970. 
 
S27 
1H NMR (CDCl3, 500 MHz): δ 5.60 (d, J = 2.1 Hz, 1H), 5.17 (s, 1H), 4.28 (s, 1H), 4.13–4.02 
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(dd, J = 12.2, 2.5 Hz, 1H), 2.83 (d, J = 16.7 Hz, 1H), 2.58 (d, J = 16.9, 1H), 2.26 (dd, J = 13.3, 
2.3 Hz, 1H), 2.10 (td, J = 13.6, 3.7 Hz, 1H), 2.06 (bs, 1H). 
13C NMR (CDCl3, 125 MHz): δ 190.0, 168.9, 167.0, 165.9, 151.6, 139.1, 134.4, 114.2, 93.9, 
75.8, 60.5, 56.9, 55.4, 52.7, 52.1, 51.6, 47.8, 39.9, 39.3, 37.6, 32.9. 
HRMS(ESI): m/z calc. for C21H28NO8 [M+H]+: 422.1815, found: 422.1814. 
 
Compounds S11 and S12 
 
Procedure: In an oven-dried round bottom flask with a stir bar, the S25 (87 mg, 0.2519 mmol) 
was dissolved in N,N-dimethylformamide (8 mL). Potassium carbonate (202 mg, 1.462 mmol) 
was added to the mixture along with dibromomethane (0.5 mL, 7.191 mmol). The round bottom 
flask was attached to a reflux condenser and stirred at 80 ºC for 15 hours. The mixture was 
poured into a seperatory funnel, diluted with water and was extracted with dicloromethane (4x). 
The organic layers were combined, dried over sodium sulfate, and concentrated in vacuo. The 
crude residue was purified by silica gel chromatography (15:1 dichloromethane/methanol) to 























































1H NMR (CDCl3, 500 MHz): δ 6.82 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 5.91 (d, J = 
1.2 Hz, 1H), 5.84 (d, J = 1.2 Hz, 1H), 5.73 (d, J = 1.7 Hz, 1H), 4.18 (s, 1H), 3.85 (d, J = 16.0 Hz, 
1H), 3.51 (s, 3H), 3.46 (s, 3H), 3.32 (d, J = 2.7 Hz, 1H), 3.01 (t, J = 2.4 Hz, 1H), 2.54 (s, 3H), 
2.49 (ddd, J = 12.1, 4.8, 1.3 Hz, 1H), 2.44 (d, J = 16.1 Hz, 1H), 2.03 (td, J = 12.7, 3.3 Hz, 1H), 
1.86 (td, J = 12.5, 4.9 Hz, 1H), 1.67 (ddd, J = 12.6, 3.2, 1.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 193.2, 150.6, 147.7, 145.3, 132.0, 123.5, 119.8, 118.0, 107.5, 
100.9, 72.0, 59.0, 57.7, 54.9, 48.7, 46.7, 44.0, 43.0, 39.8, 36.9. 
HRMS(ESI): m/z calc. for C20H24NO5 [M+H]+: 358.1654, found: 358.1652. 
 
S12 
1H NMR (CDCl3, 500 MHz): δ 7.67 (d, J = 8.3 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.05 (d, J = 
1.3 Hz, 1H), 5.98 (d, J = 1.3 Hz, 1H), 5.37 (d, J = 2.1 Hz, 1H), 3.89 (d, J = 16.2 Hz, 1H), 3.45 (s, 
3H), 3.33 (d, J = 3.3 Hz, 1H), 3.22 (t, J = 2.7 Hz, 1H), 2.70 (ddd, J = 12.0, 4.7, 2.1 Hz, 1H), 2.51 
(d, J = 16.2 Hz, 1H), 2.40 (s, 3H), 2.14 (td, J = 12.5, 3.4 Hz, 1H), 2.05 (td, J = 12.6, 4.5 Hz, 1H), 
1.87 (ddd, J = 12.5, 3.2, 1.3, 1H). 
13C NMR (CDCl3, 125 MHz): δ 192.3, 192.2, 153.6, 153.0, 145.7, 130.2, 123.8, 123.1, 113.4, 
107.9, 102.1, 67.3, 55.2, 48.8, 47.1, 46.0, 43.4, 40.3, 36.7. 
























Compounds S13 and S28 
 
Procedure: In a vial with a stir bar, the S11 (84.4 mg, 0.2361 mmol) was added along with 
sodium azide (96.6 mg, 1.486 mmol). The reaction vial was placed in an ice/water bath. The 
reaction was acidified with 50% sulfuric acid (5 mL) and stirred vigorously (open to air) for 5 
min. After this time, the reaction was allowed to stir at room temperature for 4 hours. The 
reaction was diluted with water and poured into a seperatory funnel. The mixture was basified 
with concentrated ammonium hydroxide and was extracted with dichloromethane (3x). The 
organic layers were combined, dried with sodium sulfate, and concentrated in vacuo. The residue 
was purified by column chromatography (15:1 dichloromethane/methanol) to afford and S13 
(25.3 mg, 28% yield) and S28 (32.4 mg, 37% yield) as white solids. 
S13 
1H NMR (d6-acetone, 500 MHz): δ 7.46 (bs, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 8.0 Hz, 
1H), 6.02 (d, J = 1.0 Hz, 1H), 6.00 (d, J = 1.1 Hz, 1H), 5.56 (d, J = 6.4 Hz, 1H), 4.94 (s, 1H), 
3.73 (d, J = 14.5, 1H), 3.50 (d, J = 14.5, 1H), 3.46 (s, 3H), 3.26 (d, J = 1.9 Hz, 1H), 2.75 (dd, J = 
























































13C NMR (d6-acetone, 125 MHz): δ 168.1, 151.9, 148.7, 145.9, 129.7, 123.9, 122.4, 108.3, 
104.4, 101.9, 61.6, 55.5, 55.0, 50.1, 48.0, 45.4, 42.8, 41.6, 35.1. 
HRMS(ESI): m/z calc. for C19H22N5O4 [M+H]+: 384.1672, found: 384.1661. 
 
S28 
1H NMR (CDCl3, 500 MHz): δ 6.74 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 5.95 (d, J = 
1.4 Hz, 1H), 5.87 (d, J = 1.4 Hz, 1H), 5.75 (d, J = 2.3 Hz, 1H), 4.63 (s, 1H), 3.86 (d, J = 16.0 Hz, 
1H), 3.52 (s, 3H), 3.22 (d, J = 2.9 Hz, 1H), 3.04 (t, J = 2.6 Hz, 1H), 2.50 (ddd, J = 11.7, 4.9, 1.6 
Hz, 1H), 2.48 (s, 3H), 2.45 (d, J = 16.1 Hz, 1H), 2.02 (td, J = 12.2, 3.4 Hz, 1H), 1.87 (td, J = 
12.6, 4.9 Hz, 1H), 1.65 (ddd, J = 12.9, 3.2, 1.7 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 192.9, 151.1, 148.4, 145.9, 127.6, 123.0, 120.2, 115.5, 107.6, 
101.2, 61.7, 54.9, 53.6, 48.4, 46.5, 43.6, 43.0, 39.4, 37.0. 














































Procedure: In a vial with a stir bar, S12 (6.9 mg, 0.0202 mmol) was dissolved in acetonitrile (4 
mL). Iodomethane (0.05 mL, 0.8032 mmol) was added to the reaction mixture and was allowed 
to stir for 12 hours. Water was added to the reaction and stirred for 30 minutes. The contents of 
the vial were concentrated under reduced pressure and the crude quaternary ammonium salt was 
transferred into a separate vial and dissolved in water (12 mL). Potassium carbonate (25.6 mg, 
0.1852 mmol) was added to the reaction and was stirred (capped under air) at 60 ºC in an oil bath 
for 4 hours. The reaction mixture was extracted with dichloromethane (3x). The organic layers 
were combined, dried with sodium sulfate, and concentrated under reduced pressure. The crude 
residue was purified by column chromatography (9:1 dichloromethane/methanol) on silica gel to 
afford S14 (4.2 mg, 58% yield) as a light yellow solid. 
1H NMR (CDCl3, 500 MHz): δ 7.87 (d, J = 8.3 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.50 (s, 1H), 
6.32 (s, 1H), 6.12 (d, J = 1.2 Hz, 1H), 6.08 (d, J = 1.3 Hz, 1H), 3.87 (d, J = 16.7 Hz, 1H), 3.85 (s, 
3H), 2.71 (d, J = 16.5 Hz, 1H), 2.35 (ddd, J = 13.3, 9.5, 4.5 Hz, 1H), 2.09 – 2.01 (m, 1H), 1.99 
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13C NMR (CDCl3, 125 MHz): δ 191.3, 182.9, 154.1, 153.6, 151.7, 143.8, 127.6, 127.3, 126.7, 
123.1, 113.1, 108.9, 102.2, 56.1, 55.3, 47.2, 45.3, 42.7, 36.5. (19 carbons due to symmetry) 




Procedure: In a vial with a stir bar, S29 (771.7 mg, 1.548 mmol) was dissolved in dioxane (8 
mL) and 10% NaOH (w/v) (2 mL). The contents of the vial were stirred capped under nitrogen 
for 8 hours. After this time, the reaction mixture was diluted with water and extracted with 
dichloromethane (4x). The organic layers were combined, dried over sodium sulfate, filtered, and 
condensed under reduced pressure. The crude residue was purified by column chromatography 
(9:1 dichloromethane/methanol) on silica gel to afford S15 (241.8 mg, 48% yield) as a white 
solid. Crystals suitable for X-ray crystallography were grown by vapor diffusion (inner vial: 
tetrahydrofuran, outer vial: hexanes). 
1H NMR (CDCl3, 500 MHz): δ 6.65 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 8.3 Hz, 1H), 5.50 (d, J = 
2.3 Hz, 1H), 4.77 (s, 1H), 3.83 (s, 3H), 3.47 (s, 3H), 3.35 (dd, J = 5.3, 2.9 Hz, 1H), 3.26 (t, J = 
2.5 Hz, 1H), 3.09 (d, J = 18.1 Hz, 1H), 2.60 (ddd, J = 12.2, 5.0, 1.1 Hz, 1H), 2.45 (s, 3H), 2.33 
















































(dd, J = 18.2, 5.4 Hz, 1H), 2.28 (td, J = 12.2, 3.7 Hz, 1H), 2.04 (td, J = 12.0, 4.9 Hz, 1H), 1.81 
(ddd, J = 12.4, 3.6, 1.5 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 189.8, 154.0, 144.9, 142.8, 129.2, 126.1, 120.1, 115.5, 115.3, 
89.1, 59.8, 57.2, 55.3, 47.1, 43.3, 43.0, 39.3, 34.0, 20.4. 
HRMS(ESI): m/z calc. for C19H22NO4 [M+H]+: 328.1549, found: 328.1546. 
 
X-ray Crystallographic Data for S15: 
 
X-ray Crystallographic Data for S15: Crystallographic data for the structure have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. 
CCDC 1502193. Copies of the data can be obtained, free of charge, on application to CHGC, 12 
Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336033 or email: 
deposit@ccdc.cam.ac.uk).  
 


















Crystal Data and structure refinement for cd53qsa. 
Identification code      cd53qsa 
Empirical formula      C19H21NO4 
Formula weight      327.38 
Temperature       100(2)K 
Wavelength       1.54178 Å 
Crystal System      Orthorhombic 
Space group       P212121 
Unit cell dimensions      a = 8.4444(3) Å α = 90° 
b = 10.0554(4) Å β = 90° 
c = 18.0941(7) Å ϒ = 90° 
Volume       1536.4(10) Å3 
Z        4 
Density (calculated)      1.415 g/cm3 
Absorption coefficient     0.810 mm-1 
F(000)        696 
Crystal size       0.318 x 0.182 x 0.06 mm3 
Theta range for data collection    68.373º to 4.888º 
Index ranges       -10<=h<=7, -12<=k<=11, 
-21<=l<=-20 
Reflections collected      19334 
Independent reflections     2813 [R(int) = 0.0276] 
Completeness to theta = 68.373º     99.8 % 
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Absorption correction      Integration 
Max. and min. transmission     0.99975 and 0.99883 
Refinement method      Full-matrix least-squares on F2 
Data/restraints/parameters     2813 / 0 / 221 
Goodness-of-fit on F2      1.104 
Final R indices [I>sigma(I)]     R1 = 0261, wR2 = 0.0647 
R indices (all data)      R1 = 0.268, wR2 = 0.0653 
Absolute structure (Flack) parameter    0.02(4) 
Largest diff. peak and hole     0.194 and -0.188 e. Å-3 
Compounds S16 and S17 
 
Procedure: In a vial with a stir bar, compound S15 (226.4 mg, 0.6916 mmol) was dissolved in 
methanol (4 mL). Methanesulfonic acid (2 mL) was added to the vial, which was capped and 
stirred in an oil bath at 80 ºC. After 10 min, the temperature was raised to 110 ºC and the reaction 
was stirred for 5 min. The contents were poured into a seperatory funnel along with saturated 
sodium bicarbonate and water. The mixture was further basified with 30% NH4OH and was 
extracted with dichloromethane (4x). The organic layers were combined, dried under Na2SO4, 
and were concentrated under reduced pressure. The crude residue was purified by column 
chromatography (9:1 dichloromethane/methanol) on silica gel to afford compounds S16 (7.7 mg, 



































1H NMR (CDCl3, 500 MHz): δ 8.83 (s, 1H), 6.86 (d, J = 8.1 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 
6.70 (s, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.71 (s, 3H), 3.18 (td, J = 15.0, 5.7 Hz, 1H), 3.04 (dd, J = 
13.1, 3.5, Hz, 1H), 3.05 - 2.99 (m, 1H), 2.87 (dd, J = 15.2, 2.3 Hz, 1H), 2.71 (dd, J = 16.4, 3.2 
Hz, 1H), 2.54 (s, 3H), 2.53 - 2.38 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 151.4, 149.6, 146.1, 144.2, 142.3, 130.3, 130.1, 126.1, 120.4, 
119.2, 111.3, 111.1, 63.1, 62.3, 56.3, 56.1, 53.0, 44.1, 36.1, 29.6. 
HRMS(ESI): m/z calc. for C20H24NO4 [M+H]+: 342.1705, found: 342.1695. 
 
S17 
1H NMR (CDCl3, 500 MHz): δ 6.74 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 5.12 (s, 1H), 
3.89 (s, 3H), 3.79 (s, 3H), 3.36 (s, 3H), 3.28 (dd, J = 5.9, 2.9 Hz, 1H), 3.11 (d, J = 18.7 Hz, 1H), 
2.60 (ddd, J = 12.1, 5.0, 1.5, 1H), 2.44 (s, 3H), 2.44–2.33 (m, 2H), 2.25 (dd, J = 18.8, 6.1 Hz, 
1H), 2.10 –2.02 (m, 2H), 1.85 (ddd, J = 12.4, 3.7, 1.2 Hz, 1H), 1.19 (t, J = 12.8 Hz, 1H). 
 1H NMR signals for 16 13C NMR signals for 16
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‘13C NMR (CDCl3, 125 MHz): δ 174.0, 147.4, 142.7, 130.1, 127.4, 119.8, 115.0, 91.7, 88.2, 
58.0, 57.2, 55.7, 52.6, 50.8, 46.3, 43.3, 41.1, 40.2, 32.8, 20.9. 





Procedure: In a vial with a stir bar, S30 (342.5 mg, 1.000 mmol) was mixed with sodium azide 
(475.4 mg, 7.313 mmol). The reaction mixture was placed in an ice water bath (0 ºC). To this, 
 1H NMR signals for 17 13C NMR signals for 17
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50% sulfuric acid (8 mL) was added to the vial and the reaction was allowed to stir open to air. 
After 1 hour, the reaction was stirred at room temperature for 3 hours. The reaction was poured 
into a seperatory funnel with ice water and was quenched with concentrated ammonium 
hydroxide. The mixture was extracted with dichloromethane (3x). The organic layers were 
combined, dried over Na2SO4, and were concentrated under reduced pressure. The crude residue 
was purified by column chromatography (15:1 dichloromethane/methanol) to afford S18 (182.4 
mg, 51% yield) as a yellow solid. Starting material S30 (109.5 mg, 32%) was also recovered. 
1H NMR (CDCl3, 500 MHz): δ 7.72 (d, J = 8.6, 1H), 7.49 (t, J = 5.2 Hz, 1H), 6.88 (d, J = 8.6 
Hz, 1H), 6.47 (bs, 1H), 4.84 (d, J = 6.2 Hz, 1H), 4.08 (dd, J = 14.7, 7.0 Hz, 1H), 3.93 (s, 3H), 
3.55 (dd, J = 14.7, 4.8, 1H), 3.46 (s, 3H), 3.32 (d, J = 3.2 Hz, 1H), 3.06 (dd, J = 6.3, 3.3 Hz, 1H), 
2.71 (ddd, J = 11.8, 4.8, 1.6 Hz, 1H), 2.32 (s, 3H), 2.11 (td, J = 12.3, 4.8 Hz, 1H), 1.99 (td, J = 
12.2, 3.3 Hz, 1H), 1.93 (ddd, J = 12.0, 3.3, 1.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 194.5, 169.5, 152.1, 150.9, 143.4, 128.9, 128.7, 119.6, 109.3, 
103.8, 67.0, 56.3, 55.7, 50.2, 48.5, 46.3, 43.8, 43.1, 32.9. 


























Procedure: In a vial with a stir bar, S18 (69.5 mg, 0.1939 mmol) was dissolved in acetonitrile 
(16 mL). Iodomethane (1 mL) was added to the reaction and it was allowed to stir for 20 hours. 
The reaction mixture was diluted with water and stirred for 10 min. The contents of the vial were 
concentrated under reduced pressure. The crude ammonium salt was used directly by dissolving 
it in deionized water (12 mL). Potassium carbonate (326.8 mg, 2.365 mmol) was dissolved in the 
mixture. The vial was capped and stirred in a 60 ºC oil bath for 15 hours. The reaction mixture 
was poured into water and extracted with dichloromethane (3x). The organic layers were 
combined, dried over Na2SO4, were concentrated under reduced pressure. Compound S19 (27.2 
mg, 38% yield) was present as an orange solid and was pure by 1H NMR. 
1H NMR (CDCl3, 500 MHz): δ 8.07 (dd, J = 8.1, 4.3 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 6.94 (d, 
J = 8.6 Hz, 1H), 6.33 (s, 1H), 5.90 (s, 1H), 4.31 (dd, J = 14.8, 8.1 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 
3H), 3.51 (dd, J = 14.8, 4.2 Hz, 1H), 3.21 (ddd, J = 13.1, 10.9, 6.1 Hz, 1H), 2.09–2.02 (m, 1H), 
2.03 (s, 6H), 1.82–1.71 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 184.5, 166.1, 157.5, 151.7, 151.6, 143.9, 130.2, 127.1, 126.6, 
118.6, 110.4, 108.1, 56.4, 56.1, 56.0, 46.4, 45.5 (2C), 44.8, 28.5. 
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Procedure: In a vial with a stir bar, S60 (130.0 mg, 0.2758 mmol) was dissolved in water (10 
mL). Potassium carbonate (182.0 mg, 1.317 mmol) was dissolved in water and the vial was 
capped and placed in a 60 ºC oil bath. After 20 hours of stirring, the reaction mixture was cooled 
to room temperature, made less basic with saturated ammonium chloride, and diluted with brine. 
The reaction mixture was extracted with dichloromethane (4x). The organic layers were 
combined, dried with sodium sulfate, and concentrated under reduced pressure. The crude 
residue was purified via column chromatography (9:1 dichloromethane/methanol) on silica gel to 
yield S20 (45 mg, 48% yield) as an orange solid. Crystals suitable for X-ray crystallography 
were grown by slow evaporation in a capped vial (1:1 dichloromethane/hexanes). 
1H NMR (CDCl3, 500 MHz): δ 6.94 (s, 1H), 6.80 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H), 
6.36 (d, J = 9.2 Hz, 1H), 5.91 (d, J = 9.2 Hz, 1H), 5.73 (s, 1H), 3.91 (s, 3H), 3.74 (s, 3H), 2.16–
2.09 (m, 2H), 2.12 (s, 6H), 2.00–1.93 (m, 1H), 1.85 (dt, J = 13.4, 7.3 Hz, 1H). 
13C NMR (CDCl3, 125 Hz): δ 181.9, 157.8, 152.0, 148.3, 144.2, 131.6, 128.4, 127.0, 126.4, 
118.7, 117.9, 117.1, 111.9, 56.3, 55.2, 54.5, 46.4, 45.1 (2C), 38.1.  
































HRMS(ESI): m/z calc. for C20H24NO4 [M+H]+: 342.1705, found: 342.1706. 
X-ray Crystallographic Data for S20: 
 
X-ray Crystallographic Data for S20: Crystallographic data for the structure have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. 
CCDC 1502194. Copies of the data can be obtained, free of charge, on application to CHGC, 12 
Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336033 or email: 
deposit@ccdc.cam.ac.uk).  
Crystal Data and structure refinement for cd20psa. 
Identification code      cd20psa 
Empirical formula      2(C20H23NO4), 3(CH2Cl2) 
Formula weight      937.62 
Temperature       100(2)K 
Wavelength       1.54178 Å 
Crystal System      Orthorhombic 
Space group       C221 
Unit cell dimensions      a = 18.3635(8) Å α = 90° 
b = 25.2508(11) Å β = 90° 
c = 9.9745(4) Å ϒ = 90° 
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Volume       4625.1(3) Å3 
Z        4 
Density (calculated)      1.347 g/cm3 
Absorption coefficient     3.816 mm-1 
F(000)        1960 
Crystal size       0.409 x 0.305 x 0.166 mm3 
Theta range for data collection    72.368º to 2.975º 
Index ranges       -22<=h<=22, -29<=k<=31, 
-12<=l<=-12 
Reflections collected      29417 
Independent reflections     4579 [R(int) = 0.0519]t 
Completeness to theta = 72.368º     99.8 % 
Absorption correction      Integration 
Max. and min. transmission     0.97081 and 0.93526 
Refinement method      Full-matrix least-squares on F2 
Data/restraints/parameters     4579 / 100 / 303 
Goodness-of-fit on F2      1.095 
Final R indices [I>sigma(I)]     R1 = 0.0471, wR2 = 0.1.222 
R indices (all data)      R1 = 0.0475, wR2 = 0.1226 
Absolute structure (Flack) parameter    0.047(10) 




Compounds S21 and S22 
 
Procedure: In a vial with a stir bar, S31 (9.9 mg, 0.0302 mmol) was dissolved in 0.07 M 
hydrochloric acid (10 mL) and was capped under N2. The reaction mixture was stirred in an oil 
bath at 100 ºC for 4 hours. The contents of the vial were basified with 15% ammonium 
hydroxide, diluted with water, and were extracted with dichloromethane (3x). The organic layers 
were combined, dried over sodium sulfate, and were condensed under reduced pressure. The 
crude residue was purified by column chromatography (15:1 dichloromethane/methanol) on 
silica gel to afford S21 (cepharatine A) (3.2 mg, 34% yield) and S22 (1 mg, 9% yield) as yellow 
solids. Compound S22 (sinoracutine) was isolated as a single diastereomer. Spectral data for our 
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synthetic S21 is provided below. Literature values for naturally isolated S21 can be found in the 
following reference.40 
S21 (cepharatine A) 
1H NMR (CDCl3, 500 MHz): δ 6.78 (d, J = 8.2 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.70 (d, J = 
9.4 Hz, 1H), 6.29 (d, J = 9.4 Hz, 1H), 6.12 (s, 1H), 3.94 (s, 3H), 3.91 (d, J = 12.9 Hz, 1H), 2.92–
2.85 (m, 1H), 2.73–2.59 (m, 2H), 2.24 (s, 3H), 2.24–2.21 (m, 1H), 1.40–1.35 (m, 1H). 
13C NMR (CDCl3, 125 MHz): δ 194.3, 161.6, 148.3, 144.6, 136.2, 125.8, 125.7, 124.3, 123.6, 
121.5, 108.9, 83.4, 56.4, 46.8, 44.6, 43.7, 36.4, 31.4. 
HRMS(ESI): m/z calc. for C18H20NO4 [M+H]+: 314.1392, found: 314.1385. 
S22 (sinoracutine) 
1H NMR (CDCl3, 500 MHz): δ 6.78 (d, J = 9.5 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.73 (d, J = 
8.3 Hz, 1H), 6.55 (d, J = 9.4 Hz, 1H), 5.84 (s, 1H), 3.91 (s, 3H), 3.77 (s, 1H), 3.17 (d, J = 10.0, 
9.3, 1.0 Hz, 1H), 2.92 (s, 3H), 2.82 (dt, J = 10.3, 8.1 Hz, 1H), 2.37 (ddd, J = 13.4, 7.0, 1.1 Hz, 
1H), 2.10 (ddd, J = 13.5, 8.1, 8.5 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 206.8, 175.0, 151.3, 145.8, 138.3, 127.8, 124.3, 123.4, 121.4, 
118.2, 109.6, 72.6, 56.0, 53.9, 51.6, 41.7, 36.5. 






Procedure: In a round bottom flask, S1 (1047.3 mg, 3.179 mmol) was dissolved in 15% HCl (50 
mL) and was attached to a reflux condenser. The reaction was stirred in an oil bath at 100 ºC for 
12 hours, after which the reaction mixture was diluted with water and basified with concentrated 
ammonium hydroxide. The contents were extracted with dichloromethane (6x). The organic 
layers were combined, dried over sodium sulfate, and were concentrated under reduced pressure 
to yield off-white solid S23 (777.0 mg, 78% yield). 
1H NMR (CDCl3, 500 MHz): δ 6.71 (s, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.5 Hz, 1H), 
3.82 (s, 3H), 3.01 (d, J = 18.7 Hz, 1H), 2.91 (dd, J = 5.8, 3.4 Hz, 1H), 2.66 (dd, J = 18.1, 5.6 Hz, 
1H), 2.59–2.51 (m, 2H), 2.42 (q, J = 16.6 Hz, 1H), 2.38 (s, 3H), 2.33 (dd, J = 16.6, 3.6 Hz, 1H), 





 1H NMR signals for 22 13C NMR signals for 22
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13C NMR (CDCl3, 125 Hz): δ 195.3, 145.2, 144.0, 136.6, 129.5, 127.6, 124.5, 118.5, 109.1, 
56.4, 56.2, 47.8, 44.5, 42.7, 38.6, 37.4, 36.6, 23.6. 




Procedure: In an oven dried round bottom flask, S6 (182.0 mg, 0.5315 mmol) was dissolved in 
tetrahydrofuran (20 mL) and was cooled to 0 ºC, under nitrogen. After 10 minutes, lithium 
aluminum hydride (191.3 mg, 5.041 mmol) was slowly added to the reaction vessel and was 
allowed to stir at 0 ºC. After 1 hour, water was slowly added to the round bottom flask along 
with a solution of 10% NaOH. The contents of the flask were stirred for 10 minutes. Sodium 
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concentrated under reduced pressure to afford white solid S24 (163.4 mg, 96% yield).  
1H NMR (CDCl3, 500 MHz): δ 6.67 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.3 Hz, 1H), 4.53 (dd, J = 
9.3, 4.0 Hz, 1H), 3.83 (s, 3H), 3.61–3.56 (m, 2H), 3.18 (dd, J = 5.9, 2.8 Hz, 1H), 3.02–2.75 (m, 
3H), 2.46–2.39 (m, 3H), 2.34 (s, 3H), 2.15 (td, J = 12.5, 3.5 Hz, 1H), 1.98 (td, J = 12.5, 5.0 Hz, 
1H), 1.65 (ddd, J = 12.8, 3.3, 1.9 Hz, 1H), 1.60 (td, J = 12.2, 7.5, 2.6 Hz, 1H), 1.04 (tq, J = 9.8, 
5.0 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 144.8, 142.4, 129.6, 127.4, 118.8, 112.7, 100.0, 60.2, 58.8, 56.3, 
46.5, 46.1, 44.5, 42.9, 40.5, 40.4, 31.3, 19.7. 
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Procedure: In a vial with a stir bar, sinomenine!HCl (1034.3 mg, 2.827 mmol) was dissolved 
in water (15 mL). Diacetoxyiodobenzene (1149.8 mg, 3.570 mmol) was added to the reaction 
vial. The reaction mixture was stirred open to air for 1 hour and was then basified with a 
saturated solution of sodium carbonate. The contents of the vial were poured into a seperatory 
funnel and were extracted with dichloromethane (4x). The organic layers were combined, dried 
with sodium sulfate, and were concentrated in vacuo. The crude residue was dissolved in 
methanol (15 mL) and was allowed to stir for 12 hours. The methanol was evaporated in vacuo. 
The crude residue was subsequently purified by flash chromatography on silica gel (9:1 
dichloromethane/methanol) to afford known catechol S25 (376.7 mg, 39% yield). Spectral data 
(1H NMR) was consistent with literature reported values.35 
Compound S26 
 
Procedure: In a vial with a stir bar, catechol S25 (132 mg, 0.3822 mmol) was dissolved in 
methanol (7 mL) and was cooled in an ice/water bath at 0 ºC. Sodium periodate (534 mg, 2.496 
mmol) was added to the reaction mixture and was stirred under N2 for 1 hour. After this time, the 
reaction was quenched with ethylene glycol (2 mL) and was diluted with saturated sodium 
bicarbonate. The mixture was poured into a seperatory funnel, diluted with distilled water, and 
extracted with dichloromethane (3x). The organic layers were combined, dried with sodium 
sulfate, and concentrated under reduced pressure. The residue was purified by flash 
chromatography (9:1 dichloromethane/methanol) to afford o-quinone S26 (118.1 mg, 83% yield) 























1H NMR (CDCl3, 500 MHz): δ 5.76 (s, 1H), 5.71 (d, J = 1.7 Hz, 1H), 4.01 (s, 1H), 3.90 (s, 3H), 
3.87 (d, J = 16.4 Hz, 1H), 3.54 (s, 3H), 3.45 (s, 3H), 3.20 (d, J = 2.8, 1H), 2.96 (t, J = 2.5 Hz, 
1H), 2.61 (ddd, J = 12.6, 4.5, 2.1 Hz, 1H), 2.52 (s, 3H), 2.41 (d, J = 16.4 Hz, 1H), 2.15 (ddd, J = 
11.8, 11.2, 5.0 Hz, 1H), 1.88–1.79 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 191.8, 181.3, 178.2, 168.2, 150.0, 146.2, 137.4, 117.7, 102.6, 
67.0, 58.3, 58.2, 57.3, 54.9, 47.5, 46.5, 43.6, 42.5, 40.9, 35.2. 




Procedure: In a vial with a stir bar, oxime S49 (274.0 mg, 0.7956 mmol) was dissolved in 
pyridine (10 mL). Tosyl chloride (322.0 mg, 1.689) was added to the reaction and was stirred for 
2.5 hours.  After this time, the reaction mixture was evaporated under reduced pressure 
 1H NMR signals for 26 13C NMR signals for 26














































































(azeotroped with toluene) and was purified by flash chromatography (15:1 to 9:1 
dichloromethane/methanol) on silica gel to afford tosyl oxime S29 (313.1 mg, 80% yield) as a 
white solid. 
1H NMR (CDCl3, 500 MHz): δ 7.86 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 6.61 (d, J = 
8.2 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.01 (bs, 1H) 5.14 (d, J = 16.2 Hz, 1H), 5.06 (d, J = 1.8 
Hz, 1H), 3.81 (s, 3H), 3.42 (s, 3H), 3.13 (t, J = 3.8 Hz, 1H), 2.94 (d, J = 18.2 Hz, 1H), 2.77 (d, J 
= 1.7 Hz, 1H), 2.69 (dd, J = 18.2, 5.0 Hz, 1H), 2.57 (dd, J = 12.0, 3.1 Hz, 1H), 2.43 (s, 3H), 2.41 
(s, 3H), 2.09 (td, J = 12.3, 2.9 Hz, 1H), 2.06 (d, J = 16.2 Hz, 1H), 1.93 (dt, J = 12.6, 2.2 Hz, 1H), 
1.79 (td, J = 12.9, 4.4 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 159.6, 149.6, 145.2, 145.0, 144.8, 133.1, 129.7 (2C), 129.0 
(2C), 122.4, 118.3, 109.9, 109.5, 109.3, 57.2, 56.3, 55.1, 47.8, 44.8, 42.8, 37.9, 35.7, 35.6, 24.2, 
21.9. 




Procedure: In flame-dried round-bottom flask with a stir bar, S1 (725.1 mg, 2.201 mmol) and 










































diacetoxyiodobenzene (1.640 g, 5.090 mmol) were dissolved in methanol (70 mL). The flask 
was attached to a reflux condenser and stirred at 60 ºC in an oil bath. After 48 hours, the mixture 
was concentrated under reduced pressure. The crude residue was subsequently purified by 
column chromatography (9:1 ethyl acetate/methanol) on silica gel to afford S30 (442.4 mg, 59% 




Procedure: In a vial with a stir bar, N-oxide S68 (77.2 mg, 0.2160 mmol) was dissolved in 
methanol (10 mL) and was allowed to cool to 0 ºC in an ice/water bath. After 10 min, iron(II) 
sulfate heptahydrate (84.1 mg, 0.3024 mmol) was added to the reaction. The mixture was stirred 
under N2 at room temperature for 30 min. After this time, the methanol was evaporated under 
reduced pressure and the crude residue was dissolved in water. The mixture was basified with 
15% ammonium hydroxide and it was subsequently concentrated under reduced pressure. 
Methanol was added to the mixture and filtered through Celite. Next, the mix was filtered 
through a fritted funnel. The reaction mixture was concentrated under reduced pressure and 
purified by reverse phase column chromatography to yield orange solid S31 (33.9 mg, 47% 
yield). 
1H NMR (CDCl3, 500 MHz): δ 6.96 (s, 1H), 6.81 (d, J = 8.2 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 
6.37 (d, J = 9.3 Hz, 1H), 5.92 (d, J = 9.3 Hz, 1H), 5.72 (s, 1H), 3.92 (s, 3H), 3.74 (s, 3H), 2.48 















1H), 1.83 (dt, J = 13.6, 7.2 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 184.4, 160.6, 153.4, 150.8, 147.5, 132.9, 130.6, 129.1, 129.0, 
120.7, 120.3, 118.3, 114.5, 57.6, 56.6, 47.8, 47.2, 38.8, 34.5. 
HRMS(ESI): m/z calc. for C19H22NO4 [M+H]+: 328.1549, found: 328.1545. 
 
Compounds S32 and S33 
 
Procedure: In a vial with a stir bar, S1 (172.5 mg, 0.5237 mmol) was dissolved in methanol (15 
mL). To this mixture, diacetoxyiodobenzene (428.5 mg, 1.330 mmol) was added and the reaction 
was capped and stirred under N2. The reaction mixture was concentrated under reduced pressure 
after stirring for 2 hours. The crude residue was purified via column chromatography (9:1 ethyl 
acetate/methanol) on silica gel to afford masked o-quinones S32 (58.6 mg, 29% yield) and S33 
(92.2 mg, 42% yield) as yellow and tan solids, respectively. 
S32 
1H NMR (CDCl3, 500 MHz): δ 6.27 (d, J = 10.1 Hz, 1H), 5.98 (d, J = 10.2 Hz, 1H), 5.48–5.44 
(m, 2H) 3.63 (d, J = 16.3 Hz, 1H), 3.52 (s, 3H), 3.31 (s, 3H), 3.10 (s, 3H), 3.02 (d, J = 2.6 Hz, 
1H), 2.88 (t, J = 2.3 Hz, 1H), 2.54 (ddd, J = 12.4, 4.8, 1.4 Hz, 1H), 2.48 (s, 3H), 2.36 (d, J = 









3.74 (s, 3H)2.27 (s, 3H)



































16.3, Hz, 1H), 2.09 (s, 3H), 2.08 (td, J = 12.6, 3.1 Hz, 1H), 1.93 (ddd, J = 13.1, 3.1, 1.3 Hz, 1H), 
1.74 (td, J = 12.8, 4.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 194.3, 192.1, 170.1, 151.3, 145.5, 133.7, 132.8, 126.1, 115.8, 
92.6, 63.6, 61.1, 55.1, 50.3, 50.2, 47.5, 47.0, 44.0, 42.8, 40.1, 35.8, 21.2. 
HRMS(ESI): m/z calc. for C22H28NO7 [M+H]+: 418.1866, found: 418.1857. 
 
S33 
1H NMR (CDCl3, 500 MHz): δ 6.30 (d, J = 10.1 Hz, 1H), 6.22 (d, J = 10.0 Hz, 1H), 5.58 (d, J = 
2.2 Hz, 1H), 3.68 (d, J = 16.4 Hz, 1H), 3.60 (s, 1H), 3.53 (s, 3H), 3.52 (s, 3H), 3.36 (s, 3H), 3.20 
(d, J = 2.6 Hz, 1H), 3.13 (s, 3H), 2.91 (t, J = 2.3 Hz, 1H), 2.55 (ddd, J = 12.4, 4.9, 1.6 Hz, 1H), 
2.49 (s, 3H), 2.36 (d, J = 16.4 Hz, 1H), 2.05 (td, J = 12.4, 3.1 Hz, 1H), 1.96 (ddd, J = 13.2, 3.4, 
1.6 Hz, 1H), 1.76 (td, J = 12.8, 4.8 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 194.9, 192.3, 151.0, 148.0, 132.9, 131.1, 127.0, 117.0, 92.5, 
71.7, 58.8, 58.6, 55.2, 50.3, 50.2, 47.6, 46.9, 44.1, 42.4, 40.2, 35.8. 







Key 1H NMR signals for 32
3.52 (s, 3H)
5.48 - 5.44 (m, 1H)






























































































Compounds S34 and S35 
 
Procedure: In a round bottom flask with a stir bar, S33 (127.7 mg, 0.3050) was dissolved in 
dichloromethane (12 mL) and cooled to 0 ºC in an ice/water bath. Trifluoroacetic acid (0.5 mL, 
6.530 mmol) was added to the reaction mixture. After 1 hour, the reaction was stirred at room 
temperature. After 1.5 hours, the reaction was quenched with a saturated solution of sodium 
carbonate and was extracted with dichloromethane (4x). The organic layers were combined, 
dried with sodium sulfate, and concentrated under reduced pressure. The crude residue was 
purified by silica gel chromatography (15:1 dichloromethane/methanol) to afford S34 (16.7 mg, 
15% yield) and 35 (26.6 mg, 23% yield) as light yellow and light orange solids, respectively. 
S34 
1H NMR (CDCl3, 500 MHz): δ 5.86 (s, 1H), 5.75 (d, J = 2.0 Hz, 1H), 4.17 (s, 1H), 3.90 (d, J = 
16.2 Hz, 1H), 3.78 (s, 3H), 3.55 (s, 3H), 3.52 (s, 3H), 3.21 (d, J = 2.9 Hz, 1H), 3.01 (t, J = 2.6 
Hz, 1H), 2.60 (td, J = 2.6 Hz, 1H), 2.52 (s, 3H), 2.49 (d, J = 16.3 Hz, 1H), 2.11–2.04 (m, 1H), 
1.92–87 (m, 2H). 






















































15% yield 23% yield
82 
 
66.5, 58.9, 58.6, 56.4, 55.0, 48.1, 46.6, 44.6, 42.6, 41.3, 35.4. 
HRMS(ESI): m/z calc. for C20H24NO6 [M+H]+: 374.1604, found: 374.1598. 
 
S35 
1H NMR (d6-DMSO, 500 MHz): δ 8.63 (s, 1H), 7.77 (s, 1H), 6.35 (s, 1H), 5.84 (d, J = 2.1 Hz, 
1H), 4.20 (s, 1H), 4.18 (d, J = 16.0 Hz, 1H), 3.69 (s, 3H), 3.40 (s, 3H), 3.34 (s, 3H), 3.20 (d, J = 
3.0 Hz, 1H), 2.90 (t, J = 2.6 Hz, 1H), 2.40 (s, 3H), 2.38–2.34 (m, 1H), 2.35 (d, J = 15.5 Hz, 1H), 
1.83–1.75 (m, 1H), 1.70–1.65 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 193.5, 151.4, 149.4, 147.7, 138.4, 121.9, 116.9, 116.1, 99.1, 
71.3, 57.0, 56.0, 55.7, 54.9, 49.2, 47.1, 45.0, 42.6, 41.0, 35.7. 








































































8.63 (s, 1H) or
7.77 (s, 1H)




Compounds S36 and S37 
 
Procedure: In an oven-dried round-bottom flask, S30 (192 mg, 0.5591 mmol), hydroxylamine 
hydrochloride (264 mg, 3.799 mmol), and sodium acetate (465 mg, 5.669 mmol) were added to 
methanol (20 mL). The flask was attached to a reflux condenser and stirred at reflux temperature. 
After 48 hours, the contents of the flask were concentrated under reduced pressure. The residue 
was dissolved in water and basified with a 15% ammonium hydroxide solution. The reaction 
mixture was extracted with dichloromethane (6x), dried over sodium sulfate, and concentrated 
under reduced pressure. The crude residue was purified by silica gel chromatography (15:1 
dichloromethane/ methanol) to afford oxime S36 (57.0 mg, 29% yield) and a bis-oxime S37 
(82.0 mg, 39% yield) as light yellow and tan solids, respectively. 
S36 
1H NMR (CDCl3, 500 MHz): δ 7.63 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.99 (s, 1H), 
5.14 (d, J = 16.5 Hz, 1H), 4.78 (d, J = 2.1 Hz, 1H), 3.92 (s, 3H), 3.45 (s, 3H), 3.28 (d, J = 3.5 Hz, 
1H), 2.97 (dd, J = 2.2, 2.0 Hz, 1H), 2.69 (dd, J = 12.0, 4.3, 1.7 Hz, 1H), 2.37 (s, 3H), 2.14 (ddd, J 
= 12.6, 3.3, 1.6 Hz, 1H), 2.09–2.03 (m, 1H), 2.05 (d, J = 16.6 Hz, 1H), 1.92 (td, J = 12.6, 5.0 Hz, 
1H). 
13C NMR (CD3OD, 125 MHz): δ 195.9, 154.7, 152.7, 151.5, 146.6, 131.1, 129.0, 120.0, 110.2, 
103.6, 68.9, 56.6, 55.2, 49.2, 46.2, 43.5, 39.4, 36.0, 34.4. 


































1H NMR (d6-acetone, 500 MHz): δ 7.51 (bs, 1H), 7.48 (d, J = 8.8 Hz, 1H), 6.76 (d, J = 8.7 Hz, 
1H), 5.23 (d, J = 16.4 Hz, 1H), 4.69 (d, J = 1.8 Hz, 1H), 4.58 (d, J = 3.6 Hz, 1H), 3.82 (s, 3H), 
3.35 (s, 3H), 2.84 (dd, J = 3.9, 1.7 Hz, 1H), 2.60 (s, 1H), 2.53 (d, J = 11.6, 4.9, 1.5 Hz, 1H), 2.32 
(s, 3H), 2.14 (s, 1H), 2.05–2.01 (m, 1H), 1.97 (td, J = 12.0, 3.3 Hz, 1H), 1.90 (d, J = 16.5 Hz, 
1H), 1.78 (td, J = 12.3, 4.8 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 152.4, 151.9, 151.1, 150.1, 146.7, 128.8, 124.8, 115.3, 110.5, 
104.1, 56.5, 55.1, 54.5, 49.7, 44.9, 43.7, 38.9, 35.8, 34.2. 




















7.63 (d, 1H) 6.79 (d, 1H)














3.82 (s, 3H)2.60  or 2.14
(s, 1H)
2.60  or 2.14
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Procedure: In a vial with a stir bar, S37 (20.0 mg, 0.0536 mmol) and 4-toluenesulfonyl chloride 
(52.6 mg, 0.2759 mmol) were dissolved in pyridine (5 mL) and were stirred under an atmosphere 
of N2. After 4.5 hours, the mixture was transferred to a seperatory funnel and was diluted with 
water and saturated sodium bicarbonate. The contents were extracted with dichloromethane (3x). 
The organic layers were combined, dried with sodium sulfate, and were concentrated under 
reduced pressure. The crude residue was purified by flash chromatography (15:1 
dichloromethane/methanol) on silica gel to afford S38 (21.7 mg, 77% yield) as a yellow solid. 
1H NMR (CD3OD, 500 MHz) δ 7.81 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.34 (d, J = 
8.0 Hz, 2H), 6.77 (d, J = 8.7 Hz, 1H), 5.17 (d, J = 16.4 Hz, 1H), 4.98 (d, J = 2.2 Hz, 1H), 4.64 (d, 
J = 3.6 Hz, 1H), 3.87 (s, 3H), 3.33 (s, 3H), 2.82 (t, J = 2.9 Hz, 1H), 2.59 (dd, J = 12.2, 3.9 Hz, 
1H), 2.39 (s, 3H), 2.35 (s, 3H), 2.09 (d, J = 16.3 Hz, 1H), 2.10 - 2.05 (m, 1H), 2.01 (td, J = 12.3, 
3.4 Hz, 1H), 1.78 (td, J = 12.6, 4.7 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 159.9, 150.7, 150.1, 146.6, 146.5, 134.2, 130.8 (2C), 129.9 
(2C), 128.7, 127.0, 123.6, 115.3, 110.8, 109.9, 56.6, 55.4, 54.1, 45.1, 43.7, 39.5, 35.7, 35.4, 30.9, 
21.7. 





























Procedure: In a vial with a stir bar, S30 (171.3 mg, 0.4989 mmol) was dissolved in 
dichloromethane (12 mL). The reaction was capped, placed under nitrogen and cooled to 0 ºC in 
an ice/water bath after 15 minutes, m-chloroperbenzoic acid (~75%) (210.7 mg, 0.9157 mmol) 
was slowly added. The reaction was stirred at room temperature for 3.5 hours. The reaction was 
concentrated under reduced pressure and was purified by silica gel chromatography (9:1 
dichloromethane/methanol) to afford S39 (164.4 mg, 92% yield) as a yellow solid. 
1H NMR (CDCl3, 500 MHz): δ 7.67 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 5.27 (d, J = 
2.1 Hz, 1H), 4.55 (t, J = 2.8 Hz, 1H), 4.39 (d, J = 15.8 Hz, 1H), 3.95 (s, 3H), 3.84 (d, J = 1.8 Hz, 
1H), 3.43 (s, 3H), 3.27 (ddd, J = 12.4, 2.2, 1.6 Hz, 1H), 3.26 (s, 3H), 3.08 (dt, J = 12.8, 3.0 Hz, 
1H), 2.85 (td, J = 13.1, 4.3 Hz, 1H), 2.63 (d, J = 15.8 Hz, 1H), 2.00 (dt, J = 13.5, 2.5 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 194.2, 194.1, 152.6, 146.8, 145.7, 125.9, 121.0, 118.6, 114.4, 
110.5, 73.1, 60.7, 57.1, 55.5, 54.3, 39.5, 39.4, 31.4, 28.3. 














































Procedure: In a round bottom flask with a stir bar, S39 (377.0 mg, 1.049 mmol) was dissolved 
in methanol (24 mL). The reaction mixture was cooled to 0 ºC in an ice/water bath. After 10 min, 
iron(II) sulfate heptahydrate (535.0 mg, 1.924 mmol) was added slowly to the reaction mixture 
and was allowed to stir under nitrogen for 2 hours. The contents of the flask were concentrated 
under reduced pressure. The reaction mixture was subsequently taken up in water and basified 
with aqueous 15% ammonium hydroxide. An extraction was performed with ethyl acetate (3x) 
and the organic layers were combined, dried with sodium sulfate, and concentrated under 
reduced pressure. The crude mixture was purified via silica gel chromatography (30:1 to 15:1 
dichloromethane/methanol) to afford S40 as a yellow solid (107.3 mg, 39% yield). 
1H NMR (CDCl3, 500 MHz): δ 7.69 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 6.05 (bs, 1H), 
5.33 (dd, J = 2.2, 1H), 4.33 (d, J = 15.9 Hz, 1H), 3.93 (s, 3H), 3.59 (dd, J = 3.3 Hz, 1H), 3.43 (s, 
3H), 3.22 (t, J = 2.8 Hz, 1H), 2.82 (ddd, J = 12.1, 5.0, 1.8 Hz, 1H), 2.58 (td, J = 12.5, 3.5 Hz, 
1H), 2.51 (d, J = 15.9 Hz, 1H), 2.05 (ddd, J = 12.9, 3.8, 1.9 Hz, 1H), 1.94 (td, J = 12.6, 5.0 Hz, 
1H). 
13C NMR (CDCl3, 125 MHz): δ 196.7, 192.8, 153.0, 152.5, 144.6, 129.6, 126.9, 119.9, 113.8, 
109.0, 60.3, 56.1, 55.0, 49.8, 46.1, 42.4, 38.7, 34.6. 


























Procedure: In a vial with a stir bar, S40 (107.3 mg, 0.3258 mmol) was dissolved in pyridine (10 
mL). The reaction was cooled to 0 ºC in an ice water bath for 10 min. Benzyl chloroformate (0.1 
mL, 0.7005 mmol) was added drop wise into the reaction vial. The reaction was capped under N2 
and was stirred for 1.5 hours at room temperature. The reaction was diluted with water, sat. 
NaHCO3 and was extracted with ethyl acetate (3x). The organic layers were combined, dried 
over Na2SO4, and were concentrated under reduced pressure. The crude residue was purified by 
column chromatography (15:1 dichloromethane/methanol) on silica gel to afford 41 (121.1 mg, 
80% yield) as a white solid. 
1H NMR (d7-DMF, 500 MHz, 80 ºC) δ 8.87 (s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.52–7.30 (m, 
5H), 7.05 (d, J = 8.5 Hz, 1H), 5.67 (d, J = 2.3 Hz, 1H), 5.25 (d, J = 12.7 Hz, 1H), 5.20 (d, J = 
12.7 Hz, 1H), 5.00 (d, J = 3.6 Hz, 1H), 4.34 (d, J = 15.7 Hz, 1H), 4.07 (ddd, J = 13.9, 5.5, 1.4 
Hz, 1H), 3.93 (s, 3H), 3.43 (s, 3H), 3.31 (dd, J = 3.8, 2.2 Hz, 1H), 2.65 (td, J = 13.5, 3.5 Hz, 1H), 
2.61 (d, J = 15.7 Hz, 1H), 2.19 (ddd, J = 13.2, 3.6, 1.1 Hz, 1H), 2.01 (td, J = 13.1, 5.5 Hz, 1H). 
13C NMR (d7-DMF, 125 MHz, 80 ºC): δ 191.5, 191.3, 155.6, 154.0, 146.0, 137.7, 136.5, 129.3, 
HN
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128.8, 128.5, 128.2, 128.0, 127.4, 127.0, 119.8, 113.5, 110.5, 69.8, 67.5, 58.7, 56.3, 55.0, 49.1, 
45.7, 41.8, 39.3. 




Procedure: In a vial with a stir bar, S30 (58.3 mg, 0.1698 mmol) was dissolved in acetonitrile 
(10 mL). Iodomethane (0.1 mL, 1.606 mmol) was added drop wise into the vial. The vial was 
capped and stirred under N2 for 26 hours. The reaction mixture was diluted with water and was 
stirred for 30 min. The contents of the vial were concentrated under reduced pressure to yield 42 
(80.7 mg, 94% yield) as a yellow solid. No further purification was necessary. 
1H NMR (d6-DMSO, 500 MHz) δ 9.57 (s, 1H), 7.55 (d, J = 8.6, 1H), 7.10 (d, J = 8.7, 1H), 5.41 
(d, J = 1.4 Hz, 1H), 4.28 (d, J = 2.6 Hz, 1H), 4.15 (d, J = 15.9 Hz, 1H), 4.12 (t, J = 2.6 Hz, 1H), 
3.89 (s, 3H), 3.59–3.52 (m, 1H), 3.54 s, 3H), 3.31 (s, 3H), 3.06 (s, 3H), 3.02–2.94 (m, 2H), 2.59 
(td, J = 14.2, 4.2 Hz, 1H), 2.11–2.02 (m, 1H). 
13C NMR (d6-DMSO, 125 MHz): δ 190.9, 186.8, 171.8, 155.0, 152.9, 145.1, 127.2, 125.7, 
121.2, 111.2, 111.0, 72.5, 58.0, 56.6, 55.2, 54.6, 51.1, 46.9, 28.7, 22.9. 
N
H













































Procedure: In a vial with a stir bar, S42 (100.9 mg 0.2079 mmol) was dissolved in water (10 
mL). Potassium carbonate (359.0 mg, 2.597 mmol) was added to the mixture and the vial was 
capped and placed in an oil bath at 65 ºC. The mixture was stirred for 15 hours. The contents of 
the vial were poured into a seperatory funnel and diluted with water. The mixture was extracted 
with dichloromethane (3x). The organic layers were combined, dried with Na2SO4, and were 
concentrated under reduced pressure to afford S43 (40.0 mg, 54% yield) as an orange solid, 
which was pure by NMR. 
1H NMR (CDCl3, 500 MHz) δ 7.83 (d, J = 8.5 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.52 (s, 1H), 
6.35 (s, 1H), 4.40 (d, J = 17.0 Hz, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 2.93 (td, J = 11.8, 3.7 Hz, 1H), 
2.56 (d, J = 16.8 Hz, 1H), 2.12 (s, 6H), 2.10–2.02 (m, 1H), 2.01–1.93 (m, 1H), 1.75 (td, J = 11.4, 
3.3 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 192.8, 184.0, 155.8, 153.6, 150.9, 144.1, 130.4, 126.9, 126.1, 
118.2, 113.3, 109.6, 56.0, 55.8, 55.2, 53.6, 46.3, 44.9, 44.2, 34.0. 
N
H









































Procedure: In a vial with a stir bar, S43 (129.3 mg, 0.3618 mmol) was dissolved in 
dichloromethane (10 mL). The reaction vial was capped and stirred under N2 at 0 ºC. After 5 
min, m-chloroperbenzoic acid (267.0 mg, 1.160 mmol) was placed into the vial. The reaction 
was stirred at room temperature for 1.5 hours and was immediately concentrated under reduced 
pressure. The crude residue was purified by flash chromatography (9:1 
dichloromethane/methanol) on silica gel to afford N-oxide S44 (97.2 mg, 72% yield) as a yellow 
solid. 
1H NMR (CD3OD, 500 MHz) δ 7.76 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.71 (s, 1H), 
6.59 (s, 1H), 4.35 (d, J = 16.7 Hz, 1H), 3.97 (s, 3H), 3.87 (s, 3H), 3.27 (td, J = 12.4, 4.1 Hz, 1H), 
2.95 (s, 3H), 2.90 (s, 3H), 2.84 (td, J = 12.0, 4.5 Hz, 1H), 2.57 (d, J = 16.5 Hz, 1H), 2.53 (td, J = 
11.9, 3.9 Hz, 1H), 2.43 (td, J = 12.0, 4.5 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 193.8, 185.2, 158.0, 155.0, 153.4, 145.0, 130.9, 128.0, 126.5, 
120.7, 115.1, 112.1, 68.4, 59.5, 57.5, 56.9, 56.7, 47.5, 44.9, 44.9. 






































Procedure: In a vial with a stir bar, S44 (55.7 mg, 0.1559 mmol) was dissolved in methanol (7 
mL). The vial was capped and stirred in an ice/water bath at 0 ºC. After 5 min, iron sulfate 
heptahydrate (75.1 mg, 0.2701 mmol) was added to the mixture. The reaction required 1 hour of 
stirring at room temperature and was diluted with water. The reaction was quenched with 15% 
ammonium hydroxide and extracted with dichloromethane (4x). The organic layers were 
combined, dried over sodium sulfate, and were concentrated under reduced pressure. The crude 
residue was purified by flash chromatography (9:1 dichloromethane/methanol) on silica gel to 
afford S45 (33.9 mg, 63% yield) as a yellow solid. 
1H NMR (CD3OD, 500 MHz) δ 7.70 (d, J = 8.6 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.19 (s, 1H), 
6.01 (s, 1H), 3.97–3.92 (m, 1H), 3.96 (s, 3H), 3.80 (s, 3H), 2.91–2.79 (m, 2H), 3.54 (td, J = 13.7, 
4.3 Hz, 1H), 2.29 (s, 3H), 2.01–1.96 (m, 1H), 1.26–1.17 (m, 1H). 
13C NMR (CD3OD, 125 MHz): δ 186.2, 164.8, 160.5, 153.0, 145.2, 133.2, 126.7, 121.6, 119.9, 
118.5, 110.9, 104.2, 56.8, 55.7, 50.5, 44.7, 43.9, 37.4, 36.5. 
 1H and 13C NMR signals for 44
4.35 (d, 1H)
2.57 (d, 1H)





































In a vial with a stir bar, S45 (18.9 mg, 0.0550 mmol) was dissolved in pyridine (7 mL) and was 
cooled to 0 ºC in an ice water bath. After 10 min, benzyl chloroformate (0.03 mL, mmol) was 
added to the mixture, which was capped and stirred under N2 at room temperature. After 45 min, 
the reaction was diluted with saturated sodium bicarbonate and was extracted with ethyl acetate 
(3x). The organic layers were combined, dried over sodium sulfate, and were concentrated under 
reduced pressure. The crude residue was purified by column chromatography (15:1 
dichloromethane/methanol) on silica yield to afford S46 (21.3 mg, 81% yield) as a yellow solid. 
1H NMR (d7-DMF, 500 MHz, 80 ºC): δ 8.03 (s, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.41–7.27 (m, 
5H), 7.24 (d, J = 8.8 Hz, 1H), 6.77 (s, 1H), 6.59 (s, 1H), 5.04 (d, J = 12.7 Hz, 1H), 4.98 (d, J = 
13.0 Hz, 1H), 4.32 (d, J = 16.9 Hz, 1H), 3.99 (s, 3H), 3.83 (s, 3H), 3.13 (s, 1H), 3.04–2.96 (m, 
1H), 2.80–2.76 (m, 1H), 2.66 (s, 3H), 2.63–2.55 (m, 1H), 2.12 (dt, J = 7.9, 1.6 Hz, 1H). 
13C NMR (d7-DMF, 125 MHz, 80 ºC): δ 191.8, 182.9, 156.6, 155.6, 153.9, 151.8, 144.1, 137.8, 
131.0, 128.6, 128.3, 127.9, 127.7, 126.8, 126.7, 126.5, 118.8, 114.3, 111.2, 66.5, 63.9, 56.3, 55.9, 

































47.2, 45.7, 44.4, 44.3. 




Procedure: In a vial with a stir bar, S36 (38.5 mg, 0.1074 mmol) was dissolved in pyridine (5 
mL). Next, 4-toluenesulfonyl chloride (68.1 mg, 0.3572 mmol) was added to the mixture and 
allowed to stir for 24 hours. The pyridine was blow-dried open to air for a period of 12 hours. 
The resulting residue was purified by column chromatography (15:1 dichloromethane/methanol) 
on silica gel to afford tosyl oxime S47 (40.5 mg, 74% yield) as a light yellow solid. 
1H NMR (CDCl3, 500 MHz): δ 7.85 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.6 Hz, 1H), 7.30 (d, J = 
8.2 Hz, 2H), 6.78 (d, J = 8.6 Hz, 1H), 5.15 (d, J = 16.5 Hz, 1H), 4.92 (d, J = 2.2 Hz, 1H), 3.91 (s, 
3H), 3.35 (s, 3H), 3.30 (d, J = 3.4 Hz, 1H), 2.98 (t, J = 2.6 Hz, 1H), 2.74 (dd, J = 11.6, 4.8 Hz, 
1H), 2.41 (s, 3H), 2.38 (s, 3H), 2.12–2.05 (m, 2H), 2.09 (d, J = 16.4 Hz, 1H), 1.93 (td, J = 13.5, 
5.2 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 192.8, 158.7, 152.2, 150.0, 149.8, 145.1, 144.5, 132.7, 129.7 
(2C), 129.0 (2C), 126.2, 119.8, 109.1, 107.6, 67.1, 56.3, 55.2, 47.9, 45.5, 43.2, 38.8, 35.8, 34.9, 










































Procedure: In a vial with a stir bar, S47 (40.5 mg, 0.0790 mmol) was dissolved in dioxane (15 
mL). Next, 10% NaOH (5 mL) were added to the reaction mixture, which was stirred for 15 
hours. The reaction mixture was diluted with water and was extracted with dichloromethane 
(4x). The organic layers were combined, dried over sodium sulfate, and were concentrated under 
reduced pressure. The crude residue was purified by flash chromatography (9:1 
dichloromethane/methanol) on silica gel to afford S48 (13.1 mg, 49% yield) as a yellow solid. 
1H NMR (CDCl3, 500 MHz): δ 7.41 (d, J = 8.7, 1H), 6.81 (d, J = 8.7 Hz, 1H), 5.50 (d, J = 2.6 
Hz, 1H), 4.83 (s, 1H), 3.96 (s, 3H), 3.47 (s, 3H), 3.44 (t, J = 2.7 Hz, 1H), 3.35 (d, J = 2.8 Hz, 
1H), 2.81 (ddd, J = 12.4, 5.4, 1.7 Hz, 1H), 2.46 (s, 3H), 2.40 (td, J = 12.4, 3.9 Hz, 1H), 2.22 (td, 
J = 11.8, 4.8 Hz, 1H), 2.02 (ddd, J = 12.7, 3.9, 1.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 190.9, 188.5, 153.9, 149.7, 144.7, 137.2, 124.9, 120.1, 115.2, 
114.5, 88.5, 69.3, 57.0, 55.4, 47.3, 44.2, 43.5, 42.2, 33.7. 














































Procedure: In a vial with a stir bar, S1 (120 mg, 0.3667 mmol) was dissolved in methanol (10 
mL). Hydroxylamine hydrochloride (173.0 mg, 2.290 mmol) and sodium acetate (294.0 mg, 
3.584 mmol) were added to the reaction vial. The vial was capped and stirred in an oil bath at 80 
ºC. After 15 hours, the methanol was evaporated under reduced pressure and taken up in water. 
The contents were basified with 15% ammonium hydroxide. The mixture was poured into a 
seperatory funnel, diluted with water and extracted with dichloromethane (10x). The organic 
layers were combined, dried with sodium sulfate, and were condensed under reduced pressure to 
afford known oxime S49 (123.8 mg, 99% yield) as an off-white solid. Spectral data (1H and 13C 















































Procedure: In a vial with a stir bar, S49 (89.8 mg, 0.2607 mmol) was dissolved in methanol (7 
mL). Ammonium formate (157.3 mg, 2.495 mmol) and 10% palladium on activated charcoal 
(82.3 mg) were added to the vessel. The vial was capped and stirred at 80 ºC in an oil bath for 2 
hours. The mixture was cooled, filtered through Celite, and washed with methanol. The mixture 
was taken up in water and extracted with dichloromethane (8x). The organic layers were 
combined, dried with sodium sulfate, concentrated in vacuo to afford known primary amine S50 
(47.7 mg, 55% yield) as a white solid. Spectral data (1H NMR) was consistent with literature 
reported values.33  
Compound S51 
 
Procedure: In a vial with a stir bar, S1 (102.4 mg, 0.3109 mmol) was dissolved in 30% 
hydrogen peroxide (10 mL). The vial was capped and stirred under N2 for 3 days. The reaction 
was diluted in water and was extracted with dichloromethane (20x). The organic layers were 
combined, dried over Na2SO4, and was concentrated under reduced pressure. The crude residue 
was purified by reverse phase column chromatography to afford S51 (64.0 mg, 60% yield) as a 













































Procedure: In a vial with a stir bar, S51 (64.0 mg, 0.1855 mmol) was dissolved in methanol (7 
mL). Under inert atmosphere, the vial was capped and was cooled to 0 ºC in a water/ice bath. 
After 10 min, iron sulfate heptahydrate (76.2 mg, 0.2741 mmol) was added to the vial and stirred 
at 0 ºC for 25 min. After this time, the mixture was stirred at room temperature for 13 min, 
diluted with water, and quenched with 15% ammonium hydroxide. An extraction was performed 
with dichloromethane (15x). The organic layers were combined, dried over Na2SO4, and were 
concentrated under reduced pressure. The crude residue was purified by reverse phase column 
chromatography to afford S52 (31.0 mg, 53% yield) as a white solid. Spectral Data (1H NMR) 
was consistent with literature reported values.33 
Compound S53 
 
Procedure: In a vial with a stir bar, S52 (31.0 mg, 0.0983 mmol) was dissolved in pyridine (6 
mL). The vial was capped under N2 and cooled to 0 ºC in an ice/water bath. After 10 min, benzyl 
chloroformate (0.25 mL, 1.751 mmol) was syringed into the solution and was stirred in ice for 15 
min. The reaction was allowed to stir at room temperature for 16 hours and was subsequently 
diluted with saturated sodium bicarbonate and water. The contents were extracted with 




































concentrated under reduced pressure. The crude residue was purified by flash chromatography 
(15:1 dichloromethane/methanol) to afford S53 (39.0 mg, 88% yield) as a white solid. 
1H NMR (d7-DMF, 80 ºC, 500 MHz) δ 7.65–7.47 (m, 5H), 6.94 (d, J = 8.3 Hz, 1H), 6.69 (d, J = 
8.2 Hz, 1H), 5.98 (d, J = 2.5 Hz, 1H) 5.39–5.31 (m, 2H), 4.90 (t, J = 4.6 Hz, 1H), 4.47 (d, J = 
15.4 Hz, 1H), 4.09 (dd, J = 13.5, 5.3 Hz, 1H), 3.94 (s, 3H), 3.63 (s, 3H), 3.41 (dd, J = 17.9, 5.2 
Hz, 1H), 3.12–3.04 (m, 1H), 2.92 –2.80 (m, 2H), 2.74 (t, J = 14.0 Hz, 1H), 2.64 (d, J = 17.9 Hz, 
1H), 2.20 –2.15 (m, 1H), 1.94 (td, J = 12.9, 5.4 Hz, 1H). 
13C NMR (d7-DMF, 80 ºC, 125 MHz): δ 192.4, 155.8, 155.4, 153.1, 146.7, 146.3, 138.0, 136.5, 
129.9, 128.8, 128.2, 128.0, 123.0, 119.1, 115.2, 111.0, 69.8 (2C), 67.0, 56.4, 54.9, 49.9, 48.8, 
44.7, 40.8, 39.2. 




Procedure: In a vial with a stir bar, S3 (308.7 mg, 0.9850 mmol) was dissolved in 3-methylbut-
2-en-1-ol (0.4 mL) and was capped and stirred under N2 for 20 hours. The mixture was directly 













5.39 - 5.31 (m, 2H)


























purified by column chromatography (15:1 dichloromethane/methanol) on silica gel to provide 
S54 (226.3 mg, 58% yield) as a light orange solid. 
1H NMR (CD3OD, 500 MHz) δ 6.71 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 5.95 (d, J = 
2.2 Hz, 1H), 5.45 (t, J = 7.0 Hz, 1H), 4.39 (s, 1H), 4.38 (d, (J = 15.7 Hz, 1H), 4.24 (d, J = 6.9 Hz, 
2H), 3.46 (s, 3H), 3.39 (d, J = 3.3 Hz, 1H) 3.03 (t, J = 3.0 Hz, 1H), 2.53–2.47 (m, 1H), 2.52 (s, 
3H), 2.44 (d, J = 15.7 Hz, 1H), 2.00 (td, J = 12.3, 3.4 Hz, 1H), 1.91 (ddd, J = 13.1, 3.5, 1.8 Hz, 
1H), 1.82 (td, J = 12.7, 4.4 Hz, 1H), 1.79 (s, 3H), 1.77 (s, 3H). 
13C NMR (CD3OD, 125 MHz): δ 196.5, 151.3, 146.1, 145.5, 138.5, 131.9, 123.6, 122.7, 122.3, 
120.6, 114.7, 71.1, 67.0, 60.1, 55.0, 49.9, 48.1, 45.9, 42.9, 42.1, 36.5, 26.0, 18.4. 




Procedure: In a vial with a stir bar, S3 (202.0 mg, 0.6446 mmol) was dissolved in pyridine (5 
mL) and was cooled to 0 ºC in an ice/water bath. Acetic anhydride (3 mL) was added to the vial. 
The contents were stirred at 0 ºC for 5 min and were allowed to stir at room temperature for 14 
hours. The reaction was diluted with saturated sodium bicarbonate and extracted with 







































dichloromethane (4x). The organic layers were combined, dried over sodium sulfate, and were 
concentrated in vacuo. The crude residue was purified by flash chromatography (15:1 
dichloromethane/methanol) to afford S55 (237.0 mg, 80% yield) as a tan solid. Spectral data (1H 
NMR) was consistent with literature reported values.35 
Compounds S56 and S57 
 
Procedure: In a vial with a stir bar, S1 (151.7 mg, 0.4605 mmol) was dissolved in methanol (4 
mL). Diacetoxyiodobenzene (148.7 mg, 0.4617 mmol) was added to the mixture and was capped 
under N2. After 3 hours, the mixture was basified with Na2SO4 and was extracted with 
dichloromethane (4x). The organic layers were combined, dried with sodium sulfate, and 
concentrated under reduced pressure. The crude residue was purified by column chromatography 
(9:1 dichloromethane/methanol) on silica gel to yield S56 (25.0 mg, 15% yield) and S57 (53.3 




Procedure: In a vial with a stir bar, S1 (283.5 mg, 0.8607 mmol) was dissolved in acetonitrile (5 
























































stirred in an oil bath at 80 ºC. After 16 hours, contents of the vial were filtered through a fritted 
funnel and were lightly washed with water to afford S58 (267.9 mg, 62% yield) as a white solid. 
The chloride salt of this compound is known.48 
1H NMR (d6-DMSO, 500 MHz) δ 8.83 (s, 1H), 7.66–7.62 (m, 2H), 7.56–7.51 (m, 3H), 6.82 (d, J 
= 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 5.81 (d, J = 2.3 Hz, 1H) 5.25–5.18 (m, 1H), 5.02–4.94 
(m, 1H), 4.25–4.21 (m, 1H), 4.18 (d, J = 15.5 Hz, 1H), 3.89–3.84 (m, 1H), 3.71 (s, 3H), 3.40 (s, 
3H), 3.37–3.18 (m, 3H), 3.03 (ddd, J = 15.3, 8.7, 4.9 Hz, 1H), 2.99 (s, 3H), 2.75–2.59 (m, 2H), 
1.87 (d, J = 13.1 Hz, 1H). 
13C NMR (d6-DMSO, 125 MHz): δ 191.9, 151.6, 146.3, 145.0, 133.3 (2C), 130.4, 129.1 (2C), 
128.0, 125.8, 121.1, 118.3, 113.0, 110.7, 64.0, 63.0, 55.8 (2C), 54.7 (2C), 49.3, 46.4, 37.4, 29.8, 
26.5. 




Procedure: In a vial with a stir bar, S58 (143.0 mg, 0.2858 mmol) was dissolved in acetonitrile 
(10 mL). Potassium carbonate (330.0 mg, 2.388 mmol) was added to the vial, capped under air, 















7.66 - 7.62 (m, 2H)





















and was stirred at 60 ºC in an oil bath. After 16 hours, the contents of the vial were poured into a 
seperatory funnel and were diluted with water. The mixture was then extracted with ethyl acetate 
(4x). The organic layers were combined, dried over sodium sulfate, and were concentrated under 
reduced pressure. The crude residue was purified by column chromatography (15:1 
dichloromethane/methanol) on silica gel to generate S59 (8.2 mg, 7% yield) as an orange solid. 
1H NMR (CDCl3, 500 MHz) δ 7.86 (d, J = 8.5 Hz, 1H), 7.24–7.16 (m, 3H), 7.11–7.06 (m, 2H), 
6.99 (d, J = 8.6 Hz, 1H), 6.48 (s, 1H), 6.28 (s, 1H), 4.37 (d, J = 16.7 Hz, 1H), 3.98 (s, 3H), 3.83 
(s, 3H), 3.27 (d, J = 13.1 Hz, 1H), 3.19 (d, J = 13.0 Hz, 1H), 2.91 (ddd, J = 13.4, 11.1, 4.2 Hz, 
1H), 2.59 (d, J = 16.6 Hz, 1H) 2.09–1.96 (m, 2H), 1.93 (s, 3H), 1.72–1.64 (m, 1H). 
13C NMR (CDCl3, 125 MHz): δ 192.7, 183.7, 156.0, 153.5, 150.1, 142.6, 130.3, 129.1 (2C), 
128.3 (2C), 127.0, 126.2, 119.8, 113.6, 113.0, 109.9, 98.8, 61.8, 56.4, 56.1, 53.5, 46.8, 44.3, 
42.3, 34.3. 




Procedure: In a vial with a stir bar, S1 (208.0 mg, 0.6315 mmol) was dissolved in acetonitrile 
















7.24 - 7.16 (m, 3H)
























(15 mL). Iodomethane (0.40 mL, 6.425 mmol) was added and the vial was capped and stirred 
under N2. After 20 hours, the mixture was diluted with water, stirred for 30 min, and 
concentrated under reduced pressure. The crude residue was washed with diethyl ether through a 
funnel to afford known quaternary ammonium salt S60 (264 mg, 90% yield) as a white solid.48 
1H NMR (D2O, 500 MHz): δ 6.69 (d, J = 8.3 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 5.83 (d, J = 2.0 
Hz, 1H), 4.30 (d, J = 15.9 Hz, 1H), 3.99–3.95 (m, 1H), 3.70–3.67 (m, 1H), 3.68 (s, 3H), 3.46 (s, 
3H), 3.39 (s, 3H), 3.38–3.33 (m, 2H), 3.27 (dd, J = 13.7, 3.2 Hz, 1H), 3.19 (s, 3H), 2.88 (td, J = 
13.7, 3.4 Hz, 1H), 2.72 (d, J = 16.0 Hz, 1H), 2.27 (td, J = 14.2, 4.2 Hz, 1H), 2.07–1.98 (m, 1H). 
13C NMR (d6-DMSO, 125 MHz): δ 191.6, 151.5, 146.2, 144.9, 125.6, 120.8, 118.3, 113.0, 
110.7, 66.8, 56.9, 55.8, 54.6, 53.3, 50.9, 46.4, 39.0, 37.8, 29.9, 26.4. 
HRMS(ESI): m/z calc. for C20H26NO4 [M]+: 344.1862, found: 344.1852. 
Compound S61 
 
Procedure: In a vial with a stir bar, water (20 mL) was purged with N2 gas for 24 hours. In a 
separate vial with a stir bar, S60 (124.5 mg, 0.2557 mmol) and potassium carbonate (312.6 mg, 
2.262 mmol) were added. The vial was sealed with a stopper and placed under N2. The N2-
purged water (12 mL) was syringed into the vial containing the solids. The contents of the vial 
were purged with N2 for 5 min. The stopper was carefully replaced with a Teflon vial cap and 
was sealed with electrical tape. The vial was placed in an oil bath at 60 ºC and was allowed to 
stir for 8 hours. The vial was removed from heat, cooled to room temperature, and was poured 





















dichloromethane (4x). The organic layers were combined, dried over Na2SO4, and were 
concentrated in vacuo. The crude residue was purified by flash chromatography (9:1 
dichloromethane/methanol) on silica gel to afford S61 (34.5 mg, 39% yield) as an orange solid. 
1H NMR (CDCl3, 500 MHz) δ 6.76 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.21 (s, 1H), 
6.13 (t, J = 4.1 Hz, 1H), 4.13 (d, J = 16.8 Hz, 1H), 3.83 (s, 3H), 3.71 (s, 3H), 3.51 (d, J = 4.0 Hz, 
2H), 2.67 (d, J = 16.7 Hz, 1H), 2.56 (td, J = 12.1, 4.2 Hz, 1H), 2.43 (td, J = 11.8, 4.5 Hz, 1H), 
2.26 (s, 6H), 2.16 (td, J = 12.1, 4.6 Hz, 1H), 2.02 (td, J = 11.8, 4.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 193.3, 149.7, 145.5, 143.8, 134.6, 127.2, 126.7, 123.2, 119.1, 
116.8, 109.9, 56.3, 55.4, 55.3, 48.4, 43.8 (2C), 42.4, 31.2, 30.9. 





Procedure: In a vial with a stir bar, S18 (105.3 mg, 0.2938 mmol) was dissolved in pyridine (7 
mL). The mixture was stirred at 0 ºC in ice/water bath for 5 min. Acetyl chloride (0.3 mL, 4.204 
mmol) was added to the reaction and the vial was capped and stirred under N2 for 10 min. The 


































reaction was then stirred at room temperature for 17 hours. After this time, the mixture was 
diluted with water and saturated sodium bicarbonate solution and was extracted with 
dichloromethane (3x). The organic layers were combined, dried over sodium sulfate, and were 
concentrated under reduced pressure. The crude residue was purified by column chromatography 
(15:1 dichloromethane/methanol) on silica gel to afford S62 (60.8 mg, 47% yield) as a light 
orange solid. 
1H NMR (CDCl3, 500 MHz): δ 8.08 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 5.47–5.39 (m, 
1H), 4.94 (d, J = 6.6 Hz, 1H), 3.90 (s, 3H), 3.48 (s, 3H), 3.37 (d, J = 3.4 Hz, 1H), 3.26–3.17 (m, 
1H), 2.95 (dd, J = 6.6, 3.3 Hz, 1H), 2.70–2.62 (m, 1H), 2.57 (s, 3H), 2.40 (s, 3H), 2.34 (s, 3H), 
2.04–1.89 (m, 3H). 
13C NMR (CDCl3, 125 MHz): δ 193.0, 173.4, 168.6, 167.8, 157.2, 151.2, 138.0, 136.3, 128.3, 
126.2, 111.2, 105.8, 66.2, 56.4, 56.0, 47.9, 45.4, 43.0, 42.5, 34.7, 26.6, 21.4, 21.1. 














































mL). The mixture was purged with nitrogen for 10 minutes. Palladium on activated charcoal 
(14.8 mg, 10% w/w) was added to the reaction vial. A balloon of hydrogen was fitted over the 
vial and the reaction was stirred for 2 hours. The mixture was filtered through Celite, washed 
with methanol, and concentrated in vacuo. The crude residue was purified by C18 
chromatography to afford S63 (6.2 mg, 45% yield) as a white solid. 
1H NMR (CDCl3, 500 MHz): δ 6.87 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 5.93–5.90 (m, 
1H), 5.92 (d, J = 1.1 Hz, 1H), 5.88 (d, J = 1.0 Hz, 1H), 4.14 (s, 1H), 3.61 (d, J = 6.1 Hz, 2H), 
3.55 (s, 3H), 3.16 (s, 1H), 2.87 (dd, J = 5.4, 2.7 Hz, 1H), 2.52 (dd, J = 12.2, 4.1 Hz, 1H), 2.47 (s, 
3H), 2.04 (td, J = 12.3, 3.1 Hz, 1H), 1.92 (td, J = 12.4, 4.5 Hz, 1H), 1.51–1.46 (m, 1H). 
13C NMR (CDCl3, 125 MHz): δ 168.1, 148.1, 146.6, 144.4, 135.8, 121.9, 119.9, 108.4, 108.2, 
100.8, 64.5, 55.6, 50.0, 47.4, 45.0, 43.2, 42.7, 35.0, 29.9. 




Procedure: In a vial with a stir bar, S28 (32.4 mg, 0.0880 mmol) was dissolved in methanol (10 







































mg) was added to the reaction vial. A balloon of H2 gas was fitted to the vial and the reaction 
was stirred for 2 hours. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The crude residue was purified by C18 chromatography to 
afford S64 (18.1 mg, 60%) as a white solid. 
1H NMR (CDCl3, 500 MHz): δ 6.90 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 5.95 (d, J = 
1.5 Hz, 1H), 5.87 (d, J = 1.4 Hz, 1H), 3.92 (s, 1H), 3.81 (dd, J = 11.4, 6.6 Hz, 1H), 3.79 (d, J = 
13.2 Hz, 1H), 3.41 (s, 3H), 2.94 (d, J = 2.8 Hz, 1H), 2.46 (s, 3H), 2.42 (ddd, J = 12.2, 4.8, 1.6 
Hz, 1H), 2.34 (dt, J = 13.3, 2.9 Hz, 1H), 2.30–2.26 (m, 1H), 2.27 (d, J = 13.7 Hz, 1H), 1.97 (td, J 
= 12.3, 3.4 Hz, 1H), 1.81–1.75 (m, 1H), 1.80 (q, J = 12.4 Hz, 1H), 1.70 (dt, J = 12.8, 2.4 Hz, 
1H). 
13C NMR (CDCl3, 125 MHz): δ 207.1, 147.1, 145.1, 135.8, 122.1, 119.2, 108.1, 100.7, 84.0, 
66.2, 58.3, 48.8, 46.2, 43.9, 43.1, 43.0, 41.9, 39.5, 35.8. 
HRMS(ESI): m/z calc. for C19H25N2O4 [M+H]+: 345.1814, found: 345.1811. 
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Procedure: In a round bottom flask with a stir bar, S23 (156.2 mg, 0.4968 mmol) was dissolved 
in methanol (10 mL). The reaction mixture was cooled to –78 ºC in an acetone/dry ice bath. 
Sodium borohydride (83.7 mg, 2.213 mmol) was added to the reaction mixture. After 1 hour, the 
reaction temperature was brought up to 0 ºC. After 1 hour, the reaction mixture was diluted with 
water and concentrated under reduced pressure. The crude mixture was passed through a layer of 
silica (9:1 dichloromethane/methanol with 1% triethylamine). The organic fractions were 
concentrated under reduced pressure. The residue was further purified by C18 chromatography 
to afford amino alcohol S65 (97.2 mg, 61% yield) as a white solid. 
1H NMR (CD3OD, 500 MHz): δ 6.80 (d, J = 8.3 Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 3.93 (dd, J = 
14.6, 3.2 Hz, 1H), 3.83 (s, 3H), 3.75 (dt, J = 11.4, 4.5 Hz, 1H), 3.08 (q, J = 3.6 Hz, 1H), 2.96 (d, 
J = 17.3 Hz, 1H), 2.87–2.78 (m, 2H), 2.43 (ddd, J = 12.1, 4.7, 1.6 Hz, 1H), 2.34 (s, 3H), 1.99 (td, 
J = 12.4, 3.2 Hz, 1H), 1.93 (td, J = 13.0, 2.2 Hz, 1H), 1.76 (dt, J = 12.4, 2.7 Hz, 1H), 1.55 (q, J = 
12.4 Hz, 1H), 1.51–1.43 (m, 2H), 1.36 (dd, J = 14.6, 3.7 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 147.3, 146.7, 131.3, 126.5, 120.2, 111.0, 72.5, 59.0, 56.8, 53.7, 
48.4, 45.6, 42.6, 38.9, 38.6, 36.0, 30.9, 25.2. 

























Procedure: In an oven dried round-bottom flask with a stir bar, S10 (19.1 mg, 0.0439 mmol) 
was dissolved in tetrahydrofuran (6 mL). The contents of the flask were placed on an ice bath 
and under N2 atmosphere. After 10 min, lithium aluminum hydride (28.8 mg, 0.7589 mmol) was 
slowly added to the flask and was allowed to stir at 0 ºC for 1 hour. The reaction was quenched 
with water and 10% NaOH, placed in an Erlenmeyer flask, and was diluted with ethyl acetate. 
Next, sodium sulfate was added to the Erlenmeyer flask to take up any water. The contents were 
decanted into a round bottom flask and were concentrated in vacuo. The crude residue was 
purified by flash chromatography (15:1 dicloromethane/methanol) on silica gel to afford S66 
N
H
Key 1H and 13C NMR signals for 65
1.55 (q, 1H)







































JHa, Hc = 3.2 Hz
JHc, Hb = 3.7 Hz
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(5.6 mg, 29% yield) as a tan solid. Compound S66 was isolated as a single diastereomer. 
1H NMR (CDCl3, 500 MHz) δ 5.19 (s, 1H), 4.53 (d, J = 1.3 Hz, 1H), 4.18 (ddt, J = 12.2, 8.6, 4.4 
Hz, 1H), 3.94 (s, 1H), 3.68 (s, 3H), 3.64 (s, 3H), 3.62 (s, 3H), 3.51 (s, 3H), 3.35 (s, 3H), 3.06 (d, 
J = 3.2 Hz, 1H), 2.69–2.66 (m, 1H), 2.58 (dd, J = 11.9, 4.7 Hz, 1H), 2.53 (s, 3H), 2.51–2.46 (m, 
1H), 2.40 (dd, J = 13.0, 6.5 Hz, 1H), 2.14–2.09 (m, 1H), 1.72–1.57 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 170.9, 168.1, 153.5, 141.0, 134.9, 101.2, 97.3, 94.0, 72.4, 66.0, 
61.4, 58.9, 56.5, 54.7, 51.9, 51.1, 46.7, 42.8, 42.4, 40.9, 38.1, 36.1. 




Procedure: In a vial with a stir bar, S1•HCl (533.4 mg, 1.458 mmol) and sodium azide (454.0 
mg, 6.985 mmol) were suspended in 1:1 sulfuric acid/water and were cooled to 0 ºC in an ice 
bath. After 5 min, the reaction was stirred at room temperature for 6 hours. The reaction was 
poured into a seperatory funnel containing ice water and was basified with concentrated 
ammonium hydroxide. An extraction with dichloromethane (5x) was performed. The organic 
layers were combined, dried over sodium sulfate, and were concentrated in vacuo. The crude 






































residue was purified by flash chromatography (9:1 dichloromethane/methanol) on silica gel to 
produce lactam S67 (274.1 mg, 54% yield) as a white solid. 
1H NMR (d6-acetone, 500 MHz) δ 7.69 (bs, 1H), 7.47 (t, J = 5.3 Hz, 1H), 6.79 (d, J = 8.3 Hz, 
1H), 6.64 (d, J = 8.2 Hz, 1H), 5.12 (d, J = 6.5 Hz, 1H), 4.11 (dd, J = 14.5, 7.1 Hz, 1H), 3.80 (s, 
3H), 3.45 (s, 3H), 3.47–3.42 (m, 1H), 3.11 (t, J = 4.3 Hz, 1H), 3.04 (d, J = 18.3 Hz, 1H), 2.95 
(dd, J = 18.3, 5.4 Hz, 1H), 2.79 (dd, J = 6.4, 3.4 Hz, 1H), 2.53–2.46 (m, 1H), 2.32 (s, 3H), 2.03–
1.97 (m, 2H), 1.74–1.68 (m, 1H). 
13C NMR (d6-acetone, 125 MHz): δ 168.9, 152.3, 146.4, 145.4, 131.3, 126.3, 119.2, 110.4, 
105.8, 56.7, 56.4, 55.5, 51.0, 48.9, 46.4, 43.1, 42.9, 33.9, 24.1. 
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Procedure: In a vial with a stir bar, S20 (141.9 mg, 0.4156 mmol) was dissolved in 
dichloromethane (8 mL), capped under nitrogen, and was allowed to cool to 0 ºC in an ice/water 
bath. After 10 minutes, m-chloroperbenzoic acid (126.2 mg, 0.5486 mmol) was added to the vial 
and stirred at room temperature for 1.5 hours. After this time the dichloromethane was 
evaporated under reduced pressure. The mixture was immediately purified by column 
chromatography (9:1 dichloromethane/methanol with 2% triethylamine) on silica gel to afford N-
oxide S68 (96.2 mg, 65% yield) as an orange solid. 
1H NMR (CDCl3, 500 MHz): δ 7.14 (s, 1H), 6.74 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 
6.38 (d, J = 9.2 Hz, 1H), 5.93 (d, J = 9.2 Hz, 1H), 5.77 (s, 1H), 3.82 (s, 3H), 3.72 (s, 3H), 3.10 (s, 
3H), 3.06–2.97 (m, 2H), 2.98 (s, 3H), 2.51 (ddd, J = 13.0, 10.5, 5.5 Hz, 1H), 2.20 (ddd, J = 13.3, 
11.2, 4.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 181.5, 157.3, 151.6, 149.3, 146.6, 130.6, 128.8, 127.1, 126.4, 
117.6, 117.0, 116.6, 111.7, 65.9, 58.2, 57.6, 55.6, 55.0, 45.1, 34.5. 















3.10 (s, 3H)3.10 (s, 3H);2.98 (s, 3H)
O
5.93 (d, 1H) 181.5
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2.7. Computational analysis 
2.7.1. Calculation of physicochemical properties 
The Chembridge DiversetTM-CL and DiversetTM-EXP compound collections were used for 
computational analysis (50,000 compounds each; 100,000 compounds total). Structural data was 
obtained from the Chembridge website. 
Globularity was calculated by using Maestro version 2.8.013 and MOE 2015.10. Number of 
stereogenic centers, Fsp3, Ring Complexity Index (RCI), and Ring Fusion Density (RFD) were 
calculated using a custom Python program that implements RDKit. Source code is available at 
https://github.com/HergenrotherLab/ctdTools. 
Definitions of Reported Physiochemical Parameters 
Stereogenic center  Number of sp3–hybridized stereogenic centers (chiral centers). 
Globularity:  Inverse condition number of the covariance matrix of atomic coordinates (a 
value of 1 indicates a perfect sphere while a value of 0 indicates a two- or 
one-dimensional object)1 
Fsp3  The number of sp3–hybridized carbons in a compound divided by the sum of 
the number of sp3–hybridized and sp2–hybridized in the compound.2 
Ring Complexity 
Index: CR = R/AR; where R corresponds to total ring size and AR is the number of 
atoms belonging to the ring system.49 
Ring Fusion 
Density: RFΔ = 2!RB/AR; where RB corresponds to the number of ring bridges in 
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CHAPTER 3: CONVERSION OF FUSIDIC ACID INTO A BROAD-SPECTRUM 
ANTIBIOTIC 
3.1. Introduction 
 As mentioned in Chapter 1, there are great examples of successful conversion targets by 
application of the eNTRy rules (6DNM-NH3, debio 1452, ribocil C).1-2 This chapter outlines the 
initial strategy and attempts to convert fusidic acid (Chapter 1) into a broad-spectrum agent using 
the eNTRy rules. However, not all targets contain binding sites that can accommodate positively 
charged nitrogens, as shown for fusidic acid in this chapter. Thus, a novel polyamine amidoxime 
prodrug strategy for traversing the outer membrane of Gram-negative bacteria is described for 
the antibiotic fusidic acid.  
3.2. Approach to conversion of fusidic acid using eNTRy rules 
3.2.1. Overall strategy for conversion of fusidic acid 
 Fusidic acid displays activity in Gram-positive bacteria, but not in Gram-negative 
ESKAPE pathogens as is evident in Table 3.1. Furthermore, it displays antibacterial activity in 
efflux pump knockout strain E. coli ΔtolC and permeability deficient E. coli JW3596 (Δrfa) 





Table 3.1. Activity of fusidic acid in ESKAPE pathogens, efflux, and permeability deficient 
strains of E. coli. Minimum Inhibitory Concentration (MIC) = µg/mL; n = 3. 
 
As previously mentioned, the ideal conversion target contains the required shape and 
flexibility requirements of the eNTRy rules (Glob ≤ 0.25, RB ≤ 5).2-3 Next, installation of one or 
multiple ionizable nitrogens such that target engagement is not perturbed will be required for 
traversing the outer-membrane of Gram-negative bacteria. Unlike our successful conversion 
targets (Figure 3.1),1-2 fusidic acid falls within the shape guideline (Glob = 0.10) but outside of 
the flexibility guideline (RB = 6). Therefore, converting fusidic acid requires a two-pronged 
approach: 1) determination of the best location for a primary amine, and 2) reduction of the 
number of rotatable bonds to bring fusidic acid fully within the eNTRy rules. 
Species Strain MIC 
S. aureus ATCC 29213 0.125 
E. coli MG1655 512 
E. coli ATCC 25922 1024 
K. pneumoniae ATCC 29893 1024 
A. baumannii ATCC 19606 64 
P. aeruginosa PA01 1024 
E. cloacae ATCC 29893 512 
E. coli ΔtolC 2 





























Figure 3.1. Flexibility vs. 3-dimensionality plot of fusidic acid and successful conversion targets 
(DNM, Debio 1452, and Ribocil C). Red lines represent eNTRy rule boundaries. 
 
3.2.2. Reducing the number of rotatable bonds on fusidic acid side chain 
 Derivatives shown in Chapter 1 (Figures 1.7 and 1.8) show reduced antibiotic activity 
with shortened side chains. As such, generating derivatives similar to 1-16 (Chapter1; Figure 1.8) 
would not be the best strategy. A different approach to reduce the number of rotatable bonds is to 
restrict rotation of the side chain by addition of unsaturation, aromatic rings, or alkyl tethering 
such as those shown in Figure 3.2. These could be accessed through a known tetrasubstituted 
olefin cleavage followed by Aldol condensation to install the new side chain.4 Introduction of 






































































side chains synthesized in our lab retain activity in Gram-positive bacteria (1-18, 1-19; Chapter 
1; Figure 1.8). 
 
Figure 3.2. Proposed fusidic acid side chains with a reduced number of rotatable bonds. 
3.2.3. Introduction of a primary amine at a favorable position 
 The best locations on fusidic acid to introduce a primary amine to increase accumulation 
in Gram-negative bacteria,2-3 was determined using known SAR (Figure 3.3A) 5-8 in combination 
with a crystal structure of fusidic acid bound to its target, EF-G (Figure 3.3B).9 Addition of an 
amine to the side chain is disfavorable as SAR indicates heteroatom incorporation into the side 
chain generally leads to inactive derivatives (Chapter 1).5-6 There are, however, several positions 
on the steroidal core where installing a primary amine could be amenable as indicated in Figure 
3.3A. Derivatives of fusidic acid that combine a modified side chain from the previous section 
and a primary amine in the appropriate location (selected examples shown in Figure 3.4) would 
provide the best probability of successful activity in Gram-negative pathogens. Synthetic 
approaches to these amine-containing derivatives involve C-H functionalization reactions 



















































Glob = 0.07FA-naphthyl 
RB = 4 
Glob = 0.12 
FA-benzyl 
RB = 5 
Glob = 0.13 
FA-diene 
RB = 5 
Glob = 0.17 
FA-cyclohexyl 
RB = 4 




Figure 3.3. A) Positions on fusidic acid core suitable for amine installation. B) Crystal structure 
of fusidic acid-EF-G complex in T. thermophilus (PDB: 4WQF).9 Images generated using 
Maestro version 2.8.013 (Schrödinger, New York). 
 
 
Figure 3.4. Selected examples of proposed fusidic acid derivatives with a primary amine and 
reduced number of rotatable bonds. 
 
3.3. Primary amine installation on fusidic acid scaffold and biological evaluation 
3.3.1. Amine installation on A-ring hydroxyl 
 Due to ease of synthetic accessibility, the A-ring hydroxyl was chosen as the first site 
where simple activation of the alcohol, displacement of azide, and reduction to the amine was 
envisioned. Fusidic acid was treated with methanesulfonyl chloride in neat pyridine to produce 





























































































RB = 5 
Glob = 0.11 
FA-benzyl-NH3 
RB = 5 
Glob = 0.10 
FA-diene-NH3 
RB = 5 
Glob = 0.08 
FA-cyclohexyl-NH3 
RB = 5 
Glob = 0.15 
FA-naphthyl-C-NH3 
RB = 5 
Glob = 0.20 
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inversion of configuration. Finally, a Staudinger reduction with polymer supported 
triphenylphosphine yielded primary amine 3-3. Unfortunately, amine 3-3 was inactive in S. 
aureus (MIC > 32 µg/mL), likely indicating disruption of target engagement with EF-G, as well 
as inactive in E. coli (MIC > 32 µg/mL). 
 
Scheme 3.1. Synthesis and activity of A-ring aminated fusidic acid. MICs in µg/mL; n = 3. S. 
aureus ATCC 29213 and E. coli MG1655. 
 
3.3.2. Synthesis of C-ring amine epimers of fusidic acid 
 The lack of activity of 3-3 inspired pursuit of amination of the C-ring. Silyl protection of 
sodium fusidate with TBSCl led to protection of both the A-ring hydroxyl and the carboxylic 
acid to afford TBS ester 3-4 (Scheme 3.2), followed by pyridinium chlorochromate (PCC) 
oxidation to generate ketone 3-5. Hydrogenation of the prenyl group led to desired saturated 
derivative 3-6, which was subjected to HF•pyridine deprotection of the TBS groups giving free 
acid 3-7. Finally, Lewis acid mediated reductive amination of 3-7 with titanium(III) chloride, 
ammonium acetate, and sodium cyanoborohydride yielded primary amine epimers 3-8 and 3-9. 
MIC determination for 3-8 and 3-9 indicated that both compounds are inactive in both S. aureus 















































































MIC in S. aureus > 32 
MIC in E. coli > 32 




Scheme 3.2. Synthesis and activity of C-ring aminated epimers from fusidic acid. MICs in 
µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. 
 
3.3.3. Synthesis of fusidic acid O-glycine 
 The next modification site involved substituting the O-acyl group on fusidic acid with O-
glycine. Simple hydrolysis of the O-acyl group followed by direct acylation of the resulting 
hydroxyl led to lactonization of the hydroxyl group with the carboxylic acid. This led to a longer 
synthetic route involving reduction of the carboxylic acid, installation of an aminated acyl group, 
and finally re-oxidation of the acid. A similar re-oxidation strategy has been used in the literature 
to generate a variety of fusidic acid derivatives.20 First, silylation of the A-ring hydroxyl 
followed by lithium aluminum hydride reduction of the carboxylic acid and acetate afforded triol 
3-10 (Scheme 3.3). Selective silylation of the primary alcohol over the other two secondary 
alcohols was achieved with diphenylmethylsilyl chloride to produce 3-11. Next, acylation of the 
D-ring secondary alcohol with chloroacetic anhydride yielded α–chloro ester 3-12. Azide 
displacement of the chloride gave 3-13, followed by selective deprotection to reveal primary 
alcohol 3-14. Chemoselective oxidation of primary alcohol 3-14 with one equivalent of Dess-
Martin periodinane gave aldehyde 3-15. Next, 3-15 was further oxidized to carboxylic acid 3-16 








































































































MIC in S. aureus = 64 
MIC in E. coli > 1024 
 
3-9 
MIC in S. aureus = 128 




resulted in HF addition across the prenyl group double bond and/or C-ring hydroxyl elimination. 
Fortunately, aqueous HF resulted in solely the desired deprotection to α–azido ester 3-17. 
Staudinger reduction with polymer supported triphenylphosphine furnished the final fusidic acid 
O-glycine derivative, 3-18. 
 
Scheme 3.3. Synthesis and activity of fusidic acid O-glycine derivative. MICs in µg/mL; n = 3. 
S. aureus ATCC 29213 and E. coli MG1655. 
 
3.3.4. Biological activity and accumulation of amine derivatives in E. coli 
 The activity and accumulation of fusidic acid derivatives containing an amine on the core 
(3-3, 3-8, 3-9, and 3-18) and side chain (3-19–3-21) are summarized in Figure 3.4. These 
derivatives display no antibacterial activity in S. aureus or E. coli. Furthermore, accumulation in 
E. coli is significantly lacking. Additionally, these compounds require a long synthetic sequence 
(5-10 steps) from fusidic acid, which is not optimal. Given the lack of accumulation in addition 
to the disruption of target engagement it was clear that a new strategy for converting fusidic acid 














    DMF, 80ºC






























































































































































10 steps from fusidic acid 
3-10 3-11 3-12 
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Figure 3.5. MICs and accumulation of fusidic acid amine derivatives. Compounds 3-19–3-21 
synthesized by Martin Garcia-Chavez MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli 
MG1655. Accum. = Accumulation in E. coli MG1655. Accumulation in nmol/1012 CFU. Error = 
standard error of the mean of 3 biological replicates. 
 
3.4. Accumulation studies of fusidic acid polyamine derivatives 
3.4.1. Accumulation studies 
 The lack of accumulation of fusidic acid amine derivatives in Figure 3.5 is attributed to 
the excess of rotatable bonds. In addition, it is possible that the presence of the carboxylic acid 
was also contributing to lower accumulation, as some of our carboxylic acid-containing amines 
do not accumulate. To investigate this hypothesis compounds 3-22–3-26 (Figure 3.6) were 
synthesized. Compound 3-8 contains a single amine off of the C-ring whereas 3-22 and 3-23 
posse di- and triamine chains off the same position with the carboxylic acid intact. Furthermore, 
3-8, 3-22, and 3-23 contain the carboxylic acid functional group. Only a slight increase in 
accumulation in E. coli was observed with increasing number of amines. Conversely, when 
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E. coli: > 32 
Accum. = 73 ± 15 
3-9 
5 steps 
S. aureus: 128  
E. coli: > 1024 
Accum. = -- 
3-8 
5 steps 
S. aureus: 64 
E. coli: > 1024 
Accum. = 39 ± 9 
3-19 
4 steps 
S. aureus: > 32 
E. coli: > 32 
Accum. = 95 ± 18 
No active compounds generated 
Compounds are low accumulators 
3-18 
10 steps 
S. aureus: 64 
E. coli: > 512 
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S. aureus: 512 
E. coli: > 512 
Accum. = 62 ± 12 
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a greater increase in accumulation as the number of amines increases. In addition, 3-25 and 3-26 
accumulate to a greater extent relative to 3-22 and 3-23, which contain an acid and do not 
accumulate significantly. Although these are not direct comparisons, the carboxylic acid in 
fusidic acid is potentially detrimental to accumulation in E. coli.  
 
Figure 3.6. Accumulation of fusidic acid amine and polyamine derivatives with and without a 
carboxylic acid. Accum. = Accumulation in E. coli MG1655. Accumulation in nmol/1012 CFU. 
Error = standard error of the mean of 3 biological replicates. Compounds 3-25 and 3-26 were 
synthesized by Martin Garcia-Chavez. 
 
3.5. Bioisosteres of the carboxylic acid of fusidic acid  
3.5.1. Synthesis and biological evaluation of fusidic acid bioisosteres 
The data in Figure 3.6 and previous accumulation data led to pursuit of a suitable 
bioisostere of the carboxylic acid. Several carboxylic acid bioisosteres of fusidic acid have been 
synthesized by other labs and evaluated for antiplasmodial activity, but not antibacterial 
activity.21 Furthermore, several reviews are available for suitable bioisosteres of carboxylic 
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3-8 
RB = 7 
Accum. = 39 ± 9 
3-22 
RB = 10 
Accum. = 59 ± 21 
3-23 
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3-24 
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3-25 
RB = 11 
Accum. = 701 ± 88 
3-26 
RB = 14 
Accum. = 1769 ± 201 
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antibacterial activity in Gram-positive and Gram-negative bacteria (Figure 3.7). Hydrazide 3-37, 
2-oxo-1,3,4-oxodiazole 3-28, 2-thioxo-1,3,4-oxodiazole 3-29, acylsulfonamides 3-30 and 3-31, 
nitrile 3-32, and amidoxime ester 3-33 were all inactive in S. aureus and E. coli. Interestingly, 
amidoxime ester 3-34 displayed moderate activity in S. aureus (MIC = 8 µg/mL) while 3-33 did 
not, prompting further investigation. 
 
Figure 3.7. Antibacterial activity of fusidic acid bioisosteres. . MICs in µg/mL; n = 3. S. aureus 
ATCC 29213 and E. coli MG1655. * = solubility limit. The structures of amidoxime esters 3-33 
and 3-34 were confirmed by X-ray crystallography. 
 
3.6. Amidoxime esters of fusidic acid 
3.6.1. Synthesis and antibacterial activity of amino amidoxime esters  
 To test whether the moderate activity of 3-34 in S. aureus could be expanded to E. coli, 
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chloro-N'-hydroxyacetimidamide was coupled to fusidic acid to afford chloro amidoxime ester 3-
35 (Scheme 3.4). Nucleophilic displacement of the chlorine with sodium azide gave azido 
amidoxime ester 3-36. Both the structures 3-35 and 3-36 were confirmed by X-ray 
crystallography. Staudinger reduction of 3-36 yielded target amino amidoxime 3-37. 
Gratifyingly, the activity of 3-37 in S. aureus is greater than that of amidoxime esters 3-34–3-36. 
Other amino amidoxime esters (3-38–3-41) were generated from 3-35 and all possess similar 
activity to 3-37 in S. aureus (Figure 3.8). Piperazine amidoxime ester 3-41 displays low 
antibacterial activity in Gram-negative E. coli relative to the other amino amidoxime esters 
suggesting a higher accumulation due to the presence of two positively charged nitrogens at 
physiological pH. 
 
Scheme 3.4. Synthesis and antibacterial activity of chloro, azido, and amino amidoximes esters. 
MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. * = solubility limit. The 
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S. aureus: 1 
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Figure 3.8. Antibacterial activity of amino amidoxime esters generated from 3-37. MICs in 
µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. * = solubility limit. 
 
3.6.2. Hydrolysis of amidoxime esters to fusidic acid 
 The lack of activity of other fusidic acid derived esters (Chapter 1) and the hydrolytic 
instability of amidoximes25 led to the hypothesis of possible hydrolysis of the amidoxime esters  
to fusidic acid in the MIC testing media and possibly in bacteria. To test this hypothesis, 
hydrolysis of amino amidoxime 3-37 was monitored by LC-MS in cation adjusted Mueller 
Hinton Broth (CAMH). As shown in Figure 3.9, over the course of 72 h (and as early as 20 h), 
hydrolysis of 3-37 to fusidic acid is observed. This suggests that fusidic acid itself may be 
responsible for the antibacterial activity of amidoxime esters in S. aureus. 
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Figure 3.9. Amidoxime esters hydrolyze to fusidic acid in CAMH (2% DMSO). 
 Next, the importance of the amidoxime ester moiety was assessed by synthesizing a panel 
of derivatives that substitute the –NH2 group on the amidoxime with a carbon or sulfur atom. The 
MIC in S. aureus is used as a surrogate for hydrolysis where a low MIC indicates increased 
hydrolysis. Loss of activity was evident (Figure 3.10) when the –NH2 group on 3-34 was 
substituted for a methyl group (3-42). Inactive derivatives were also observed for benzophenone 
oxime ester 3-43 and thioamidoxime esters 3-44 and 3-45. These data suggest that the –NH2 
group on the amidoxime is critical for hydrolysis to fusidic acid.  
T = 0h; 3-37 (100); Fusidic Acid (0) 
T = 5h; 3-37 (100); Fusidic Acid (0) 
T = 20h; 3-37 (93.17); Fusidic Acid (7.33) 
T = 28h; 3-37 (69.01); Fusidic Acid (30.99) 
T = 45h; 3-37 (45.09); Fusidic Acid (54.91) 































Figure 3.10. Amidoxime ester moiety is important for hydrolysis. MIC in S. aureus is used as a 
surrogate for hydrolysis. MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. * 
= solubility limit. 
 
As general knowledge of the mechanism can guide the design of more potent derivatives, 
we next investigated the mechanistic possibilities of hydrolysis. Two possible mechanisms are 
shown in Figure 3.11: 1) nucleophilic attack of the carbonyl by water and 2) nucleophilic attack 
of the amidoxime by water. The possibility of mechanism 1 was studied through the effect of 
pKa by synthesizing a series of esters/amidoxime esters with increasing pKa of the coupling 
partner (Figure 3.12). A higher MIC (slower hydrolysis) should be observed with increasing pKa 
if hydrolysis is occurring via direct attack of the carbonyl on fusidic acid (mechanism 1) due to 
diminishing leaving group capability. Fusidic acid p-nitrophenol ester 3-45 does not display 
antibacterial activity even though p-nitrophenol has the lowest pKa of all the coupling partners. 
In fact, esters 3-45, 3-42, 3-43, and 3-47 did not display any activity. The only active compound 
was amidoxime ester 3-34. The fact that acetamide oxime used to generate 3-34 has the highest 
pKa of all the coupling partners, and lowest leaving group capability, suggests that the 
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hypothesis is supported by an 18O-labeling study in which amino amidoxime ester 3-38 was 
incubated with 18O-water (Scheme 3.5). No incorporation of the radiolabeled atom was observed 
on the carboxylic acid of fusidic acid. Control compound 3-45 was incubated with 18O-water as 
well and no hydrolysis to fusidic acid was observed. Mechanism 2 is likely occurring and the 
specific details of the hydrolysis mechanism are currently being elucidated. 
 
Figure 3.11. Mechanistic possibilities of amidoxime ester hydrolysis to fusidic acid. 
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Figure 3.12. Panel of esters with increasing pKa. Data suggests that attack of amidoxime ester 
carbonyl is not the mechanism of hydrolysis. MIC in S. aureus is used as a surrogate for 
hydrolysis. MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. * = solubility 
limit. Spectroscopic titrations and theoretical calculations data from Mehio et al.26 
 
 
Scheme 3.5. A) Incubation of amino amidoxime 3-38 with 18O-water. Low resolution ESI mass 
spectrum shown for fusidic acid, t = 0 h, and t = 18 h. B) Incubation of amino ester 3-46 with 
18O-water. Low resolution ESI mass spectrum shown for t = 0 h and t = 18 h. 
 
3.6.3. Tuning hydrolysis rate of amidoxime esters 
 To potentially increase the activity and explore if any trends existed for the rate of 
hydrolysis commercially available amidoximes were coupled to fusidic acid to yield the 
compounds shown in Figure 3.13. Benzyl amidoxime ester 3-48 displays no activity relative to 
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In addition, the rate of hydrolysis (lower MIC) for compounds 3-47, 3-33, and 3-50 increases as 
the substituent on the aromatic ring increases in electron donating capability with aniline 3-50 
displaying a faster rate of hydrolysis. These data suggest that electron donation into the 
amidoxime leads to a faster rate of hydrolysis to fusidic acid. 
 
Figure 3.13. Activity of amidoximes in S. aureus and E. coli. MIC in S. aureus is used as a 
surrogate for hydrolysis. Lower MIC = faster hydrolysis. MICs in µg/mL; n = 3. S. aureus ATCC 
29213 and E. coli MG1655. * = solubility limit. 
 
 The importance of the free –NH2 on the amidoxime was explored by generating a series 
of N-alkylated and N-arylated amidoxime esters.  Synthesis of the coupling partners was 
accomplished through the thioamide followed by treatment with hydroxylamine or through 
reaction of N-hydroxyacetimidoyl chloride with the appropriate nitrogen nucleophile. A similar 
trend in the rate of hydrolysis to that shown in Figure 3.13 was also observed for the N-alkylated 
and N-arylated derivatives (Figure 3.14). That is, the more electron-donating substituent led to a 
faster rate of hydrolysis. For N-alkylated compounds 3-51–3-53, a higher degree of N-alkylation 
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rate of hydrolysis. For N-arylated derivatives 3-54–3-57, a more electron donating group para to 
the aromatic ring yielded a faster rate of hydrolysis with p-N-dimethyl aniline 3-57 displaying 
the fastest hydrolysis. 
 
Figure 3.14. Trends in rate of hydrolysis of N-alkylated and N- arylated amidoxime esters. MIC 
in S. aureus is used as a surrogate for hydrolysis. MICs in µg/mL; n = 3. S. aureus ATCC 29213 
and E. coli MG1655. * = solubility limit. 
 
The results above suggest that amidoxime esters of fusidic acid may behave as prodrugs 
and hydrolyze to fusidic acid to ultimately kill Gram-positive bacteria. The presence of a 
electron-donating substituent on the amidoxime moiety results in a faster hydrolysis. None of the 
amidoxime ester derivatives synthesized above display activity in E. coli, a Gram-negative 
pathogen, except piperazine amidoxime 3-41 in Figure 3.8. Compound 3-41 contains two 
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3.7. Polyamine amidoxime ester prodrug strategy to broad-spectrum antibiotics 
3.7.1. Polyamine amidoxime ester prodrug strategy 
A powerful approach would be to combine the prodrug strategy with a moiety that could 
increase accumulation in Gram-negative bacteria. For example, if more positive charges were 
introduced onto the prodrug moiety, then the compound could enter the bacterial cell via the self-
promoted uptake pathway by displacing the divalent cations, which stabilize the outer 
membrane.27-30 Once inside the cell, the prodrug could hydrolyze releasing the active antibiotic, 
fusidic acid, into the periplasm and/or cytoplasm (Figure 3.15). As described in section 3.3, 
attempts to convert fusidic acid into a broad-spectrum agent using the eNTRy rules was 
unsuccessful (Figure 3.5) primarily due to 1) difficult and time-consuming methods for installing 
amines on the unactivated C-H bonds of fusidic acid,10-19 2) lack of accumulation, and 3) 
disrupted target engagement of the amine containing derivatives. However, as described in 
section 3.4, polyamine chains coupled to the carboxylic acid while not active, do increase 
accumulation in E. coli. Combining this polycationic approach with the prodrug approach for 
fusidic acid could convert the above disadvantages into advantages in that 1) installation of the 
promoiety amidoxime is facile and short in synthetic steps, 2) polycationic compounds will 
exploit the self-promoted uptake pathway and guarantee passage across the outer membrane of 
Gram-negative bacteria, and 3) an antibiotic already known to possess antibacterial activity is 
released inside of the bacterial cell. A suitable modification site is required for installation of the 




Figure 3.15. Strategy for converting fusidic acid into a broad-spectrum antibiotic using a 
polycationic prodrug. 
 
3.7.2. Amidoxime esters are the optimal promoiety for conversion strategy 
 While amidoxime prodrugs (enzymatic) exist in the literature,31-32 it was still important to 
perform a short screen of other potential prodrugs. Figure 3.16 shows the antibacterial activity of 
three common prodrugs in addition to the amidoxime: aminocarbonyloxymethyl ester 3-58, 
amino acid aminocarbonyloxymethyl ester 3-59, and acyloxymethyl ester 3-60. 
Aminocarbonyloxymethyl esters are known to undergo chemical hydrolysis with water.33 
Furthermore, when a bulky amino acid is installed to make amino acid aminocarbonyloxymethyl 
esters, the rate of hydrolysis of the prodrug is quantitative within a short period of time.33 
Prodrugs 3-58 and 3-59 were synthesized and displayed lower activity than amidoxime ester 3-
34, indicating a slower rate of hydrolysis to fusidic acid. Acyloxymethyl ester 3-60, which 
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was determined that amidoxime esters are the superior prodrug and were chosen for the 
polycationic prodrug approach to broad-spectrum antibiotics from fusidic acid. 
 
Figure 3.16. Chemical and enzymatic prodrugs of fusidic acid. MIC in S. aureus is used as a 
surrogate for hydrolysis. MICs in µg/mL; n = 3. S. aureus ATCC 29213 and E. coli MG1655. * 
= solubility limit. Compound 3-60 was synthesized by Martin Garcia-Chavez. 
 
3.7.3. Polyamine amidoxime promoiety 
 To develop this strategy the promoiety of the prodrug can be broken into two parts:  the 
polycationic portion and the amidoxime. For the polycationic segment, we selected linear 
polyamines similar to those used in section 3.4 as they are inexpensive, commercially available, 
and have shown promise in safety and tolerability studies during human clinical trials (Figure 
3.17).35-40 For example, Syprine (trientine) FDA approved for treatment of Wilson’s disease, has 
a maximum daily dose (MDD) of 2000 mg/day orally.35 A clinical trial for heart failure shows 
that trientine can be orally dosed with a maximum tolerable dose (MTD) of 3600 mg/day.37 
Other polyamine drug candidates for treatment of cancer, N1,N11-diethylnorspermine38 and CGC-
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trials. This promising data showing that polyamines are indeed tolerable in humans compelled 
further pursuit of a polyamine amidoxime promoiety. 
 
Figure 3.17. Linear polyamines are safe and tolerable in humans. 
3.7.4. Synthesis and biological activity of polyamine amidoxime ester prodrugs 
 Following the synthetic route to amino amidoxime prodrugs established in section 3.6, 
nucleophilic attack of chloro amidoxime ester 3-35 with the appropriate nitrogen nucleophile, 
N,N'-Bis(3-aminopropyl)-1,3-propanediamine was reacted with 3-35, resulting in polyamine 
amidoxime ester 3-61 (Scheme 3.6). The activity in S. aureus was similar to other amino 
amidoxime esters (MIC = 1 µg/mL). Excitingly, 3-61 was the first derivative to display 
antibacterial activity in E. coli with an MIC = 4 µg/mL. The antibacterial activity of 3-61 was 
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activity in wild-type E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae strains 
(Table 3.2A) whereas 3-37 did not, presumably due low accumulation. The activity of 3-61 was 
further assessed in clinical isolates of ESKAPE pathogens and retained good activity (Table 
3.2B). Excitingly, 3-61 exhibits the greatest fold change in MIC (128X, > 128X) against some 
clinical isolates of P. aeruginosa, a pathogen for which the eNTRy rules are still being fully 
elucidated.2-3 Polyamine amidoxime ester 3-61 displayed low toxicity to mammalian cells in 
culture (72 h IC50). 
 
Scheme 3.6. Synthesis of polyamine amidoxime ester 3-61. MICs in µg/mL; n = 3. S. aureus 
ATCC 29213 and E. coli MG1655. 
 









































S. aureus: 1 
E. coli: 4 
Species Strain MIC MIC MIC 
S. aureus ATCC 29213 0.125 1 1 
E. coli MG1655 512 > 256* 4 
E. coli ATCC 25922 1024 > 256* 8 
K. pneumoniae ATCC 27736 1024 > 256* 16 
A. baumannii ATCC 19606 64 > 256* 2 
P. aeruginosa PA01 1024 > 256* 4 
E. cloacae ATCC 29893 512 > 256* 8 





























































































































Table 3.2. A) Antibacterial activity of 3-61 in ESKAPE pathogens and cytotoxicity of fusidic 
acid and 3-61 in mammalian cells (72 h IC50). B) Antibacterial activity of 3-61 in clinical isolates 
of the Gram-negative ESKAPE pathogens. MICs in µg/mL; n = 3. 
 
 Furthermore, the relationship between the number of nitrogens on the polyamine was 
explored by synthesizing polyamine amidoximes 3-62 and 3-63 containing two and three amines 
on the polyamine chain, respectively, summarized in Table 3.3. As expected, an increase in 
antibacterial activity is observed with increasing number of nitrogens on the polyamine chain as 
3-37 and 3-62 are inactive, 3-63 exhibits moderate activity, and 3-61 shows high activity in 
Gram-negative ESKAPE pathogens consistent with increased accumulation.  
Strain MIC MIC MIC MIC Fold Change 
E. coli ATCC 
BAA-2341 
1 32 > 1024 16 > 64X 
E. coli ATCC 
BAA-2469 
0.5 > 32 > 1024 8 > 128X 
K. pneumoniae 
ATCC BAA-2146 
2 > 32 > 1024 16 > 64X 
K. pneumoniae 
ATCC BAA-2470 
0.5 > 32 > 1024 16 > 64X 
A. baumannii 
KB304 
0.25 2 256 8 32X 
A. baumannii 
WO22 
1 4 128 8 16X 
P. aeruginosa PA14 4 0.25 > 1024 8 > 128X 
P. aeruginosa CI-02 16 1 1024 8 128 
P. aeruginosa CI-03 16 1 1024 16 64 
P. aeruginosa CI-04 16 1 > 1024 16 > 64 
E. cloacae ATCC 
BAA-2341 
1 16 > 1024 16 > 64X 
E. cloacae ATCC 
BAA-2468 






























































































































Table 3.3. Polyamine amidoxime esters display greater activity in ESKAPE pathogens as the 
number of nitrogens on the polyamine chain increases due to higher accumulation. MICs in 
µg/mL; n = 3. * = solubility limit. Accumulation in E. coli MG1655. Accumulation in nmol/1012 
CFU. Error = standard error of the mean of 3 biological replicates. 
 
3.7.5. Polyamine amidoxime esters kill bacteria by binding to EF-G 
 To confirm target retention of the polyamine amidoxime esters in E. coli EF-G, resistant 
mutants were generated using the serial exposure method at 2X, 4X, and 8X the MIC in E. coli 
MG1655. Sequencing of the FusA gene (encoding for EF-G) was then performed. Mutation 
P414Q was observed within the FusA gene of the 2X resistant strain. Furthermore, the mutant 
strains were cross-resistant with fusidic acid (MIC = 1024, >1024 µg/mL) and not ciprofloxacin, 
a fluoroquinolone with a different target.41 This is further evidence to support EF-G as the target 
of polyamine amidoxime esters. Sequence alignment at the FusA genes of the Gram-negative 
ESKAPE pathogens with S. aureus revealed that the observed mutations were consistent across 
species. Proline 414 of the ESKAPE Gram-negative pathogens, including E. coli, aligns with S. 















































































































































# of nitrogens 1 2 3 4 
Species MIC MIC MIC MIC MIC 
S. aureus 
ATCC 29213 
0.125 1 1 1 1 
E. coli 
MG1655 
512 > 256* 256 32 4 
E. coli 
ATCC 25922 
1024 > 256* 256 32 8 
K. pneumoniae 
ATCC 29893 
1024 > 256* 256 64 16 
A. baumannii 
ATCC 19606 
64 > 256* 64 16 2 
P. aeruginosa 
PA01 
1024 > 256* > 256 128 4 
E. cloacae 
ATCC 29893 
512 > 256* 256 8 8 
Accumulation 
of fusidic acid 











aureus proline 406 (Figure 3.18). Mutation P406L was observed when resistant mutants of 
fusidic acid in S. aureus ATCC 29213 were grown in-house. This P406L mutation is known and 
has been observed for MRSA clinical isolates resistant to fusidic acid.42 To access resistance 
frequency for 3-61, attempts were made to grow resistant mutants using the large inoculum 
method. Unfortunately these were unsuccessful due to hydrolytic instability of the polyamine 
amidoxime moiety when generating the required compound-containing agar plates. 
 
Figure 3.18. Sequence alignment of S. aureus and Gram-negative pathogen FusA genes. S. 
aureus P406 aligns with P414 of Gram-negative pathogens, including E. coli. Alignment was 
performed with Clustal Omega 1.2.443 and visualized with ESPript 3.0.44 Protein sequences 
obtained from Uniprot: S. aureus (P68790), P. aeruginosa (Q9HWD2), A. baumannii 
(AM3M306), E. coli (P0A6M8), and K. pneumoniae (A0A0W8ANG9). 
 
3.7.6. Polyamine amidoxime ester antibacterial activity in human serum 
 The antibacterial activity of polyamine amidoxime ester 3-61 in 50% human 
serum/CAMH was determined alongside fusidic acid. Fusidic acid is known to be 97-98% 
protein bound45-47 and as a result, 4 to 700 fold changes in MIC (S. aureus) in the presence of 
human serum have been reported.45-46, 48-50 As expected, fusidic acid displays a > 2-fold change 
in MIC in E. coli and a 16-fold change in its MIC in S. aureus (Table 3.4). Polyamine 
amidoxime ester 3-61 exhibits only a 2-fold increase in MIC in both species of bacteria, 
suggesting that it could be delivered to the bacteria efficiently without much hindrance from 
protein binding. 
1       10        20        30        40        50        60
sp|P68790|EFG_STAAU           MAR       RNIGI AH DAGKTTTTER L YTG  HK GE H GA   DWM QEQ RG   L K        I          I Y     I   E  QM   E   D  EFS E T M RI T S
sp|Q9HWD2|EFG1_PSEAE          MAR       RNIGI AH DAGKTTTTER L YTG  HK GE H GA   DWM QEQ RG   TTPI RY       V          V F   VN  L  V D  AT       E  N C T V
sp|A3M306|EFG_ACIBT           MAR       RNIGI AH DAGKTTTTER L YTG  HK GE H GA   DWM QEQ RG   QTPI RY       I          I F   VS  I  V D  ATM   E   E  T S
sp|P0A6M8|EFG_ECOLI           MAR       RNIGI AH DAGKTTTTER L YTG  HK GE H GA   DWM QEQ RG   TTPI RY       I          I F   VN  I  V D  ATM   E   E  A S
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN MAR       RNIGI AH DAGKTTTTER L YTG  HK GE H GA   DWM QEQ RG   TTPI RY       I          I F   VN  I  V D  ATM   E   E  A S
        70               80        90       100       110   
sp|P68790|EFG_STAAU           ITITSAA T  W G        R N IDTPGHVDFT EVERS RVLDGA  V     GV        T   H V I          V     L      V  A   AA E ....... T LD QS E
sp|Q9HWD2|EFG1_PSEAE          ITITSAA T  W G        R N IDTPGHVDFT EVERS RVLDGA  V     GV         F  QY  V V          I     L      VV FC   V T K SRG DNY GTS E
sp|A3M306|EFG_ACIBT           ITITSAA T  W G        R N IDTPGHVDFT EVERS RVLDGA  V     GV        T F  QF H I V          I     M      M YCA   C S MGN PQ C VG Q
sp|P0A6M8|EFG_ECOLI           ITITSAA T  W G        R N IDTPGHVDFT EVERS RVLDGA  V     GV        T F  QY H I I          I     M      VM YCA   A S MAK EP VG Q
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN ITITSAA T  W G        R N IDTPGHVDFT EVERS RVLDGA  V     GV        T F  QY H V I          I     M      VM YCA   A S MAK EP VG Q
    120       130       140       150       160       170   
sp|P68790|EFG_STAAU           PQ ETVWRQA  Y VPR   VNKMD  GANF   V     RL     P    IGAE  F   T       T     IVF     K      TLH   AN A IQL     D  T G L EYS S D Q A P E E
sp|Q9HWD2|EFG1_PSEAE          PQ ETVWRQA  Y VPR   VNKMD  GANF   V     RL     P    IGAE  F   S       NK    IVY     R     RV QIK   G TPV VQL     E  G Q L E K H A N V
sp|A3M306|EFG_ACIBT           PQ ETVWRQA  Y VPR   VNKMD  GANF   V     RL     P    IGAE  F   S       NK    LAF     R     RV QMK   GANPV I V     D  K T F E T V P T T
sp|P0A6M8|EFG_ECOLI           PQ ETVWRQA  Y VPR   VNKMD  GANF   V     RL     P    IGAE  F   S       NK    IAF     R     KV QIK   GANPV LQL     E  K M L N T A H T
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN PQ ETVWRQA  Y VPR   VNKMD  GANF   V     RL     P    IGAE  F   S       NK    IAF     R     KV QIK   GANPV LQL     E  K M L G T A G T
    180        190       200       210       220       230  
sp|P68790|EFG_STAAU              DL  MK         G       IP      A E      E  AE   ELM KYL  II  V   YT D  E E  D D   R SLI V  SD   E   A E CFK N. L TEI EI E HL R E A A A T GD
sp|Q9HWD2|EFG1_PSEAE             DL  MK         G       IP      A E      E  AE   ELM KYL  G V  I   AI WND D  M Y E  AEL D   WRSSMV A  ANE      Q K Y D K T REE K L E A N EE
sp|A3M306|EFG_ACIBT              DL  MK         G       IP      A E      E  AE   ELM KYL  GVV  I   AI W E  M FE E  ADL D   WRTNMV A  ASE   D   E I D ASQ K YG V T Q A EE
sp|P0A6M8|EFG_ECOLI              DL  MK         G       IP      A E      E  AE   ELM KYL  GVV  V   AI WND D  V FE D  ADM E   WHQNLI A  ASE   E   K N A Q T YE V L N S GG
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN    DL  MK         G       IP      A E      E  AE   ELM KYL  GVV  V   AI WND D  V FE D  ADM D   WHQNLI A  ASE   E   K N A Q T YE Q L D S GG
     240       250       260       270       280       290  
sp|P68790|EFG_STAAU                       R      E     CG  FKNKGV   LDAVI  LP P     I G   EIS ELK I  V   TA      QLM     DY  S DV   E VS EA QATTNV FYP L L KP I HRA
sp|Q9HWD2|EFG1_PSEAE                      R      E     CG  FKNKGV   LDAVI  LP P     I G   ELS EIK L R L  I A   S       LV     DY   EI A  VG EA EG L T AC VP V S P A T P K SP
sp|A3M306|EFG_ACIBT                       R      E     CG  FKNKGV   LDAVI  LP P     I G   DLS DI L R L  I M   SA      Q M     EF  S EV A  IG KE IAG A T AS QV L R T K E LD
sp|P0A6M8|EFG_ECOLI                     R     E    CG  FKNKGV   LDAVI  LP P     I G   ELT EIK L R L  I V   SA    QAM    DY  S DV A  IE EA GA Q V NN IL T V P N LD
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN             R      E     CG  FKNKGV   LDAVI  LP P     I G   ELT EIK L R L  I V   SA      QAM     DY  S DV A  IE EE KA Q V NN IL T V P N LD
     300       310       320       330       340       350  
sp|P68790|EFG_STAAU                     A D   F  LAFK   D  VG LTF RVYSG    G  V N  K   ER E V K   A    VMT PY          MTS   S  R  SNP EE IA D SAE A K F T SY K T GK V
sp|Q9HWD2|EFG1_PSEAE                    A D   F  LAFK   D  VG LTF RVYSG    G  V N  K   ER D RH  P S     IAT PF  T        VLSS D   SV K  DETVEDE D NE S A S L GK V
sp|A3M306|EFG_ACIBT                     A D   F  LAFK   D  VG LTF RVYSG    G  V N  K   ER D E A R   P SA    IMN F  N        VL Q D   V R  KD TK S E S EA K V K A Y P SK I
sp|P0A6M8|EFG_ECOLI                     A D   F  LAFK   D  VG LTF RVYSG    G  V N  K   ER D D A RH  P SA    IAT PF  N        VVNS D   SV R  GK TP E S DE F T L AA F
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN           A D   F  LAFK   D  VG LTF RVYSG    G  V N K  ER D D A RH  P SA    IAT PF N        VVNS D   SV R  GK TP E S DE F T L AA F
     360       370       380       390       400       410  
sp|P68790|EFG_STAAU           GR  QMHAN R  I     GDIAA  G KD  TGDTLC     I LE M FP PVI   V  LL      E V      AV L         I   E  E   L  S Q DT YS TG GEKND S H S
sp|Q9HWD2|EFG1_PSEAE          GR  QMHAN R  I     GDIAA  G KD  TGDTLC     I LE M FP PVI   V  MV      E EVRA     LI M  VT       I  R D  E   SVA Q E K SIEKP
sp|A3M306|EFG_ACIBT           GR  QMHAN R  I     GDIAA  G KD  TGDTLC     I LE M FP PVI   V  IV      D EIRA     V L  VT         R E  D   QLA E Q D C DEKNI T
sp|P0A6M8|EFG_ECOLI           GR  QMHAN R  I     GDIAA  G KD  TGDTLC     I LE M FP PVI   V  IV      E EVRA     AI L  VT       I  R E  E   SIA K E K DPDAP
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN GR  QMHAN R  I     GDIAA  G KD  TGDTLC     I LE M FP PVI   V  IV      E EVRA     AI L  VT       I  R E  E   SIA K E K DPDAP
    420      430       440       450       460      470  
sp|P68790|EFG_STAAU          EPK KADQ KM  AL  L  EDP F   TDEE  Q II GMGELHLDI VDRMK EF VE  S    D   K   T HA     T            L     K    TQ V QE H G V G N
sp|Q9HWD2|EFG1_PSEAE          EPK KADQ KM  AL  L  EDP F   TDEE  Q II GMGELHLDI VDRMK EF VE   T    E  I  GK A    S RV     S  T           I     R    G Q K G S G
sp|A3M306|EFG_ACIBT          EPK KADQ KM  AL  L  EDP F  TDEE  Q II GMGELHLDI VDRMK EF VE   T    E  I  GR A    S RV    S  T          I    R    S K H G A G
sp|P0A6M8|EFG_ECOLI           EPK KADQ KM  AL  L  EDP F   TDEE  Q II GMGELHLDI VDRMK EF VE   T    E  L  GR A    S RV     S  T           I     R    G K W N A N
tr|A0A0W8ANG9|A0A0W8ANG9_KLEPN EPK KADQ KM  AL  L  EDP F   TDEE  Q II GMGELHLDI VDRMK EF VE   T    E  L  GR A    S RV     S  T           I     R    G K W N A N
     480       490        500       510             520     
sp|P68790|EFG_STAAU            N G P V YRE          GK   Q GG G  G                      F  V      T K A V   R S  R QY V I P E G GFE C A M S F SS .Q Q FS D H EFT N T...... A E
sp|Q9HWD2|EFG1_PSEAE           N G P V YRE          GK   Q GG G  G                      F A I K  A   TI EIE  VR S  R QF H I AD G  Q TKDNV F CW RFSA VDEKGNITE LV E
sp|A3M306|EFG_ACIBT            N G P V YRE          GK   Q GG G  G                      F A I K  A   TIK V E E  VR T  K F HV V PLD G YE M KT . Q F K Y RLE VEA...A KE A
sp|P0A6M8|EFG_ECOLI            N G P V YRE          GK   Q GG G  G                      F A V K  A   TIR V DVE  AK S  R QY HV I PLE P GYE Q QK T H V DMY PGS...N K I
















Table 3.4. MIC of polyamine amidoxime 3-61 and fusidic acid in 50% human serum/CAMH. 
Human serum was purchased from BioIVT. Filtration: 30k Dalton membrane; Ultrafiltrate. 
MICs in µg/mL; n = 3. N.D. = Not determined. % protein bound data from literature.47, 51-52. 




 Installation of a primary amine to convert Gram-positive only antibiotics into broad-
spectrum agents using the eNTRy rules does not always lead to active derivatives, and can be 
synthetically challenging. This polyamine amidoxime ester prodrug strategy to broad-spectrum 
antibiotics is the first use of a prodrug designed to cross the outer membrane of Gram-negative 
bacteria while retaining the activity of the parent antibiotic. As such, the strategy holds great 
promise for fusidic acid, as well as other clinically approved Gram-positive only antibiotics. 
Future work is aimed towards assessing the MTD and pharmacokinetics of 3-61 in an 
appropriate mouse model of infection. As Gram-negative bacterial resistance continues to rise, 
MIC MIC MIC MIC 
CAMH 0.25 0.008 512 4 
50% HS/CAMH > 1 0.008 > 1025 8 
Fold change > 4X 0X > 2X 2X 
% protein bound 71-87% 40% 97-98% N.D. 
E. coli MG1655 
MIC MIC MIC MIC 
CAMH N.D. 0.125 0.125 1 
50% HS/CAMH N.D. 0.125 2 2 
Fold change N.D. 0X 16X 2X 
% protein bound 71-87% 40% 97-98% N.D. 




























































































































molecular weapons to combat this problem may already exist in the pipeline or clinic, and simply 
require a cleavable, outer membrane penetrable polyamine linker. 
3.9. Materials, methods, and characterization 
3.9.1 Materials and methods for biological experiments 
Bacterial Strains 
S. aureus ATCC 29213, E. coli MG1655, E. coli ATCC 25922, E. coli ATCC BAA-
2341, E. coli ATCC BAA-2469, E. cloacae ATCC BAA-2341, E. cloacae ATCC BAA-2468, K. 
pneumoniae ATCC 27736, K. pneumoniae ATCC BAA-2146, K. pneumoniae ATCC BAA-
2470, A. baumannii 19606 were obtained from ATCC. E. coli JW3596 and E. coli ΔtolC 
obtained from the KEIO Collection. E. cloacae ATCC 29893 was provided by W. van der Donk 
(UIUC). A. baumannii WO22 was obtained from the University of Illinois-Chicago Medical 
School. A. baumannii KB304 was provided by J. Quale. 
Antimicrobial susceptibility tests 
Susceptibility testing was performed in biological triplicate, using the micro-dilution 
broth method as outlined by the Clinical and Laboratory Standards Institute. Bacteria were 
cultured with cation-adjusted Muller-Hinton broth (Sigma-Aldrich, Cat# 90922) in round-bottom 
96-well plates (Corning, Cat# 3788). Human serum (Ultrafiltrate, unspecified gender, 30K 
Dalton membrane filtered) was purchased from BioIVT (Hicksville, NY) 
Accumulation Assay (Performed by Emily Geddes) 
See section 2.6.2 (Chapter 2) 
Cell culture 
HFF1 cells were obtained from ATCC. HFF1 cells were grown in DMEM with 15% fetal 
bovine serum (Gemini Benchmark, Cat# 100-106), 100 U/mL penicillin, and 100 µg/mL 
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streptomycin. All cells were cultured at 37 ºC in a 5% CO2 environment. Media was prepared by 
the University of Illinois School of Chemical Sciences Cell Media Facility. 
Cell viability 
 Cells seeded (HFF1: 1,000 cells/well) a 384-well plate. Cells were treated with 
investigational compounds in DMSO. Doxorubicin was used as a dead control. After 72 h post-
treatment, cell viability was assessed using the Alamar Blue method. Stock Alamar Blue solution 
[5 µL, 190 µM resazurin (Sigma-Aldrich, Cat# R7017) in sterile 1X PBS] was added to each 
well, and was measured with plate reader (SpectraMax M3, Molecular Devices) by fluorescence 
(ex 555 nm, em 585 nm, cutoff 570 nm, autogain). Percent death was determined by normalizing 
to DMSO-treated cells and doxorubicin-treated cells. 
Selection of resistant mutants of fusidic acid in S. aureus 
 Resistant mutants of fusidic acid were selected via the large inoculum method. Briefly, S. 
aureus ATCC 29213 (1x109 CFU) were plated on 100 mm plates of LB agar containing 4, 2, 1, 
and 0.5 µg/mL. Colonies were visible after incubation at 37 ºC for 24 h. Resistant colonies were 
confirmed by streaking on selective media with the same concentration of fusidic acid and an 
MIC experiment of n = 1. 
Selection of resistant mutants of 3-61 in E. coli 
 Resistant mutants of 3-61 were selected via the serial exposure method. Briefly, E. coli 
MG1655 (1x108 CFU/mL) were subjected to a standard MIC experiment. The cells from the well 
with the highest concentration of antibiotic with observable growth were grown and plated at 
1x108 CFU/mL for another MIC experiment. Several iterations (19) of this process were 
conducted until resistance was observed (2X, 4X, and 8X the MIC of 3-61). Resistant colonies 
were confirmed by an MIC experiment (n = 3) with 3-61. This method of growing resistant 
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mutants has been previously used for ciprofloxacin (cipro).53 Two lineages were maintained with 
serial exposure to cipro throughout the experiment. 
Sequencing of FusA 
 FusA was amplified by colony PCR. Colonies were picked and diluted in 100 µL sterile 
H2O. PCR reactions are setup by combining MiFi Mix (Bioline, London, UK), 20 µM primer 
mix [FusA-F and FusA-R (S. aureus ATCC 29213)42 or ECMGFusA-F and ECMGFusA-R (E. 
coli MG1655)], template DNA, and H2O. Reaction was performed on C1000 Thermal Cycler 
(Bio-Rad, Hercules, CA) with the following conditions: 30 cycles of denaturation (30 s at 94 ºC), 
annealing (30 s; at 45 ºC) and extension step (72 ºC for 2 min), followed by a final extension step 
(72 ºC for 10 min). Thermal Cycler conditions from Chen et al.42 A 10 µL portion of PCR 
reaction mixture was analyzed by agarose gel to confirm product. PCR reaction was purified 
using GeneJET PCR Purification Kit (Thermo Scientific). PCR amplicons were submitted to the 
Core DNA Sequencing Facility at the University of Illinois at Urbana-Champaign for Sanger 
sequencing with overlapping primers [FusA_-68_-49, FusA_404_425, FusA 946_968, and 
FusA_down_47_25 (S. aureus ATCC 29213)42 or ECMGFusA_-32_-53, ECMGFusA_400_419, 
ECMGFusA_947_966, ECMGFusA_down_34_55 (E. coli MG1655)]. All primers were 









Supplementary Table 3.1. Primers for sequencing of FusA in S. aureus ATCC 29213:42 
Primer Sequence 
FusA-F 5’ – TTTACCCTGAGTGTGTTCT – 3’ 
FusA-R 5’ – TACATTTAAGCTCACCTTGT – 3’ 
FusA_-68_-49 5’ – TCATGCTTAGGGCATCGCCA – 3’ 
FusA_404_425 5’ – ACAAAATGGACAAATTAGGTGC – 3’ 
FusA_946_968 5’ – GTTATGACTGACCCTTATGTTGG – 3’ 
FusA_down_47_25 5’ – GCTCACCTTGTATTTTAACCTAG – 3’ 
 
Supplementary Table 3.2. Primers for sequencing of FusA in E. coli MG1655:  
Primer Sequence 
ECMGFusA-F 5’ – TTCGCACACTACCGTTGGTTATCC – 3’ 
ECMGFusA-R 5’ – ACTATAGTGCTCTCCCCTTCAG – 3’ 
ECMGFusA_-32_-53 5’ – AGCCCGCTTTGGGCTACTTAAA – 3’ 
ECMGFusA_400_419 5’ – ATCAACATCATCGACACCCC – 3’ 
ECMGFusA_947_966 5’ – GTGGTTCTGCGTTCAAGAAC – 3’ 
ECMGFusA_down_34_55 5’ – TATAGTGCTCTCCCCTTCAGGA – 3’ 
 
3.9.2. Materials, methods, and characterization for chemical synthesis 
General considerations 
Fusidic acid was purchased from J&K Scientific, Ltd. and Hebei Shengmei Medical 
Technology Co. Ltd. Sodium fusidate was purchased from Alfa Aesar or AvaChem Scientific. 
Other chemical reagents were purchased from commercial sources and used without further 
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purification. Anhydrous solvents used during these studies were dried after being passed through 
columns with activated alumina under nitrogen using a PureSolv MD-5 (Inert previously 
Innovative Technology, Inc.) solvent purification system. Flash chromatography was performed 
using silica gel (230–400 mesh). 
Various NMR experiments (including 2-D) were conducted in the NMR facilities at 
UIUC. 1H NMR and 13C NMR experiments were recorded on Varian Unity spectrometers at 500 
MHz and 125 Hz, respectively and/or a Bruker Avance III HD 500 MHz NMR system equipped 
with a CryoProbe. Spectra were obtained in the following solvents (reference peaks also included 
for 1H and 13C NMRs): CDCl3 (1H NMR: 7.26 ppm; 13C NMR: 77.26 ppm), CD3OD (1H NMR: 
3.31 ppm; 13C NMR: 49.10 ppm), d7-DMF (1H NMR: 2.75 ppm; 13C NMR: 34.90 ppm), d6-
DMSO (1H NMR: 2.50 ppm; 13C NMR: 39.52 ppm). NMR experiments were performed at room 
temperature unless otherwise indicated. Chemical shift values are reported in parts per million 
(ppm) for all 1H NMR and 13C NMR spectra. 1H NMR multiplicities are reported as: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, pentet = pent., sextet, = sex, heptet 
= hept. High–resolution mass spectra were obtained using Waters Q-TOF Ultima ESI and 
Agilent 6230 ESI TOF LC/MS spectrometers. 
Final compounds for biological assays were purified using a Teledyne ISCO ACCQPrep 
HP125 Preparative HPLC (Column: Teledyne ISCO RediSep Prep C18 - 20 mm x 250 mm, 100 
Å, 5-micron). 
Purity of final compounds assessed for biological activity were purified to ≥ 95% as 
assessed by an Agilent 6230 LC/MS TOF (Column: Agilent ZORBAX Eclipse Plus C18 Rapid 
Resolution HT 2.1 x 100mm, 1.8-micron) and/or and Agilent Technologies 1290 Infinity II 
151 
 
UHPLC equipped with a Phenomenex Kinetex column (2.1 mm ID x 50mm, 1.7-micron particle 
size, 100 Å pore size). 
Methods and Characterization 
Characterization data for compounds synthesized by Martin Garcia-Chavez is not provided. 
Chapter 1 fusidic acid derivatives: 
Compound 1-24 (See Compound 3-3) 
Compound 1-30 (See Compound 3-8) 
Compound 1-31 (See Compound 3-9) 
Compound 1-36 (See Compound 3-17) 
Compound 1-37 (See Compound 3-18) 
Chapter 3 fusidic acid derivatives: 
Compound 3-3 (1-24) 
 
Procedure: A vial with a stir bar was charged with 3-2 (526.6 mg, 0.87 mmol), polymer 
supported triphenylphosphine (3 mmol/g, 478.7 mg, 1.44 mmol, 4.9 eq), excess triethylamine 
(0.3 mL), and water (0.1 mL), which were dissolved in THF (3 mL). The vial was capped and 
placed in an 80 ºC oil bath and was allowed to stir for 18 h. The vial was poured into a 
seperatory funned and was diluted with brine and water. The mixture was extracted with 
chloroform (5x), dried over Na2SO4, and was concentrated under reduced pressure. The mixture 































acid). The resulting solid was submitted to reverse phase Preparative HPLC (MeCN/H2O, 0.1% 
formic acid) to afford 3-3 (36.0 mg, 24% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.78 (d, J = 8.3 Hz, 1H), 5.14 (t, J = 6.7 Hz, 1H), 4.30–4.27 (m, 
1H), 3.06–3.00 (m, 1H), 2.74 (td, J = 11.4, 4.3 Hz, 1H), 2.57–2.48 (m, 1H), 2.38–2.32 (m, 1H), 
2.74 (td, J = 11.4, 4.3 Hz, 1H), 2.57–2.48 (m, 1H), 2.38–2.32 (m, 1H), 2.30 (dt, J = 13.2, 2.8 Hz, 
1H), 2.21–2.08 (m, 4H), 1.98 (s, 3H), 1.94–1.69 (m, 9H), 1.67 (s, 3H), 1.61 (s, 3H), 1.34 (s, 3H), 
1.23 (d, J = 14.2 Hz, 1H), 1.21–1.13 (m, 2H), 0.98 (d, J = 6.2 Hz, 3H), 0.94 (s, 3H). (45 non-
exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 177.0, 173.1, 143.2, 136.2, 132.9, 125.0, 75.9, 68.5, 58.1, 
50.5, 50.0, 44.3, 44.2, 40.6, 40.2, 37.6, 37.6, 37.5, 34.9, 33.1, 30.6, 29.3, 28.6, 26.0, 24.3, 24.0, 
22.5, 21.0, 18.0 (2C), 15.6. 
HRMS(ESI): m/z calc. for C31H50NO5 [M+H]+: 516.3689, found: 516.3691. 
Compounds 3-8 (1-30) and 3-9 (1-31) 
 
Procedure: A vial with a stir bar was charged with 3-7 (633.9 mg, 1.22 mmol), ammonium 
acetate (634.2 mg, 8.23 mmol, 6.7 eq), titanium(III) chloride (216 µL, 3.70 mmol, 3.0 eq), and 
sodium cyanoborohydride (582.6 mg, 9.27 mmol, 7.6 eq), which were dissolved in MeOH (12 
mL). The vial was capped and placed in an 80 ºC oil bath and was allowed to stir for 20 h. The 













































extracted with chloroform (6x), dried over Na2SO4, and was concentrated under reduced 
pressure. The mixture was purified by flash chromatography using silica gel (9:1 
chloroform/methanol with 1% formic acid). The resulting solid was submitted to reverse phase 
Preparative HPLC (MeCN/H2O, 0.1% formic acid) to afford separation of epimers 3-8 (145.5 
mg, 23% yield) and 3-9 (38.2 mg, 6% yield) as analytically pure (≥95%) white solids. 
3-8 
1H NMR (CD3OD, 500 MHz) δ 5.77 (d, J = 8.7 Hz, 1H), 4.90–4.86 (m, 1H), 3.73–3.69 (m, 1H), 
2.85–2.79 (m, 1H), 2.43 (dt, J = 13.3, 8.1 Hz, 1H), 2.37–2.26 (m, 2H), 2.17 (td, J = 14.1, 4.2 Hz, 
1H), 2.13–2.02 (m, 4H), 1.99 (s, 3H), 1.87 (tdd, J = 13.7, 4.4, 2.7 Hz, 1H), 1.82–1.67 (m, 3H), 
1.62 (td, J = 12.6, 3.9 Hz, 1H), 1.58–1.40 (m, 5H), 1.33 (s, 3H), 1.29 (d, J = 14.1 Hz, 1H), 1.27–
1.17 (m, 3H), 1.11 (s, 3H), 1.00 (s, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 1.9 Hz, 3H), 0.88 
(d, J = 1.8 Hz, 3H). (47 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 176.3, 172.8, 141.0, 136.6, 75.0, 72.0, 50.4, 49.7, 49.0 (by 
DEPT 135), 43.8, 40.9, 40.1, 39.9, 39.2, 37.4, 35.5, 32.7, 30.9, 30.6, 30.5, 30.4, 29.3, 28.7, 25.4, 
23.1, 23.1, 22.7, 21.0, 20.9, 17.2, 16.4. 
HRMS(ESI): m/z calc. for C31H52NO5 [M+H]+: 518.3845, found: 518.3843. 
3-9 
1H NMR (CD3OD, 500 MHz) δ 5.74 (d, J = 8.2 Hz, 1H), 3.76–3.73 (m, 1H), 5.14 (td, J = 11.5, 
5.5 Hz, 1H), 2.72–2.62 (m, 2H), 2.44 (ddd, J = 13.1, 8.7, 6.3 Hz, 1H), 2.31 (td, J = 11.8, 5.1 Hz, 
1H), 2.20 (td, J = 12.4, 1.5 Hz, 1H), 2.05 (dd, J = 14.1, 8.5 Hz, 1H), 2.00 (s, 3H), 1.97–1.86 (m, 
4H), 1.83–1.66 (m, 3H), 1.62–1.40 (m, 4H), 1.36–1.08 (m, 6H), 1.24 (s, 3H), 1.04 (s, 3H), 1.01 
(s, 3H), 0.90 (d, J = 6.8 Hz, 3H), 0.89 (s, 3H), 0.88 (s, 3H). (47 non-exchangeable protons) 
154 
 
13C NMR (CD3OD, 125 MHz): δ 173.2 (2C), 140.7, 136.2, 75.9, 71.8, 51.7, 50.0, 48.6, 48.5, (by 
HSQC), 44.9, 40.3, 40.3, 40.0, 39.8, 37.7, 35.7, 34.6, 33.7, 31.1, 30.9, 29.4, 28.9, 28.1, 23.2, 
23.1, 22.2, 21.7, 21.1, 20.3, 18.1, 16.6. 
HRMS(ESI): m/z calc. for C31H52NO5 [M+H]+: 518.3845, found: 518.3842. 
Compound 3-17 (1-36) 
 
Procedure: A polyethylene (HDPE) container with a stir bar was charged with 3-16 (121.2 mg, 
0.18 mmol) and THF (8 mL). Excess (1 mL) aqueous HF (48%) was slowly added to the 
solution. The reaction was stirred for 26 hours. At this time, 1 mL of HF was added to the 
reaction. The container was capped and was allowed to stir for 3 h. The reaction was quenched 
with 10% NaOH solution, was poured into a seperatory funned, which was diluted with brine 
and water. The mixture was extracted with chloroform (4x), dried over Na2SO4, and was 
concentrated under reduced pressure. The mixture was purified by flash chromatography using 
silica gel (100% EtOAc). The resulting solid was submitted to reverse phase Preparative HPLC 
to afford 3-17 (72.2 mg, 72% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 6.06 (d, J = 8.5 Hz, 1H), 5.10 (t, J = 7.3 Hz, 1H), 4.37–4.33 (m, 
1H), 3.82 (d, J = 17.0 Hz, 1H), 3.78–3.75 (m, 1H), 3.73 (d, J = 17.0 Hz, 1H), 3.11–3.05 (m, 1H), 
2.47 (t, J = 8.1 Hz, 1H), 2.35 (dt, J = 13.1, 2.6 Hz, 1H), 2.23–2.01 (m, 5H), 1.90–1.82 (m, 2H), 

































Hz, 1H), 1.38 (s, 3H), 1.36 (d, J = 14.0 Hz, 1H), 1.18–1.05 (m, 3H), 0.97 (s, 3H), 0.93 (s, 3H), 
0.92 (d, J = 6.7 Hz, 3H). (46 protons) 
HRMS(ESI): m/z calc. for C31H47N3O6Na [M+Na]+: 580.3363, found: 580.3359. 
Compound 3-18 (1-37) 
 
Procedure: A vial with a stir bar was charged with 3-17 (58.7 mg, 0.11 mmol), polymer 
supported triphenylphosphine (3 mmol/g, 190.1 mg, 0.57 mmol, 5.4 eq), excess triethylamine 
(0.2 mL), and water (0.2 mL), which were dissolved in THF (5 mL). The vial was capped and 
placed in an 80 ºC oil bath and was allowed to stir for 19 h. The vial was poured into a 
seperatory funned and was diluted with brine and water. The mixture was extracted with 
chloroform (5x), dried over Na2SO4, and was concentrated under reduced pressure. The mixture 
was purified by flash chromatography using silica gel (9:1 chloroform/methanol with 1% formic 
acid). The resulting solid was submitted to reverse phase Preparative HPLC (MeCN/H2O, 0.1% 
formic acid) to afford 3-18 (35.7 mg, 64% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.93 (d, J = 8.4 Hz, 1H), 5.15 (t, J = 7.0 Hz, 1H), 4.32–4.28 (m, 
1H), 3.76 (d, J = 17.3 Hz, 1H), 3.69 (d, J = 18.1 Hz, 1H), 3.68–3.65 (m, 1H), 3.08–3.01 (m, 1H), 
2.54 (dt, J = 13.4, 8.3 Hz, 1H), 2.36–2.23 (m, 3H), 2.21–2.08 (m, 4H), 1.89–1.58 (m, 6H), 1.67 
(s, 3H), 1.62 (s, 3H), 1.53 (ddd, J = 11.0, 7.0, 2.6 Hz, 1H), 1.48 (ddd, J = 13.6, 4.7, 2.2 Hz, 1H), 
1.39 (s, 3H), 1.29 (d, J = 14.2 Hz, 1H), 1.17–1.08 (m, 2H), 1.00 (s, 3H), 0.95 (s, 3H), 0.89 (d, J = 

































13C NMR (CD3OD, 125 MHz): δ 179.0, 168.3, 140.1, 138.4, 132.8, 125.1, 77.9, 72.6, 68.7, 
50.8, 50.2, 50.0, 44.1, 40.8, 40.0, 38.3, 37.9, 37.4, 36.9, 33.1, 31.1, 31.0, 30.7, 29.3, 26.0, 23.9, 
23.9, 22.5, 18.0, 18.0, 16.6. 
HRMS(ESI): m/z calc. for C31H49NO6Na [M+Na]+: 554.3468, found: 554.3471. 
Compound 3-27 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (1.00 g, 1.94 mmol) 
and excess hydrazine (470 µL), which were dissolved in MeCN (10 mL) and DMF (2 mL). The 
solution was treated with HOBt (327.0 mg, 2.33 mmol, 1.2 eq) and EDCI (412 µL, 2.33 mmol, 
1.2 eq). The vial was capped and placed in an 80 ºC heating block and was allowed to stir for 26 
h. The vial was poured into a seperatory funnel and was diluted with brine and water. The 
mixture was extracted with chloroform (3x), dried over Na2SO4, and was concentrated under 
reduced pressure. The mixture was purified via flash chromatography on silica gel (9:1 
chloroform/methanol). The resulting solid was submitted to reverse phase Preparative HPLC to 
afford 3-27 (153.4 mg, 18% yield) as an analytically pure (≥95%) white solid. 1H NMR data and 





































Procedure: A vial equipped with a stir bar was charged with 3-27 (56.2 mg, 0.11 mmol), 
carbonydiimidazole (110.4 mg, 0.68 mmol, 6.4 eq), and excess triethylamine (0.5 mL), which 
were dissolved in THF (5 mL). The vial was capped and stirred at room temperature for 16 h. 
The vial was poured into a seperatory funnel and was diluted with brine and water. The mixture 
was extracted with chloroform (3x), dried over Na2SO4, and was concentrated under reduced 
pressure. The mixture was purified via flash chromatography on silica gel (1:1 EtOAC/Hexanes). 
The resulting solid was submitted to reverse phase Preparative HPLC to afford 3-28 (26.6 mg, 
45% yield) as an analytically pure (≥95%) white solid. 1H, 13C NMR data and mass (high-
resolution ESI) were consistent with literature reported data.21 
Compound 3-29 
 
Procedure: A vial equipped with a stir bar was charged with 3-27 (44.6 mg, 0.08 mmol), carbon 
disulfide (10 µL, 0.28 mmol, 3.3 eq), and potassium hydroxide (14.8 mg, 0.26 mmol, 3.1 eq), 
which were dissolved in MeOH (4 mL). The vial was capped and stirred at room temperature for 



























































phase Preparative HPLC to afford 3-29 (11.9 mg, 25% yield) as an analytically pure (≥95%) 




Procedure: A vial equipped with a stir bar was charged with fusidic acid (506.3 mg, 0.98 mmol) 
and (Z)-4-chloro-N’-hydroxybenzimidamide (201.9 mg, 1.18 mmol, 1.2 eq), which were 
dissolved in MeCN (12 mL) and DMF (3 mL). The solution was treated with HOBt (172.9 mg, 
1.28 mmol, 1.3 eq) and EDCI (225 µL, 1.27 mmol, 1.3 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 13 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was concentrated under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-33 (586.1 mg, 89% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.57 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 5.72 (d, J = 8.9 
Hz, 1H), 5.15 (s, 2H), 5.08 (t, J = 7.0 Hz, 1H), 4.34–4.31 (m, 1H), 3.70–3.67 (m, 1H), 3.06–3.01 
(m, 1H), 2.54–2.39 (m, 2H), 2.28 (dt, J = 12.9, 2.8 Hz, 1H), 2.23–2.02 (m, 7H), 1.98 (s, 3H), 





































3H), 1.21 (d, J = 14.4 Hz, 1H), 1.12–1.03 (m, 2H), 0.94 (s, 3H), 0.88 (s, 3H), 0.87 (d, J = 6.8 Hz, 
3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 167.9, 155.6, 147.7, 136.9, 132.7, 129.9, 129.1, 128.9 
(2C), 128.2 (2C), 123.2, 74.4, 71.5, 68.2, 49.5, 48.8, 43.7, 39.6, 39.0, 36.9, 36.7, 35.8, 35.6, 31.9, 
30.1, 30.0, 29.3, 28.5, 25.8, 23.8, 23.4, 21.1, 21.1, 18.0, 17.6, 16.1. 
HRMS(ESI): m/z calc. for C38H54N2O6Cl [M+H]+: 669.3670, found: 669.3674. 
Compound 3-34 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (283.5 mg, 0.55 mmol) 
and (Z)-N'-hydroxyacetimidamide (35.3 mg, 0.48 mmol, 1.2 eq), which were dissolved in MeCN 
(10 mL) and DMF (1 mL). The solution was treated with HOBt (65.2 mg, 0.49 mmol, 1.2 eq) 
and EDCI (107 µL, 0.49 mmol, 1.2 eq). The vial was capped and placed in an 80 ºC heating 
block and was allowed to stir for 20 h. The vial was poured into a seperatory funnel and was 
diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 
Na2SO4, and was concentrated under reduced pressure. The mixture was purified via flash 
chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted to 
reverse phase Preparative HPLC to afford 3-34 (54.2 mg, 23% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.68 (d, J = 8.8 Hz, 1H), 5.07 (t, J = 8.6 Hz, 1H), 4.70 (bs, 2H), 






































(dt, J = 13.1, 3.2 Hz, 1H), 2.23–2.02 (m, 5H), 2.00 (s, 3H), 1.93 (s, 3H), 1.88–1.78 (m, 2H), 
1.76–1.67 (m, 2H), 1.65 (s, 3H), 1.60–1.52 (m, 3H), 1.58 (s, 3H), 1.49 (ddd, J = 12.7, 4.6, 2.6 
Hz, 1H), 1.37 (s, 3H), 1.23 (dd, J = 14.3, 1.2 Hz, 1H), 1.14–1.03 (m, 2H), 0.96 (s, 3H), 0.90 (d, J 
= 6.9 Hz, 3H), 0.89 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.2, 168.0, 155.1, 147.1, 132.7, 129.4, 123.3, 74.4, 71.5, 
68.4, 49.5, 48.8, 43.6, 39.6, 39.1, 37.1, 36.6, 36.2, 35.7, 32.3, 30.3, 30.1, 29.3, 28.4, 25.9, 24.1, 
23.2, 21.1, 21.0, 18.0, 17.8, 17.2, 16.1. 
HRMS(ESI): m/z calc. for C33H53N2O6 [M+H]+: 573.3904, found: 573.3917. 
Compound 3-35 
 
Procedure: An oven-dried round-bottom flask equipped with a stir bar was charged with fusidic 
acid (5.00 g, 9.67 mmol) and (Z)-2-chloro-N'-hydroxyacetimidamide (2.17 g, 19.90 mmol, 2.0 
eq), which were DMF (10 mL). The solution was treated with HOBt (1.63 g, 10.6 mmol, 1.1 eq) 
and EDCI (1.88 mL, 13.8 mmol, 1.1 eq). The vial was capped and placed in an 80 ºC heating 
block and was allowed to stir for 19 h. The vial was poured into a seperatory funnel and was 
diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 
Na2SO4, and was concentrated under reduced pressure. The mixture was purified via flash 
chromatography on silica gel (9:1 EtOAc/methanol). The resulting solid was submitted to 





































(≥95%) white solid. Suitable crystals for X-ray crystallography were grown using slow 
evaporation. 
1H NMR (CDCl3, 500 MHz) δ 5.70 (d, J = 8.8 Hz, 1H), 5.08 (t, J = 7.0 Hz, 1H), 4.97 (s, 2H), 
4.37–4.33 (m, 1H), 4.16 (d, J = 12.7 Hz, 1H), 4.13 (d, J = 12.8 Hz, 1H), 3.76–3.74 (m, 1H), 
3.07–3.01 (m, 1H), 2.57–2.40 (m, 2H), 2.29 (dt, J = 13.1, 3.1 Hz, 1H), 2.26–2.04 (m, 5H), 1.99 
(s, 3H), 1.90–1.81 (m, 2H), 1.77–1.70 (m, 2H), 1.66 (s, 3H), 1.61–1.45 (m, 6H), 1.59 (s, 3H), 
1.38 (s, 3H), 1.24 (d, J = 14.3 Hz, 1H), 1.16–1.04 (m, 2H), 0.97 (s, 3H), 0.91 (d, J = 6.8 Hz, 3H), 
0.90 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 167.6, 153.9, 148.1, 133.0, 128.8, 123.1, 74.4, 71.5, 
68.4, 49.4, 48.9, 43.8, 40.6, 39.6, 39.1, 37.2, 36.4, 36.3, 35.7, 32.5, 30.4, 30.1, 29.3, 28.5, 25.9, 
24.3, 23.1, 21.1, 21.0, 18.0, 17.8, 16.1. 
HRMS(ESI): m/z calc. for C33H52N2O6Cl [M+H]+: 607.3514, found: 607.3507. 
Compound 3-36 
 
Procedure: A vial with a stir bar was charged with 3-35 (1.46 g, 2.42 mmol) and sodium azide 
(806.1 mg, 12.4 mmol, 5.1 eq), which were dissolved in DMF (7 mL). The vial was capped and 
placed in an 80 ºC heating block and was allowed to stir for 2 h. The vial was poured into a 
seperatory funnel and was diluted with brine and water. The mixture was extracted with 
chloroform (4x), dried over Na2SO4, and was concentrated under reduced pressure. The mixture 




































resulting solid was submitted to reverse phase Preparative HPLC to afford 3-36 (1.11 g, 75% 
yield) as an analytically pure (≥95%) white solid. Crystals suitable for X-ray crystallography 
were grown using slow evaporation. 
1H NMR (CDCl3, 500 MHz) δ 5.71 (d, J = 8.8 Hz, 1H), 5.08 (t, J = 7.0 Hz, 1H), 4.95 (s, 2H), 
4.36–4.33 (m, 1H), 4.00 (s, 2H), 3.77–3.74 (m, 1H), 3.07–3.02 (m, 1H), 2.57–2.40 (m, 2H), 2.29 
(dt, J = 13.1, 3.1 Hz, 1H), 2.26–2.04 (m, 5H), 1.99 (s, 3H), 1.90–1.81 (m, 2H), 1.78–1.70 (m, 
2H), 1.66 (s, 3H), 1.63–1.47 (m, 6H), 1.59 (s, 3H), 1.38 (s, 3H), 1.24 (d, J = 14.3 Hz, 1H), 1.16–
1.05 (m, 2H), 0.97 (s, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.90 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 167.7, 153.4, 148.0, 132.9, 128.9, 123.1, 74.3, 71.5, 
68.4, 49.9, 49.4, 48.9, 43.8, 39.6, 39.1, 37.2, 36.4, 36.3, 35.6, 32.5, 30.4, 30.1, 29.3, 28.5, 25.9, 
24.3, 23.0, 21.2, 20.9, 18.0, 17.9, 16.1. 
HRMS(ESI): m/z calc. for C33H51N5O6Na [M+Na]+: 636.3737, found: 636.3741. 
Compound 3-37 
 
Procedure: A vial with a stir bar was charged with 3-36 (452.8 mg, 0.74 mmol), 3 mmol/g 
polymer-supported triphenyphosphine (720.8 mg, 2.16 mmol, 2.9 eq), THF (10 mL) and DMF (5 
mL). The vial was capped and placed in an 80 ºC heating block and was allowed to stir for 2 h. 
The vial was poured into a seperatory funnel and was diluted with brine and water. The mixture 
was extracted with chloroform (6x), dried over Na2SO4, and was concentrated under reduced 




































dichloromethane/methanol). The resulting solid was submitted to reverse phase Preparative 
HPLC to afford 3-37 (165.4 mg, 38% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.83 (d, J = 8.6 Hz, 1H), 5.13 (t, J = 6.5 Hz, 1H), 4.36–4.31 (m, 
1H), 4.69–3.65 (m, 1H), 3.15–4.08 (m, 1H), 2.61 (ddd, J = 13.4, 9.0, 4.2 Hz, 1H), 2.46–2.38 (m, 
1H), 2.34–2.04 (m, 7H), 1.95 (s, 3H), 1.92–1.59 (m, 6H), 1.67 (s, 3H), 1.61 (s, 3H), 1.54 (ddd, J 
= 11.0, 6.9, 2.5 Hz, 1H), 1.49 (ddd, J = 13.1, 4.3, 2.2 Hz, 1H), 1.40 (s, 3H), 1.35–1.28 (m, 1H), 
1.21 (d, J = 14.1 Hz, 1H), 1.18–1.10 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H), 0.90 (d, J = 6.8 Hz, 3H). 
(47 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 171.1, 169.1, 158.7, 148.8, 132.2, 128.5, 122.8, 74.4, 71.0, 
67.0, 49.3, 48.5, 48.2, 43.6, 40.6, 39.3, 38.5, 36.9, 36.4, 35.9, 35.3, 31.4, 29.6, 29.5, 28.5, 27.8, 
24.5, 22.5, 22.4, 21.0, 19.7, 16.5, 15.1. 
HRMS(ESI): m/z calc. for C33H54N3O6 [M+H]+: 588.4013, found: 588.3996. 
Compound 3-38 
 
Procedure: A vial with a stir bar was charged with 3-35 (671.4 g, 1.11 mmol), an excess of 
methylamine in ethanol, and DMF (5 mL). The vial was capped and placed in an 80 ºC heating 
block and was allowed to stir for 2 h. The vial was poured into a seperatory funnel and was 
diluted with brine and water. The mixture was extracted with chloroform (6x), dried over 
Na2SO4, and was concentrated under reduced pressure. The mixture was purified via flash 




































to reverse phase Preparative HPLC to afford 3-38 (112.1 mg, 17% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.83 (d, J = 8.7 Hz, 1H), 5.13 (t, J = 7.4 Hz, 1H), 4.35–4.31 (m, 
1H), 4.68–3.64 (m, 1H), 3.27 (d, J = 14.4 Hz, 1H), 3.22 (d, J = 14.4 Hz, 1H), 3.13–3.08 (m, 1H), 
3.65–3.57 (m, 1H), 2.46–2.38 (m, 1H), 2.36 (s, 3H), 2.33–2.05 (m, 6H), 1.94 (s, 3H), 1.91–1.58 
(m, 6H), 1.66 (s, 3H), 1.60 (s, 3H), 1.57–1.45 (m, 2H), 1.40 (s, 3H), 1.20 (d, J = 14.1 Hz, 1H), 
1.17–1.08 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.90 (d, J = 6.8 Hz, 3H). (50 non-exchangeable 
protons) 
13C NMR (CD3OD, 125 MHz): δ 172.4, 170.3, 158.4, 150.0, 133.6, 130.1, 124.3, 75.9, 72.5, 
68.5, 50.8, 50.8, 49.9, 45.1, 40.8, 40.1, 38.4, 37.8, 37.4, 36.8, 35.1, 32.9, 31.1, 31.0, 30.1, 29.3, 
26.0, 24.0, 23.9, 22.5, 21.1, 18.0 (2C), 16.6. 
HRMS(ESI): m/z calc. for C34H56N3O6 [M+H]+: 602.4169, found: 602.4158. 
Compound 3-39 
 
Procedure: A vial with a stir bar was charged with 3-35 (75.3 mg, 0.12 mmol), benzylamine (15 
µL, 0.14 mmol, 1.1 eq), and DMF (5 mL). The vial was capped and placed in an 80 ºC heating 
block and was allowed to stir for 2 h. The DMF was blow-dried with nitrogen until a sticky paste 
remained. The mixture was submitted to reverse phase Preparative HPLC to afford 3-39 (6.2 mg, 





































1H NMR (CDCl3, 500 MHz) δ 7.36–7.28 (m, 5H), 5.73 (d, J = 8.7 Hz, 1H), 5.26 (s, 2H), 5.10 (t, 
J = 7.0 Hz, 1H), 4.37–4.32 (m, 1H), 3.78 (d, J = 13.1 Hz, 1H), 3.76–3.73 (m, 1H), 3.72 (d, J = 
13.3 Hz, 1H), 3.44 (d, J = 14.3 Hz, 1H), 3.40 (d, J = 14.6 Hz, 1H), 2.29 (dt, J = 13.2, 3.0 Hz, 
1H), 2.25–2.05 (m, 5H), 2.00 (s, 3H), 1.90–3.81 (m, 2H), 1.78–1.70 (m, 2H), 1.66 (s, 3H), 1.63–
1.48 (m, 7H), 1.60 (s, 3H), 1.38 (s, 3H), 1.24 (d, J = 14.0 Hz, 1H),1.17–1.05 (m, 2H), 0.97 (s, 
3H), 0.92 (d, J = 6.8 Hz, 3H), 0.91 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 168.1, 157.2, 147.3, 139.6, 132.7, 129.5, 128.7 (2C), 
128.3 (2C), 127.5, 123.3, 77.5, 77.2, 77.0, 74.4, 71.5, 68.5, 53.3, 49.5, 48.9, 47.7, 43.7, 39.6, 
39.1, 37.2, 36.4, 36.4, 35.7, 32.6, 30.5, 30.1, 29.3, 28.5, 25.9, 24.4, 23.0, 21.2, 21.0, 18.1, 17.9, 
16.1. 
HRMS(ESI): m/z calc. for C40H60N2O6 [M+H]+: 678.4482, found: 678.4492. 
Compound 3-40 
 
Procedure: A vial with a stir bar was charged with 3-35 (1.18 g, 1.93 mmol), ethylenediamine 
(155 µL, 2.32 mmol, 1.2 eq), MeCN (10 mL), and DMF (1 mL). The vial was capped and 
allowed to stir at room temperature for 30 h. The vial was poured into a seperatory funnel and 
was diluted with brine and water. The mixture was extracted with chloroform (6x), dried over 
Na2SO4, and was condensed under reduced pressure. The mixture was purified via flash 




































to reverse phase Preparative HPLC to afford 3-40 (76.7 mg, 6% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) ä 5.83 (d, J = 8.7 Hz, 1H), 5.12 (t, J = 7.1 Hz, 1H), 4.33–4.30 (m, 
1H), 3.67–3.64 (m, 1H), 3.43 (d, J = 16.0,  Hz, 1H), 3.38 (d, J = 16.0 Hz, 1H), 3.19 (dhept, J = 
9.5, 5.8 Hz, 1H), 3.12–3.07 (m, 1H), 2.98 (t, J = 5.9 Hz, 1H), 2.59 (ddd, J = 13.2, 8.4, 6.4 Hz, 
1H), 2.43–2.35 (m, 1H), 2.31–2.02 (m, 6H), 1.93 (s, 3H), 1.90–1.56 (m, 6H), 1.65 (s, 3H), 1.59 
(s, 3H), 1.53 (ddd, J = 11.3, 6.8, 2.5 Hz, 1H), 1.47 (ddd, J = 13.4, 4.3, 2.4 Hz, 1H), 1.19 (d, J = 
14.3 Hz, 1H), 1.16–1.09 (m, 2H), 0.99 (s, 3H), 0.91 (s, 3H), 0.89 (d, J = 6.8 Hz, 3H). (51 non-
exchangeable protons) 
13C NMR (CD3OD, 125 MHz): ä 172.6, 170.3, 155.1, 149.9, 133.6, 130.1, 124.3, 76.0, 72.5, 
68.6, 50.8, 50.0, 45.1, 44.5, 44.1, 41.5, 40.8, 40.1, 38.4, 37.9, 37.4, 36.9, 32.9, 31.1, 31.0, 30.1, 
29.3, 26.0, 24.0, 23.9, 22.5, 21.1, 18.0 (2C), 16.6. 
HRMS(ESI): m/z calc. for C35H56N3O6 [M+H]+: 614.4169, found: 614.4188. 



























Procedure: A vial equipped with a stir bar was charged with 3-35 (499.4 mg, 0.82 mmol), 
piperazine (72.9 mg, 0.85 mmol, 1.0 eq) and DMF (4 mL). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 2 h. The vial was poured into a seperatory funnel 
and was diluted with brine and water. The mixture was extracted with chloroform (6x), dried 
over Na2SO4, and was condensed under reduced pressure. The mixture was separated via flash 
chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted to 
reverse phase Preparative HPLC to afford 3-41 (204.1 mg, 38% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.83 (d, J = 8.6 Hz, 1H), 5.13 (t, J = 6.8 Hz, 1H), 4.35–4.31 (m, 
1H), 3.68–3.65 (m, 1H), 3.14–3.07 (m, 2H), 3.00–2.87 (m, 5H), 2.66–2.36 (m, 6H), 2.33–2.05 
(m, 6H), 1.93 (s, 3H), 1.92–1.58 (m, 6H), 1.66 (s, 3H), 1.61 (s, 3H), 1.56–1.45 (m, 2H), 1.40 (s, 
3H), 1.19 (d, J = 14.2 Hz, 1H), 1.17–1.10 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.90 (d, J = 6.8 Hz, 
3H). (55 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 172.3, 170.2, 157.8, 150.0, 133.6, 123.0, 124.3, 76.0, 72.5, 
68.5, 58.4, 54.5, 50.8, 49.9, 46.3, 45.1, 40.8, 40.0, 38.4, 37.8, 37.4, 36.8, 32.9, 31.1, 31.0, 30.1, 
29.4, 26.0, 24.1, 23.9, 22.5, 21.2, 18.0 (4C), 16.6. 











































Procedure: A vial equipped with a stir bar was charged with fusidic acid (588.0 mg, 1.14 mmol) 
and propan-2-one oxime (369.3 mg, 5.05 mmol, 4.4 eq), which were dissolved in MeCN (12 
mL) and DMF (3 mL). The solution was treated with HOBt (184.5 mg, 1.36 mmol, 1.2 eq) and 
EDCI (225 µL, 1.27 mmol, 1.1 eq). The vial was capped and placed in an 80 ºC heating block 
and was allowed to stir for 24 h. The vial was poured into a seperatory funnel and was diluted 
with brine and water. The mixture was extracted with chloroform (3x), dried over Na2SO4, and 
was condensed under reduced pressure. The mixture was purified via flash chromatography on 
silica gel (100% EtOAc). The resulting solid was submitted to reverse phase Preparative HPLC 
to afford 3-42 (182.2 mg, 28% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.67 (d, J = 8.6 Hz, 1H), 5.05 (t, J = 7.2 Hz, 1H), 4.33–4.29 (m, 
1H), 3.70–3.66 (m, 1H), 3.52–2.35 (m, 1H), 2.26 (dt, J = 12.9, 2.6 Hz, 1H), 2.22–2.01 (m, 7H), 
1.97 (s, 3H), 1.92 (s, 6H), 1.84–1.74 (m, 2H), 1.72–1.65 (m, 2H), 1.61 (s, 3H), 1.58–1.41 (m, 
4H), 1.54 (s, 3H), 1.34 (s, 3H), 1.18 (d, J = 14.2 Hz, 1H), 1.13–1.02 (m, 2H), 0.92 (s, 3H), 0.88–
0.84 (m, 3H), 0.85 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.0, 168.1, 163.8, 148.1, 132.6, 128.8, 123.2, 74.4, 71.4, 
68.2, 49.5, 48.7, 43.7, 39.5, 39.0, 36.8, 36.7, 35.7, 35.5, 31.8, 30.1, 29.9, 29.1, 28.4, 25.8, 23.7, 
23.4, 22.0, 21.1, 21.0, 17.9, 17.6, 17.2, 16.1. 





































Procedure: A vial equipped with a stir bar was charged with fusidic acid (544.5 mg, 1.05 mmol) 
and diphenylmethanone (567.2 mg, 2.88 mmol, 2.7 eq), which were dissolved in MeCN (10 mL) 
and DMF (2 mL). The solution was treated with HOBt (179.8 mg, 1.17 mmol, 1.1 eq) and EDCI 
(225 µL, 1.27 mmol, 1.2 eq). The vial was capped and placed in an 80 ºC heating block and was 
allowed to stir for 21 h. The vial was poured into a seperatory funnel and was diluted with brine 
and water. The mixture was extracted with chloroform (3x), dried over Na2SO4, and was 
condensed under reduced pressure. The mixture was purified via flash chromatography on silica 
gel (100% EtOAc). The resulting solid was submitted to reverse phase Preparative HPLC to 
afford 3-43 (126.5 mg, 17% yield) as an analytically pure (>95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.55 (d, J = 8.0 Hz, 2H), 7.49–7.39 (m, 4H), 7.32 (t, J = 7.7 Hz, 
2H), 7.30–7.27 (m, 2H), 5.42 (d, J = 8.2 Hz, 1H), 4.95 (t, J = 6.4 Hz, 1H), 3.66–3.62 (m, 1H), 
3.41 (t, J = 7.6 Hz, 1H), 2.56 (d, J = 15.4 Hz, 1H), 2.41 (dd, J = 14.9, 8.2 Hz, 1H), 2.04–1.96 (m, 
1H), 1.95–1.87 (m, 1H), 1.89 (s, 3H), 1.80–1.50 (m, 9H), 1.64 (s, 3H), 1.52 (s, 3H), 1.45–1.37 
(m, 2H), 1.18–1.02 (m, 2H), 1.10 (s, 3H), 1.01 (s, 3H), 0.95 (s, 3H), 0.89 (d, J = 6.8 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.2, 170.8, 165.4, 150.8, 134.7, 132.7, 132.4, 131.0, 129.6, 
129.5, 129.2 (2C), 128.8 (2C), 128.4 (4C), 128.4 (4C), 123.7, 80.9, 71.4, 69.3, 55.9, 50.6, 42.9, 




































HRMS(ESI): m/z calc. for C44H57NO6Na [M+Na]+: 718.4084, found: 718.4111. 
Compound 3-44 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (427.8 mg, 0.83 mmol) 
and methyl (Z)-N-hydroxyethanimidothioate (177.5 mg, 1.69 mmol, 2.0 eq), which were 
dissolved in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (177.6 mg, 
1.16 mmol, 1.4 eq) and EDCI (190 µL, 1.07 mmol, 1.3 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 20 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-44 (108.7 mg, 22% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.62 (d, J = 7.8 Hz, 1H), 5.07 (t, J = 6.6 Hz, 1H), 4.37–4.34 (m, 
1H), 3.68–3.64 (m, 5H), 3.53 (t, J = 7.4 Hz, 1H), 2.64 (dd, J = 14.8, 2.0 Hz, 1H), 2.56 (dd, J = 
15.0, 8.3 Hz, 1H), 2.36 (s, 3H), 2.31–2.22 (m, 1H), 2.25 (s, 3H), 2.05–1.93 (m, 2H), 2.00 (s, 3H), 
1.77–1.61 (m, 3H), 1.67 (s, 3H), 1.57 (s, 3H), 1.50–1.38 (m, 2H), 1.24 (dd, J = 14.9, 2.3 Hz, 1H), 



































13C NMR (CDCl3, 125 MHz): δ 171.0, 170.5, 164.5, 150.8, 132.6, 129.8, 123.8, 81.1, 71.6, 
69.6, 56.1, 50.7, 42.7, 41.1, 40.2, 37.9, 36.8, 35.0, 34.6, 30.8, 29.8 (2C), 29.5, 26.1, 25.9, 24.6, 
23.7, 23.1, 21.8, 21.7, 19.2, 18.0, 16.1, 13.8. 
HRMS(ESI): m/z calc. for C34H53NO6SNa [M+Na]+: 626.3491, found: 626.3477. 
Compound 3-45 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (405.6 mg, 0.78 mmol) 
and isopropyl (Z)-N-hydroxyethanimidothioate (135.0 mg, 1.01 mmol, 1.3 eq), which were 
dissolved in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (146.1 mg, 
0.95 mmol, 1.2 eq) and EDCI (180 µL, 1.02 mmol, 1.3 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 20 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was separated via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-45 (22.2 mg, 4% yield) as an analytically pure 
(≥95%) white solid. Mixture of Z and E isomers. 
1H NMR (CDCl3, 500 MHz) δ 5.61 (d, J = 8.2 Hz, 1H), 5.09 (t, J = 6.4 Hz, 1H), 4.36–4.33 (m, 
1H), 3.71–3.68 (m, 1H), 3.57–3.52 (m, 1H), 3.45 (hept, J = 6.7 Hz, 1H), 2.67 (d, J = 5.0 Hz, 1H), 









































1.84–1.63 (m, 8H), 1.69 (s, 3H), 1.59 (s, 3H), 1.53–1.41 (m, 3H), 1.37 (d, J = 3.8 Hz, 3H), 1.35 
(d, J = 3.7 Hz, 3H), 1.33–1.11 (m, 8H), 1.17 (s, 3H), 1.16 (s, 3H), 1.00 (s, 3H), 0.93–0.78 (m, 
3H), 0.91 (d, J = 6.8 Hz, 1H), 0.85 (d, J = 6.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 170.9, 170.4, 163.3, 150.3, 132.6, 130.2, 123.9, 81.2, 71.6, 
69.7, 56.1, 50.9, 45.5, 42.5, 41.3, 40.4, 37.8, 37.0, 35.4, 35.3, 34.7, 32.1, 30.8, 30.2, 30.0, 29.5, 
27.9, 26.1, 25.9, 24.6, 24.4, 23.9, 23.5, 22.9, 21.7, 19.4, 18.0, 16.1, 14.3. 
HRMS(ESI): m/z calc. for C36H57NO6SNa [M+Na]+: 654.3804, found: 654.3828. 
Compound 3-46 
 
Procedure: An oven-dried round-bottom flask equipped with a stir bar was charged with fusidic 
acid (572.9 mg, 1.11 mmol) and p-nitrophenol (746.1 g, 5.36 mmol, 4.8 eq), which were 
dissolved in DMF (4 mL). The solution was treated with HOBt (258.4 g, 1.69 mmol, 1.5 eq), and 
DIPEA (1.20 mL, 6.89 mmol, 6.2 eq) and was stirred for 15 min. Next, PyBOP (873.4 mg, 1.68 
mmol, 1.5 eq) was added to the reaction. The vial was capped and was allowed to stir at room 
temperature for 21 h. The contents of the vial were poured into a seperatory funnel and were 
diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 
Na2SO4, and was condensed under reduced pressure. The mixture was purified via flash 
chromatography on silica gel (100% EtOAc). The resulting solid was submitted to reverse phase 


































1H NMR (CDCl3, 500 MHz) δ 8.25 (d, J = 9.4 Hz, 1H), 7.29 (d, J = 9.1 Hz, 1H), 5.95 (d, J = 8.4 
Hz, 1H), 5.14 (t, J = 7.0 Hz, 1H), 4.39–4.36 (m, 1H), 3.77–3.73 (m, 1H), 4.17–3.12 (m, 1H), 
2.69–2.51 (m, 2H), 2.37 (dt, J = 12.8, 3.1 Hz, 1H), 1.93–1.85 (m, 2H), 1.84 (s, 3H), 1.80–1.68 
(m, 3H), 1.66 (s, 3H), 1.63–1.56 (m, 4H), 1.60 (s, 3H), 1.52 (ddd, J = 12.3, 4.5, 2.3 Hz, 1H), 1.40 
(s, 3H), 1.34 (d, J = 14.4 Hz, 1H), 1.19–1.06 (m, 2H), 0.99 (s, 3H), 0.95 (s, 3H), 0.92 (d, J = 6.8 
Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 170.6, 167.0, 155.8, 152.4, 145.2, 133.3, 129.1, 125.4 (2C), 
122.9, 122.1 (2C), 74.8, 71.6, 68.4, 49.5, 49.0, 44.9, 39.7, 39.3, 37.2, 36.5, 36.2, 35.7, 32.5, 30.4, 
30.1, 29.2, 28.8, 26.0, 24.3, 23.1, 21.2, 21.0, 18.2, 18.0, 16.1. 
HRMS(ESI): m/z calc. for C37H51NO8Na [M+Na]+: 660.3512, found: 660.3523. 
Compound 3-47 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (500.1 mg, 0.97 mmol) 
and (Z)-N’-hydroxybenzimidamide (393.6 mg, 2.89 mmol, 3.0 eq), which were dissolved in 
MeCN (10 mL) and DMF (2 mL). The solution was treated with HOBt (164.2 mg, 1.07 mmol, 
1.1 eq) and EDCI (206 µL, 1.16 mmol, 1.2 eq). The vial was capped and placed in an 80 ºC 
heating block and was allowed to stir for 20 h. The vial was poured into a seperatory funnel and 
was diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 




































chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted to 
reverse phase Preparative HPLC to afford 3-47 (233.1 mg, 36% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.64 (d, J = 7.8 Hz, 2H), 7.42 (t, J = 7.4 Hz, 1H), 7.35 (t, J = 7.5 
Hz, 2H), 5.74 (d, J = 8.8 Hz, 1H), 5.10 (t, J = 6.9 Hz, 1H), 5.06 (s, 2H), 4.35–4.31 (m, 1H), 
3.72–3.68 (m, 1H), 3.07–3.02 (m, 1H), 2.56–2.42 (m, 2H), 2.29 (dt, J = 13.1, 2.9 Hz, 1H), 2.26–
2.08 (m, 5H), 2.01 (s, 3H), 1.99–1.94 (m, 2H), 1.88–1.77 (m, 2H), 1.74–1.67 (m, 2H), 1.65 (s, 
3H), 1.62–1.44 (m, 4H), 1.59 (s, 3H), 1.23 (d, J = 14.1 Hz, 1H), 1.14–1.04 (m, 2H), 0.95 (s, 3H), 
0.90 (s, 3H), 0.89 (d, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 170.6, 167.0, 155.8, 152.4, 145.2, 133.3, 129.1, 125.4 (2C), 
122.9, 122.1 (2C), 74.8, 71.6, 68.4, 49.5, 49.0, 44.9, 39.7, 39.3, 37.2, 36.5, 36.2, 35.7, 32.5, 30.4, 
30.1, 29.2, 28.8, 26.0, 24.3, 23.1, 21.2, 21.0, 18.2, 18.0, 16.1. 
HRMS(ESI): m/z calc. for C38H55N2O6 [M+H]+: 635.4060, found: 635.4044. 
Compound 3-48 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (571.5 mg, 1.11 mmol) 
and (Z)-N’-hydroxy-2-phenylacetimidamide (211.7 mg, 1.41 mmol, 1.3 eq), which were 
dissolved in MeCN (10 mL) and DMF (2 mL). The solution was treated with HOBt (194.6 mg, 
1.27 mmol, 1.1 eq) and EDCI (235 µL, 1.33 mmol, 1.2 eq). The vial was capped and placed in an 




































funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-48 (176.9 mg, 25% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.35–7.24 (m, 5H), 5.69 (d, J = 8.8 Hz, 1H), 5.07 (t, J = 7.2 Hz, 
1H), 4.60 (bs, 2H), 4.34–4.30 (m, 1H), 3.72–3.70 (m, 1H), 3.57 (d, J = 15.3 Hz, 1H), 3.53 (d, J = 
15.3 Hz, 1H), 3.04–2.98 (m, 1H), 2.27 (dt, J = 13.2, 3.0 Hz, 1H), 2.22–2.04 (m, 5H), 2.01 (s, 
3H), 1.87–1.67 (m, 6H), 1.64 (s, 3H), 1.60–1.44 (m, 4H), 1.57 (s, 3H), 1.35 (s, 3H), 1.22 (d, J = 
14.3 Hz, 1H), 1.14–1.03 (m, 2H), 0.95 (s, 3H), 0.90–0.87 (m, 3H), 0.89 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 168.0, 157.0, 147.3, 135.2, 132.7, 129.3, 129.1 (4C), 
127.6, 123.3, 74.4, 71.5, 68.3, 49.5, 48.8, 43.6, 39.6, 39.1, 37.5, 37.0, 36.6, 36.0, 35.6, 32.1, 30.3, 
30.0, 29.3, 28.5, 25.8, 24.0, 23.3, 21.2, 21.1, 18.0, 17.7, 16.1. 
HRMS(ESI): m/z calc. for C39H57N2O6 [M+H]+: 649.4217, found: 649.4227. 
Compound 3-49 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (588.0 mg, 1.14 mmol) 
and (Z)-N’-hydroxypyrazine-2-carboximidamide (555.9 mg, 4.02 mmol, 3.5 eq), which were 








































1.31 mmol, 1.1 eq) and EDCI (242 µL, 1.37 mmol, 1.2 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 26 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-49 (334.2 mg, 46% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 9.39 (s, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.52 (dd, J = 2.6, 1.6 Hz, 
1H), 5.77 (d, J = 8.7 Hz, 1H), 5.11 (t, J = 7.1 Hz, 1H), 4.38–4.34 (m, 1H), 3.76–3.72 (m, 1H), 
3.11–3.05 (m, 1H), 2.60–2.44 (m, 2H), 2.33 (dt, J = 13.2, 3.2 Hz, 1H), 2.28–2.08 (m, 5H), 2.00 
(s, 3H), 1.92–1.70 (m, 6H), 1.66 (s, 3H), 1.62–1.48 (m, 2H), 1.60 (s, 3H), 1.39 (s, 3H), 1.25 (d, J 
= 14.4 Hz, 1H), 1.16–1.05 (m, 2H), 0.97 (s, 3H), 0.92 (s, 3H), 0.91 (d, J = 7.0 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 167.9, 152.3, 148.4, 146.1, 143.9, 143.6, 143.0, 132.9, 
128.9, 123.2, 74.5, 71.5, 68.4, 51.0, 49.6, 48.9, 43.8, 39.7, 39.1, 37.2, 36.6, 36.2, 35.6, 32.3, 30.4, 
30.1, 29.4, 28.6, 25.9, 24.2, 23.2, 21.1, 18.0, 17.8, 16.1. 







































Procedure: A vial equipped with a stir bar was charged with fusidic acid (506.1 mg, 0.98 mmol) 
and (Z)-2-amino-N’-hydroxybenzimidamide (426.5 mg, 2.82 mmol, 2.9 eq), which were 
dissolved in MeCN (10 mL) and DMF (2 mL). The solution was treated with HOBt (169.1 mg, 
1.10 mmol, 1.1 eq) and EDCI (210 µL, 1.19 mmol, 1.2 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 22.5 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was separated via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-50 (16.3 mg, 3% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.29 (d, J = 8.0 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 6.71–6.67 (m, 
2H), 5.81 (d, J = 8.8 Hz, 1H), 5.26 (bs, 2H), 5.12 (t, J = 7.0 Hz, 1H), 4.95 (s, 2H), 4.38–4.35 (m, 
1H), 3.77–3.74 (m, 1H), 3.10–3.05 (m, 1H), 2.59–2.44 (m, 2H), 2.32 (dt, J = 13.1, 2.9 Hz, 1H), 
2.28–2.08 (m, 5H), 1.98 (s, 3H), 1.92–1.82 (m, 2H), 1.79–1.72 (m, 2H), 1.68 (s, 3H), 1.64–1.48 
(m, 6H), 1.62 (s, 3H), 1.40 (s, 3H), 1.26 (d, J = 13.9 Hz, 1H), 1.18–1.05 (m, 2H), 0.98 (s, 3H), 
0.94–0.91 (m, 3H), 0.93 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.3, 167.9, 156.5, 147.8, 146.6, 132.9, 131.5, 129.3, 127.9, 
123.3, 117.2, 116.8, 114.0, 74.5, 71.5, 68.5, 49.5, 49.0, 43.8, 39.7, 39.2, 37.3, 36.5, 36.4, 35.7, 
32.6, 30.5, 30.2, 29.4, 28.6, 25.9, 24.4, 23.0, 21.2, 21.0, 18.1, 17.9, 16.1. 








Procedure: A vial equipped with a stir bar was charged with fusidic acid (48.0 mg, 0.09 mmol) 
and (Z)-N'-hydroxy-N-methylacetimidamide (8.2 mg, 0.09 mmol, 1.0 eq), which were dissolved 
in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (16.5 mg, 0.11 mmol, 
1.2 eq) and EDCI (22 µL, 0.12 mmol, 1.3 eq). The vial was capped and placed in an 80 ºC 
heating block and was allowed to stir for 16 h. The vial was poured into a seperatory funnel and 
was diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 
Na2SO4, and was condensed under reduced pressure. The mixture was purified via flash 
chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted to 
reverse phase Preparative HPLC to afford 3-51 (22.8 mg, 42% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.67 (d, J = 8.8 Hz, 1H), 5.09 (t, J = 7.4 Hz, 1H), 4.91 (q, J = 5.0 
Hz, 1H), 4.37–4.32 (m, 1H), 3.75 (q, J = 2.6 Hz, 1H), 3.06–3.00 (m, 1H), 2.85 (d, J = 5.0, 3H), 
2.54–2.40 (m, 2H), 2.29 (dt, J = 13.2, 3.3 Hz, 1H), 2.26–2.05 (m, 5H), 2.01 (s, 3H), 1.95 (s, 3H), 
1.91–1.81 (m, 2H), 1.80–1.71 (m, 2H), 1.67 (s, 3H), 1.60 (s, 3H), 1.64–1.48 (m, 6H), 1.39 (s, 







































13C NMR (CDCl3, 125 MHz): δ 171.3, 168.1, 157.5, 146.9, 132.7, 129.7, 123.4, 74.4, 71.5, 
68.5, 49.4, 48.9, 43.6, 39.6, 39.2, 37.3, 36.5, 36.4, 35.7, 32.7, 30.5, 30.2, 29.7, 29.4, 28.5, 25.9, 
24.5, 22.9, 21.2, 20.9, 18.0, 17.9, 16.1, 14.9. 
HRMS(ESI): m/z calc. for C34H55N2O6 [M+H]+: 587.4060, found: 587.4066. 
Compound 3-52 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (43.2 mg, 0.08 mmol) 
and (Z)-N'-hydroxy-N,N-dimethylacetimidamide (10.2 mg, 0.10 mmol, 1.2 eq), which were 
dissolved in MeCN (7 mL) and DMF (2 mL). The solution was treated with HOBt (15.5 mg, 
0.10 mmol, 1.2 eq) and EDCI (20 µL, 0.11 mmol, 1.4 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 14 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-52 (15.8 mg, 31% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.70 (d, J = 8.7 Hz, 1H), 5.10 (t, J = 7.2 Hz, 1H), 4.34 (q, J = 2.5 
Hz, 1H), 3.75 (q, J = 2.6 Hz, 1H), 3.05–3.00 (m, 1H), 2.89 (s, 6H), 2.52–2.40 (m, 2H), 2.30 (dt, J 






































(m, 2H), 1.66 (s, 3H), 1.60 (s, 3H), 1.63–1.49 (m, 5H), 1.39 (s, 3H), 1.27–1.22 (m, 2H), 1.16–
1.05 (m, 2H), 0.97 (s, 3H), 0.92 (d, J = 6.9 Hz, 3H), 0.90 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.3, 168.8, 163.5, 147.0, 132.5, 129.8, 123.5, 74.5, 71.6, 
68.5, 49.5, 48.9, 43.6, 39.6, 39.1, 38.5 (2C), 37.3, 36.4, 36.4, 35.7, 32.6, 30.5, 30.2, 29.3, 28.6, 
25.9, 24.4, 23.0, 21.4, 21.0, 18.1, 17.9, 16.1, 12.6. 
HRMS(ESI): m/z calc. for C35H57N2O6 [M+H]+: 601.4217, found: 601.4205. 
Compound 3-53 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (283.5 mg, 0.55 mmol) 
and (Z)-N'-hydroxy-N,N-diisopropylacetimidamide (100.2 mg, 0.63 mmol, 1.2 eq), which were 
dissolved in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (117.1 mg, 
0.76 mmol, 1.4 eq) and EDCI (130 µL, 0.73 mmol, 1.3 eq). The vial was capped and placed in an 
80 ºC heating block and was allowed to stir for 20 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was condensed under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-53 (7.3 mg, 2% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.73 (d, J = 8.7 Hz, 1H), 5.01 (t, J = 7.1 Hz, 1H), 4.36–4.32 (m, 






































6.2 Hz, 2H), 2.30 (dt, J = 13.4, 3.3 Hz, 1H), 2.25–2.04 (m, 5H), 2.01 (s, 3H), 1.99 (s, 3H), 1.85 
(td, J = 13.1, 3.1 Hz, 2H), 1.79–1.71 (m, 2H), 1.66 (s, 3H), 1.64–1.48 (m, 7H), 1.60 (s, 3H), 1.38 
(s, 3H), 1.30–1.22 (m, 12H), 1.17–1.04 (m, 2H), 0.97 (s, 3H), 0.92 (d, J = 7.2 Hz, 3H), 0.91 (s, 
3H). 
13C NMR (CDCl3, 125 MHz): δ 171.1, 168.9, 161.9, 146.5, 132.4, 130.1, 123.6, 74.4, 71.6, 
68.6, 49.5, 48.9, 47.2 (2C), 43.5, 39.6, 39.1, 37.3, 36.5, 36.4, 35.7, 32.6, 30.5, 30.2, 29.4, 28.7, 
25.9, 24.4, 23.0, 21.4 (2C), 21.3, 21.1 (2C), 21.0, 18.1, 17.9, 16.1, 14.1. 
HRMS(ESI): m/z calc. for C39H65N2O6 [M+H]+: 657.4843, found: 657.4869. 
Compound 3-54 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (512.6 mg, 0.99 mmol) 
and (Z)-N'-hydroxy-N-phenylacetimidamide (351.2 mg, 2.4 mmol, 2.4 eq), which were dissolved 
in MeCN (10 mL) and DMF (3 mL). The solution was treated with HOBt (176.3 mg, 1.2 mmol, 
1.2 eq) and EDCI (230 µL, 0.13mmol, 1.3 eq). The vial was capped and placed in an 80 ºC 
heating block and was allowed to stir for 17 h. The vial was poured into a seperatory funnel and 
was diluted with brine and water. The mixture was extracted with chloroform (3x), dried over 
Na2SO4, and was concentrated under reduced pressure. The mixture was separated via flash 
chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted to 
























































(a and b). There were several overlapping signals from both tautomers in the 1H and 13C NMR. 
An analytically pure (≥95%) white solid was isolated. 
1H NMR (CDCl3, 500 MHz) δ 7.47 (b, d, J = 8.1 Hz, 2H), 7.32 (a, t, J = 7.8 Hz, 2H), 7.20 (a, q, 
J = 8.1 Hz, 1H), 7.12 (a, d, J = 7.9 Hz, 2H), 6.93 (b, t, J = 7.3 Hz, 2H), 6.82 (a, s, 1H), 6.48 (b, s, 
1H), 5.74 (a, d, J = 8.9 Hz, 1H), 5.71 (b, d, J = 9.2 Hz, 1H), 5.07 (a/b, t, J = 7.0 Hz, 1H), 4.34–
4.28 (a/b, m, 1H), 3.70–3.65 (a/b, cm, 1H), 3.06–2.99 (a/b, m, 1H), 2.54–2.40 (a/b, m, 2H), 2.27 
(a/b, dt, J = 13.0, 2.9 Hz, 1H), 2.23–2.04 (a/b, m, 5H), 2.10 (b, s, 3H), 2.01 (a, s, 3H), 1.92 (b, s, 
3H), 1.88 (a, s, 3H), 1.85–1.73 (a/b, m, 2H), 1.71–1.65 (a/b, m, 2H), 1.61 (a/b, s, 3H), 1.58–1.41 
(a/b, m, 6H), 1.55 (a/b, s, 3H), 1.35 (b, s, 3H),1.34 (a, s, 3H), 1.20 (a/b, d, J = 14.4 Hz, 1H), 1.19 
(b, d, J = 14.1 Hz, 1H), 1.11–1.02 (a/b, m, 2H), 0.92 (a/b, s, 3H), 0.88 (a/b, s, 3H), 0.86 (a/b, d, J 
= 6.8 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.3, 171.1, 168.3, 167.7, 158.6, 154.8, 147.6, 147.5, 139.7, 
137.8, 132.6, 132.4, 129.3, 129.0, 128.9, 126.3, 125.9, 123.3, 123.2, 122.5, 119.9, 74.3, 74.3, 
71.4, 68.2, 68.1, 49.5, 48.7, 43.6, 43.6, 39.5, 39.0, 39.0, 36.8, 36.7, 35.6, 35.5, 31.8, 30.0, 29.9, 
29.2, 28.5, 28.4, 25.8, 25.8, 23.7, 23.5, 21.1, 21.1, 17.9, 17.6, 17.5, 16.3, 16.0, 15.7. (several 
overlapping signals) 





























































Procedure: A vial equipped with a stir bar was charged with fusidic acid (549.8 mg, 1.06 mmol) 
and (Z)-N-(4-bromophenyl)-N’-hydroxyacetimidamide (584.5 mg, 2.6 mmol, 2.4 eq), which 
were dissolved in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (182.5 
mg, 1.2 mmol, 1.1 eq) and EDCI (250 µL, 0.14 mmol, 1.3 eq). The vial was capped and placed 
in an 80 ºC heating block and was allowed to stir for 12 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was concentrated under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-55 (554.6 mg, 72% yield) as a mixture of 
tautomers (a and b). There were several overlapping signals from both tautomers in the 1H and 
13C NMR. An analytically pure (≥95%) white solid was isolated. 
1H NMR (CDCl3, 500 MHz) δ 7.44 (a, d, J = 8.7 Hz, 2H), 7.42 (b, d, J = 8.7 Hz, 2H), 7.29 (b, d, 
J = 8.9 Hz, 2H), 7.01 (a, d, J = 7.9 Hz, 2H), 6.76 (a, s, 1H), 6.65 (b, s,1H), 5.74 (a, d, J = 9.2 Hz, 
1H), 5.71 (b, d, J = 9.1 Hz, 1H), 5.06 (a/b, t, J = 6.6 Hz, 1H), 4.35–4.29 (a/b, m, 1H), 3.72–3.66 
(a/b, m, 1H), 3.06–2.99 (a/b, m, 1H), 2.53–2.38 (a/b, m, 2H), 2.31–2.03 (a/b, m, 6H), 2.09 (b, s, 
3H), 2.00 (a, s, 3H), 1.90 (b, s, 3H),1.87 (a, s, 3H), 1.85–1.75 (a/b, m, 2H), 1.72–1.65 (a/b, m, 
2H), 1.62 (b, s, 3H), 1.61 (a, s, 3H), 1.99–1.42 (a/b, m, 6H), 1.55 (a/b, s, 3H), 1.35 (b, s, 3H),1.34 
(a, s, 3H), 1.19 (a/b, d, J = 14.3 Hz, 1H), 1.11–1.02 (a/b, m, 2H), 0.94 (b, s, 3H), 0.93 (a, s, 3H), 
0.90–0.84 (a/b, m, 6H). 
13C NMR (CDCl3, 125 MHz): δ 171.3, 171.2, 168.3, 167.7, 158.3, 154.3, 147.8, 138.9, 137.0, 
132.7, 132.5, 131.7, 129.0, 127.5, 123.3, 123.1, 121.3, 119.8, 114.7, 74.4, 74.3, 71.5, 68.2, 68.2, 
49.5, 48.8, 43.7, 43.7, 39.5, 39.1, 39.0, 36.8, 36.8, 36.7, 35.8, 35.7, 35.6, 31.9, 31.8, 30.1, 30.1, 
184 
 
29.9, 29.3, 29.2, 28.6, 28.5, 25.8, 25.8, 23.8, 23.8, 23.4, 23.4, 21.2, 21.1, 21.1, 18.0, 17.6, 17.6, 
16.5, 16.1, 15.7. (several overlapping signals) 
HRMS(ESI): m/z calc. for C39H57N2O6Br [M+H]+: 727.3322, found: 727.3303. 
Compound 3-56 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (562.8 mg, 1.09 mmol) 
and (Z)-N’-hydroxy-N-(4-methoxyphenyl)acetimidamide (578.2 mg, 3.2 mmol, 2.9 eq), which 
were dissolved in MeCN (10 mL) and DMF (4 mL). The solution was treated with HOBt (187.5 
mg, 1.22 mmol, 1.1 eq) and EDCI (250 µL, 0.14 mmol, 1.3 eq). The vial was capped and placed 
in an 80 ºC heating block and was allowed to stir for 20 h. The vial was poured into a seperatory 
funnel and was diluted with brine and water. The mixture was extracted with chloroform (3x), 
dried over Na2SO4, and was concentrated under reduced pressure. The mixture was purified via 
flash chromatography on silica gel (9:1 chloroform/methanol). The resulting solid was submitted 
to reverse phase Preparative HPLC to afford 3-56 (574.6 mg, 78% yield) as an analytically pure 
(≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.06 (d, J = 8.9 Hz, 2H), 6.82 (d, J = 8.9 Hz, 2H), 6.65 (s, 1H), 
5.72 (d, J = 8.8Hz, 1H), 5.05 (t, J = 6.2 Hz, 1H), 4.31–4.27 (m, 1H), 3.75 (s, 3H), 3.67–3.64 (m, 
1H), 3.02–2.97 (m, 1H), 2.50–2.39 (m, 2H), 2.29–2.03 (m, 6H), 2.00 (s, 3H), 1.77 (s, 3H), 1.82–
1.72 (m, 2H), 1.71–1.64 (m, 2H), 1.60 (s, 3H), 1.57–1.40 (m, 6H), 1.54 (s, 3H), 1.32 (s, 3H), 







































13C NMR (CDCl3, 125 MHz): δ 171.1, 167.7, 158.3, 155.5, 147.4, 132.5, 130.5, 129.1, 128.3 
(2C), 123.2, 114.4 (2C), 74.3, 71.4, 68.1, 55.5, 49.5, 48.7, 43.6, 39.5, 39.0, 36.7 (2C), 35.6, 35.5, 
31.7, 30.0, 29.9, 29.2, 28.4, 25.8, 23.6, 23.5, 21.1, 17.9, 17.5 (2C), 16.0, 15.6. 
HRMS(ESI): m/z calc. for C40H59N2O7 [M+H]+: 679.4363, found: 679.4341. 
Compound 3-57 
 
Procedure: A vial equipped with a stir bar was charged with fusidic acid (29.4 mg, 0.06 mmol) 
and (Z)-N-(4-(dimethylamino)phenyl)-N’-hydroxyacetimidamide (11.5 mg, 0.06 mmol, 1.0 eq), 
which were dissolved in MeCN (3 mL) and DMF (3 mL). The solution was treated with HOBt 
(10.9 mg, 0.07 mmol, 1.3 eq) and EDCI (15 µL, 0.08 mmol, 1.5 eq). The vial was capped and 
placed in an 80 ºC heating block and was allowed to stir for 15 h. The vial was poured into a 
seperatory funnel and was diluted with brine and water. The mixture was extracted with 
chloroform (3x), dried over Na2SO4, and was concentrated under reduced pressure. The mixture 
was separated via flash chromatography on silica gel (9:1 chloroform/methanol). The resulting 
solid was submitted to reverse phase Preparative HPLC to afford 3-57 (6.5 mg, 17% yield) as an 
analytically pure (≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) ™ 7.05 (d, J = 8.8 Hz, 2H), 6.67 (d, J = 8.9 Hz, 2H), 6.61 (s, 1H), 
5.77 (d, J = 8.7 Hz, 1H), 5.11 (t, J = 6.9 Hz, 1H), 4.36–4.33 (m, 1H), 3.76–3.73 (m, 1H), 2.95 (s, 







































1.84 (m, 1H), 1.81 (s, 3H), 1.79–1.70 (m, 2H), 1.66 (s, 3H), 1.63–1.48 (m, 7H), 1.60 (s, 3H), 
1.38 (s, 3H), 1.26 (d, J = 14.4 Hz, 1H), 1.16–1.06 (m, 2H), 0.93–0.90 (m, 6H), 0.92 (s, 3H). 
13C NMR (CDCl3, 125 MHz): ™ 171.2, 168.0, 156.3, 149.6, 147.3, 132.8, 129.6, 128.4 (2C), 
126.8, 123.3, 112.8 (2C), 74.5, 71.6, 68.5, 49.5, 48.9, 43.7, 40.8 (2C), 39.7, 39.2, 37.2, 36.5, 
36.4, 35.7, 32.6, 30.5, 30.2, 29.4, 28.5, 25.9, 24.4, 23.0, 21.3, 21.0, 18.1, 17.9, 16.1, 15.7. 
HRMS(ESI): m/z calc. for C41H62N3O6 [M+H]+: 692.4639, found: 692.4634. 
Compound 3-58 
 
Procedure: A vial with a stir bar was charged with fusidic acid (468.2 mg, 0.91 mmol), 
chloromethyl propylcarbamate (640.1 mg, 4.22 mmol, 4.6 eq), excess triethylamine (0.6 mL), 
and DMF (15 mL). The vial was capped was allowed to stir at room temperature for 24 h. The 
reaction mixture was poured into a seperatory funnel containing water and brine. Next, the 
mixture underwent an extraction (3x) with chloroform, drying with Na2SO4, and concentration 
under reduced pressure. Purification was performed using silica gel chromatography (9:1 
chloroform/methanol). The mixture was submitted to reverse phase Preparative HPLC to afford 
3-58 (325.9 mg, 57% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CDCl3, 500 MHz) δ 5.72 (d, J = 5.6 Hz, 1H), 5.68 (d, J = 6.0 Hz, 1H), 5.68 (d, J = 7.7 
Hz, 1H), 5.21 (t, J = 5.9 Hz, 1H), 5.02 (t, J = 7.3 Hz, 1H), 4.31–4.28 (m, 1H), 3.69–3.62 (m, 1H), 
3.10 (q, J = 6.8 Hz, 2H), 3.02–2.97 (m, 1H), 2.44–2.30 (m, 3H), 2.24 (dt, J = 13.0, 3.2 Hz, 1H), 






































(s, 3H), 1.57–1.40 (m, 6H), 1.53 (s, 3H), 1.32 (s, 3H), 1.24 (d, J = 14.5 Hz, 1H), 1.10–1.00 (m, 
2H), 0.92 (s, 3H), 0.89–0.82 (m, 7H), 0.84 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 171.0, 168.9, 154.7, 149.4, 132.6, 129.5, 123.1, 79.9, 74.7, 
71.4, 68.1, 49.4, 48.7, 44.2, 42.8, 39.5, 39.0, 36.8, 36.7, 35.6, 35.5, 31.7, 30.0, 29.9, 28.9, 28.4, 
25.8, 23.6, 23.5, 23.0, 21.1, 21.0, 17.8, 17.7, 16.1, 11.2. 
HRMS(ESI): m/z calc. for C36H57NO8Na [M+Na]+: 654.3982, found: 654.3972. 
Compound 3-61 
 
Procedure: A vial with a stir bar was charged with 3-35 (665.3 mg, 1.10 mmol) and N,N'-Bis(3-
aminopropyl)-1,3-propanediamine (225 µL mg, 1.10 mmol, 1 eq), which were dissolved in DMF 
(4 mL). The vial was capped and placed in an 80 ºC heating block and was allowed to stir for 1 
h. The vial was poured into a seperatory funnel and was diluted with brine and water. The 
mixture was extracted with chloroform (10x), dried over Na2SO4, and was concentrated under 
reduced pressure. The mixture was ran through a short plug of silica gel and first eluted with 9:1 
chloroform/methanol to recover starting material and fusidic acid (hydrolysis product). Next, the 
plug was eluted with 3:7 chloroform/methanol. The resulting solid was filtered through a 0.2 
micron, 15 mm syringe filter to afford 3-61 (371.1 mg, 38% yield), which was submitted to 
reverse phase Preparative HPLC (MeCN/H2O, 0.1% formic acid). The fractions containing 












































extracted with chloroform (10x). The combined organic layers were concentrated under reduced 
pressure to afford 3-61 (30.7 mg, 3% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.78 (d, J = 8.2 Hz, 1H), 5.08 (t, J = 6.9 Hz, 1H), 4.30–4.26 (m, 
1H), 4.63–4.60 (m, 1H), 3.09–3.03 (m, 1H), 2.69–2.48 (m, 9H), 2.42–2.33 (m, 1H), 2.29–2.00 
(m, 13H), 1.89 (s, 3H), 1.87–1.75 (m, 2H), 1.75–1.51 (m, 9H), 1.62 (s. 3H), 1.56 (s, 3H), 1.51–
1.40 (m, 2H), 1.36 (s, 3H), 1.15 (d, J = 14.6 Hz, 1H), 1.12–1.04 (m, 2H), 0.95 (s, 3H), 0.88 (s, 
3H), 0.85 (d, J = 6.7 Hz, 3H). (65 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 170.9, 168.9, 157.5, 148.6, 132.1, 128.6, 122.8, 74.5, 71.0, 
67.1, 49.3, 48.5, 47.0, 46.9, 46.1, 43.6, 39.3, 39.3, 38.6, 36.9, 36.4, 35.9, 35.4, 32.7, 32.1, 31.4, 
29.6, 29.5, 29.0, 28.8, 28.6, 27.9 (2C), 24.5, 22.5, 22.4, 21.0, 19.8 (2C), 19.7, 16.5, 15.1. 
HRMS(ESI): m/z calc. for C42H75N6O6 [M+H]+: 759.5751, found: 759.5754. 
Compound 3-62 
 
Procedure: A vial with a stir bar was charged with 3-35 (269.5 mg, 0.44 mmol) and 1,3-
propanediamine (40 µL mg, 0.47 mmol, 1.1 eq), which were dissolved in DMF (10 mL). The 
vial was capped and placed in an 80 ºC heating block and was allowed to stir for 1 h. The vial 
was poured into a seperatory funnel and was diluted with brine and water. The mixture was 
extracted with chloroform (10x), dried over Na2SO4, and was concentrated under reduced 
pressure. The mixture was ran through a short plug of silica gel and first eluted with 9:1 





































plug was eluted with 3:7 chloroform/methanol. The resulting solid was filtered through a 0.2 
micron, 15 mm syringe filter to afford 3-62 (111.2 mg, 39% yield), which was submitted to 
reverse phase Preparative HPLC (MeCN/H2O, 0.1% formic acid). The fractions containing 
product were poured into water, basified with sodium bicarbonate (saturated solution) and were 
extracted with chloroform (10x). The combined organic layers were concentrated under reduced 
pressure to afford 3-62 (11.9 mg, 4% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.84 (d, J = 8.7 Hz, 1H), 5.13 (t, J = 7.1 Hz, 1H), 4.35–4.31 (m, 
1H), 3.69–3.64 (m, 1H), 3.34 (d, J = 14.7 Hz, 1H), 3.26 (d, J = 14.7 Hz, 1H), 3.13–3.08 (m, 1H), 
2.79 (t, J = 6.9 Hz, 1H), 2.70–2.57 (m, 3H), 2.48–2.37 (m, 1H), 2.33–2.05 (m, 5H), 1.94 (s, 3H), 
1.92–1.58 (m, 8H), 1.66 (s. 3H), 1.61 (s, 3H), 1.54 (ddd, J = 11.1, 6.7, 2.5 Hz, 1H), 1.48 (ddd, J 
= 13.7, 4.7, 2.4 Hz, 1H), 1.40 (s, 3H), 1.20 (d, J = 14.2 Hz, 1H), 1.17–1.09 (m, 2H), 1.00 (s, 3H), 
0.93 (s, 3H), 0.90 (d, J = 6.9 Hz, 3H). (53 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 172.5, 170.4, 159.0, 150.1, 133.7, 130.1, 124.3, 76.0, 72.5, 
68.6, 50.8, 50.0, 49.7, 47.2, 45.1, 40.8, 40.7, 40.1, 38.4, 37.9, 37.4, 36.9, 32.9, 32.3, 31.1, 31.0, 
30.1, 29.4, 26.0, 24.0, 23.9, 22.5, 21.2, 18.0 (2C), 16.6. 










































Procedure: A vial with a stir bar was charged with 3-35 (526.6 mg, 0.87 mmol) and N1-(3-
aminopropyl)propane-1,3-diamine (135 µL mg, 0.97 mmol, 1.1 eq), which were dissolved in 
DMF (10 mL). The vial was capped and placed in an 80 ºC heating block and was allowed to stir 
for 1 h. The vial was poured into a seperatory funnel and was diluted with brine and water. The 
mixture was extracted with chloroform (10x), dried over Na2SO4, and was concentrated under 
reduced pressure. The mixture was ran through a short plug of silica gel and first eluted with 9:1 
chloroform/methanol to recover starting material and fusidic acid (hydrolysis product). Next, the 
plug was eluted with 3:7 chloroform/methanol. The resulting solid was filtered through a 0.2 
micron, 15 mm syringe filter to afford 3-63 (174.1 mg, 29% yield), which was submitted to 
reverse phase Preparative HPLC (MeCN/H2O, 0.1% formic acid). The fractions containing 
product were poured into water, basified with sodium bicarbonate (saturated solution) and were 
extracted with chloroform (10x). The combined organic layers were concentrated under reduced 
pressure to afford 3-63 (47.6 mg, 8% yield) as an analytically pure (≥95%) white solid. 
1H NMR (CD3OD, 500 MHz) δ 5.85 (d, J = 8.9 Hz, 1H), 5.14 (t, J = 7.1 Hz, 1H), 4.35–4.31 (m, 
1H), 3.68–3.64 (m, 1H), 3.14–3.08 (m, 1H), 2.94–2.79 (m, 4H), 2.72–2.57 (m, 2H), 2.46–2.38 
(m, 1H), 2.33–2.05 (m, 7H), 1.94 (s, 3H), 1.92–1.57 (m, 13H), 1.67 (s, 3H), 1.61 (s, 3H), 1.53 
(ddd, J = 11.3, 7.0, 2.3 Hz, 1H), 1.48 (ddd, J = 13.4, 4.7, 2.4 Hz, 1H), 1.40 (s, 3H), 1.20 (d, J = 
14.2 Hz, 1H), 1.18–1.09 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H), 0.90 (d, J = 7.0 Hz, 3H). (59 non-
exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 172.4, 170.4, 159.1, 150.3, 133.7, 130.1, 124.3, 76.0, 72.5, 
68.6, 50.8, 50.0, 49.6, 49.4, 49.3, 49.1, 48.9, 48.8, 48.6, 45.2, 40.8, 40.1, 38.3, 37.9, 37.5, 37.4, 
36.9 (2C), 33.0, 32.9, 31.1, 31.0, 30.1, 29.4, 28.8, 26.0, 24.0, 23.9, 22.6, 22.5, 21.3, 21.2, 18.1, 
18.0, 16.6 (2C). 
191 
 
HRMS(ESI): m/z calc. for C39H68N5O6 [M+H]+: 702.5170, found: 702.5151. 
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